0001079973-23-000353.txt : 20230317 0001079973-23-000353.hdr.sgml : 20230317 20230317170400 ACCESSION NUMBER: 0001079973-23-000353 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230317 DATE AS OF CHANGE: 20230317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProtoKinetix, Inc. CENTRAL INDEX KEY: 0001128189 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943355026 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-32917 FILM NUMBER: 23743618 BUSINESS ADDRESS: STREET 1: 109 W. MAIN ST. CITY: DALTON STATE: OH ZIP: 44618 BUSINESS PHONE: 330-445-4971 MAIL ADDRESS: STREET 1: 109 W. MAIN ST. CITY: DALTON STATE: OH ZIP: 44618 FORMER COMPANY: FORMER CONFORMED NAME: RJV NETWORK INC DATE OF NAME CHANGE: 20010130 10-K 1 pktx_10k-123122.htm FORM 10-K
0001128189 false 2022 FY 0001128189 2022-01-01 2022-12-31 0001128189 2022-06-30 0001128189 2022-12-31 0001128189 2021-12-31 0001128189 2021-01-01 2021-12-31 0001128189 us-gaap:CommonStockMember 2020-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001128189 us-gaap:RetainedEarningsMember 2020-12-31 0001128189 2020-12-31 0001128189 us-gaap:CommonStockMember 2021-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001128189 us-gaap:RetainedEarningsMember 2021-12-31 0001128189 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001128189 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001128189 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001128189 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001128189 us-gaap:CommonStockMember 2022-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001128189 us-gaap:RetainedEarningsMember 2022-12-31 0001128189 2015-01-01 2015-12-31 0001128189 2015-12-31 0001128189 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001128189 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001128189 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001128189 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001128189 us-gaap:PatentsMember 2020-12-31 0001128189 PKTX:PatentApplicationRightsMember 2020-12-31 0001128189 us-gaap:PatentsMember 2021-01-01 2021-12-31 0001128189 PKTX:PatentApplicationRightsMember 2021-01-01 2021-12-31 0001128189 us-gaap:PatentsMember 2021-12-31 0001128189 PKTX:PatentApplicationRightsMember 2021-12-31 0001128189 us-gaap:PatentsMember 2022-01-01 2022-12-31 0001128189 PKTX:PatentApplicationRightsMember 2022-01-01 2022-12-31 0001128189 us-gaap:PatentsMember 2022-12-31 0001128189 PKTX:PatentApplicationRightsMember 2022-12-31 0001128189 PKTX:PatentApplicationRightsMember 2015-01-01 2015-12-31 0001128189 PKTX:GrantYoungMember PKTX:TechnologyTransferAgreementMember 2015-12-31 0001128189 PKTX:GrantYoungMember PKTX:TechnologyTransferAgreementMember 2015-01-01 2015-12-31 0001128189 PKTX:PatentApplicationRightsMember 2016-01-01 2016-12-31 0001128189 srt:MinimumMember 2022-01-01 2022-12-31 0001128189 srt:MaximumMember 2022-01-01 2022-12-31 0001128189 us-gaap:StockOptionMember 2022-12-31 0001128189 us-gaap:StockOptionMember 2022-03-15 0001128189 us-gaap:StockOptionMember 2022-03-01 2022-03-15 0001128189 us-gaap:StockOptionMember 2022-12-07 0001128189 us-gaap:StockOptionMember srt:MinimumMember 2022-12-07 0001128189 us-gaap:StockOptionMember srt:MaximumMember 2022-12-07 0001128189 us-gaap:StockOptionMember 2022-12-01 2022-12-07 0001128189 us-gaap:StockOptionMember 2020-12-31 0001128189 us-gaap:StockOptionMember 2021-12-31 0001128189 PKTX:StockOption1Member 2022-12-31 0001128189 PKTX:StockOption2Member 2022-12-31 0001128189 PKTX:StockOption3Member 2022-12-31 0001128189 us-gaap:WarrantMember 2020-12-31 0001128189 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001128189 us-gaap:WarrantMember 2021-12-31 0001128189 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001128189 us-gaap:WarrantMember 2022-12-31 0001128189 PKTX:Warrant1Member 2022-12-31 0001128189 PKTX:Warrant1Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant2Member 2022-12-31 0001128189 PKTX:Warrant2Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant3Member 2022-12-31 0001128189 PKTX:Warrant3Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant4Member 2022-12-31 0001128189 PKTX:Warrant4Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant5Member 2022-12-31 0001128189 PKTX:Warrant5Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant6Member 2022-12-31 0001128189 PKTX:Warrant6Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant7Member 2022-12-31 0001128189 PKTX:Warrant7Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant8Member 2022-12-31 0001128189 PKTX:Warrant8Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant9Member 2022-12-31 0001128189 PKTX:Warrant9Member 2022-01-01 2022-12-31 0001128189 us-gaap:PrivatePlacementMember 2022-03-31 0001128189 us-gaap:PrivatePlacementMember 2022-04-04 0001128189 us-gaap:PrivatePlacementMember 2022-05-12 0001128189 us-gaap:WarrantMember 2019-07-01 2019-07-15 0001128189 us-gaap:WarrantMember 2019-07-15 0001128189 us-gaap:WarrantMember 2022-12-31 0001128189 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsMember 2022-12-31 0001128189 PKTX:InvestorsOneMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsOneMember 2022-12-31 0001128189 PKTX:InvestorsTwoMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsTwoMember 2022-12-31 0001128189 PKTX:InvestorsThreeMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsThreeMember 2022-12-31 0001128189 PKTX:InvestorsFourMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsFourMember 2022-12-31 0001128189 PKTX:InvestorsFiveMember 2021-01-01 2021-12-31 0001128189 PKTX:InvestorsFiveMember 2021-12-31 0001128189 PKTX:InvestorsSixMember 2021-01-01 2021-12-31 0001128189 PKTX:InvestorsSixMember 2021-12-31 0001128189 PKTX:InvestorsSevenMember 2021-01-01 2021-12-31 0001128189 PKTX:InvestorsSevenMember 2021-12-31 0001128189 PKTX:InvestorsEightMember 2021-01-01 2021-12-31 0001128189 PKTX:InvestorsEightMember 2021-12-31 0001128189 PKTX:InvestorsNineMember 2021-01-01 2021-12-31 0001128189 PKTX:InvestorsNineMember 2021-12-31 0001128189 srt:ChiefFinancialOfficerMember 2022-01-01 2022-12-31 0001128189 srt:ChiefFinancialOfficerMember 2021-01-01 2021-12-31 0001128189 PKTX:ChiefExecutiveandDirectorOfficerMember 2022-12-01 2022-12-07 0001128189 PKTX:ChiefExecutiveandDirectorOfficerMember 2022-12-07 0001128189 PKTX:CFOMember 2022-12-01 2022-12-07 0001128189 PKTX:CFOMember 2022-12-07 0001128189 PKTX:ChiefExecutiveandOfficerMember 2022-03-01 2022-03-15 0001128189 srt:DirectorMember 2022-03-01 2022-03-15 0001128189 2022-03-01 2022-03-15 0001128189 PKTX:ChiefExecutiveandDirectorOfficerMember 2022-03-01 2022-03-15 0001128189 PKTX:ChiefExecutiveandDirectorOfficerMember 2022-03-15 0001128189 PKTX:CFOMember 2022-03-01 2022-03-15 0001128189 PKTX:CFOMember 2022-03-15 0001128189 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001128189 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001128189 PKTX:ConsultantMember 2017-01-01 2017-01-02 0001128189 PKTX:ConsultantMember 2019-04-01 2019-04-02 0001128189 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001128189 srt:ChiefExecutiveOfficerMember 2022-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

U. S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to _____________

 

Commission File Number: 000-32917

 

PROTOKINETIX, INCORPORATED

(Name of small business issuer as specified in its charter)

 

 

Nevada 94-3355026

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

109 W Main St

Dalton, Ohio 44618

(Address of principal executive offices, including zip code)

 

  Registrant’s telephone number, including area code: 330-455-4971

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A        

 

Securities registered pursuant to Section 12(g) of the Act:

$.0000053 par value common stock

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act:   

Yes     No  

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act:  

Yes     No  

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No  

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  No  

 

 
 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Securities Exchange Act of 1934.

 

Large accelerated filer     Accelerated filer 

Non-accelerated filer

 

  Smaller reporting company
Emerging growth company     

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

Indicate by the check mark whether the registration has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the fi ling refl ect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive offi cers during the relevant recovery period pursuant to §240.10D-1(b).

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes   No

 

Auditor PCAOB ID: 731 Auditor Name: Davidson & Company LLP Auditor Location: Vancouver, British Columbia, Canada

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $9,886,980  based upon the closing price of our common stock which was $0.035 as of June 30, 2022, the last business day of the Company’s most recently completed second fiscal quarter.  Shares of common stock held by each officer and director and by each person or group who owns 10% or more of the outstanding common stock amounting to shares have been excluded in that such persons or groups may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

 

As of December 31, 2022, there were 322,880,151 shares of our common stock that were issued and outstanding.

  

 
 

 

 

TABLE OF CONTENTS

FORM 10-K ANNUAL REPORT

_________________________

 

PROTOKINETIX, INCORPORATED

 

Part 1     Page  
Item 1. Business     3  
Item 1A Risk Factors     5  
Item 1B Unresolved Staff Comments     10  
Item 2 Properties     10  
Item 3 Legal Proceedings     10  
Item 4 Mine Safety Disclosures     10  
           
Part II          
Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities     11  
Item 6 [Reserved]     14  
Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations     14  
Item 7A Quantitative and Qualitative Disclosures About Market Risk     16  
Item 8 Financial Statements and Supplementary Data     17  
Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure     17  
Item 9A Controls and Procedures     17  
Item 9B Other Information     18  
Item 9C  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections      18  
           
Part III          
Item 10 Directors, Executive Officers and Corporate Governance     19  
Item 11 Executive Compensation     21  
Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters     23  
Item 13 Certain Relationships and Related Transactions, and Director Independence     24  
Item 14 Principal Accountant Fees and Services     25  
           
Part IV          
Item 15 Exhibits and Financial Statement Schedules     26  
Item 16 Form 10-K Summary     27  
Signatures       28  

 

 

 

2 
 

 

PART I

 

ITEM 1.  BUSINESS

 

ProtoKinetix, Incorporated (“ProtoKinetix,” “we,” “us,” “our,” or the “Company”) is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGPs®.  The Company has recently been in the process of directing major efforts to the practical side of commercial validation. The commercial applications for AAGPs® in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP® to market.

ProtoKinetix was incorporated as RJV Network, Inc. under the laws of the State of Nevada on December 23, 1999 for the primary purpose of developing an internet-based listing site that would provide detailed commercial real estate property listings and related data.  In July 2003, the Company entered into an assignment of license agreement with BioKinetix Research, Incorporated for the assignment of rights relating to proprietary technologies of BioKinetix Research, Incorporated for the creation and commercialization of “superantibodies.”  On July 8, 2003, the Company changed its name to “ProtoKinetix, Incorporated.”

The Company’s executive (or corporate) offices are located at 109 W Main St, Dalton, Ohio 44618.  Our telephone number is (330) 445-4971 and our website is www.protokinetix.com ..

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this Annual Report on Form 10-K for the fiscal year ended December 31, 2022 as well as some statements in press releases and some oral statements of the Company’s officers during presentations about the Company include “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”).  All statements, other than statements of historical facts, included herein and therein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases.  Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not considered to be) guarantees of future performance. Our results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, among others:

 

  Our capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;

 

  Our plans to develop and commercialize products from the AAGP® molecule;

 

  Ongoing testing of the AAGP® molecule;

 

  Our intellectual property position;

 

  Our commercialization, marketing and manufacturing capabilities and strategy;

 

  Our ability to retain key members of our senior management and key scientific consultants;

 

  The effects of competition;

 

  Our potential tax liabilities resulting from conducting business in the United States and Canada;

 

  The effect of further sales or issuances of our common stock and the price and volume volatility of our common stock; and
     
    Our common stock’s limited trading history.

 

3 
 

 

Finally, our future results will depend upon various other risks and uncertainties, including, but not limited to, those detailed in the section entitled “Risk Factors” included elsewhere in this Annual Report.  All forward looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this section and elsewhere in this Annual Report.  Other than as required under securities laws, we do not assume a duty to update these forward looking statements, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.

 

Recent Developments  

 

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn.

 

As of the date of this filing, the Company has regained a significant portion of its operational capacity and we continue to move forward with our research goals. Our supply of the patented AAGP® molecule has been manufactured and stored in the United States and we have adequate inventory to carry out the projects currently underway. The Company engages contract research organizations (CROs) located in both the United States and Canada. The CROs contracted by the Company for research projects have been able to meet milestone goals without disruption due to the pandemic. In January of 2020, Protokinetix signed a master supply agreement with University of Alberta that clears the way for testing of additional patients in the Phase I clinical trials. The global pandemic halted all work on clinical trials and research testing for most of 2020. Phase I trials were able restart mid-year 2021 but new strains of covid continue to plague the US and Canada. We cannot accurately predict a completion date of Phase I trials.

We continue to monitor the status of the pandemic and will adjust our strategy accordingly in order to mitigate the impact on our research projects. The Company survived the adverse effects of the 2020 Covid-19 outbreak and as at December 31, 2022 continues to carry out operations including raising funds for ongoing research and product development.

On February 11, 2022, the Company held its first annual stockholder meeting. The meeting was held solely by means of remote communication due to COVID-19 concerns. At the meeting, the Company: (i) elected Clarence Smith and Ed McDonough as directors of the Company; (ii) approved the amendment and restatement of the Company’s Articles of Incorporation to, among other things, increase the number of authorized shares of common stock to 500,000,000; (iii) voted, in an advisory vote, to approve the compensation of the Company’s named executive officers; (iv) voted, in an advisory vote, to conduct an advisory vote on compensation of the Company’s named executive officers every three years; and (v) approved the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the Company’s independent accounting firm for the 2022 fiscal year.

During the year 2022 the Company developed an ophthalmic formulation and completed efficacy testing in a dry eye formulation and various dosages. Phase I clinical trials conducted by Dr. James Shapiro were reactivated but access to qualified patients has been slow and progress minimal since global pandemic. The Company is making a concerted effort to find strategic partners and is the impressive accumulation of research data to attract potential partners or buyers of the Company. Industry leaders in biochemistry and pharmaceuticals, both domestic and international, are potential partners.

 

Research and Development

 

Our business depends on our ability to sponsor research and development activities.  For the year ended December 31, 2021, the Company incurred total research and development expenses of $435,872.  For the year ended December 31, 2022, the Company incurred total research and development expenses of $448,873.  In order to reach the Company’s goals of developing a marketable product, we will need to increase the funding of our research and development activities which at this time is limited by our ability to raise money to fund the Company.

 

4 
 

 

ITEM 1A.  RISK FACTORS

 

The Company’s securities are highly speculative and involve a high degree of risk, including among other items the risk factors described below.  The below risk factors are intended to generally describe certain risks that could materially affect the Company and its current business operations and activities.

 

You should carefully consider the risks described below and elsewhere herein in connection with any decision whether to acquire, hold or sell the Company’s securities.  If any of the contingencies discussed in the following paragraphs or other materially adverse events actually occur, the business, financial condition and results of operations could be materially and adversely affected.  In such case, the trading price of our common stock could decline, and you could lose all or a significant part of your investment.

 

Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect the Company's current and projected business operations and its financial condition and results of operations.

Actual events involving reduced or limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Although we did not have any cash or cash equivalent balances on deposit with Silicon Valley Bank, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, or result in breaches of our financial and/or contractual obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.

We continue to face significant business disruption and related risks resulting from the COVID-19 pandemic, which could have a material adverse effect on our business and results of operations.  

The ongoing and developing COVID-19 pandemic has caused a broad impact globally. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, any resulting recession or economic slowdown will have a negative impact on our business and results of operations.

 

As of the date of this filing, the Company has regained a significant portion of its operational capacity and we continue to move forward with our research goals. Our supply of the patented AAGP® molecule has been manufactured and stored in the United States and we have adequate inventory to carry out the projects currently underway. The Company engages contract research organizations (CROs) located in both the United States and Canada. The CROs contracted by the Company for research projects have been able to meet milestone goals without disruption due to the pandemic. Clinical trials in Edmonton, Canada, under the supervision of Dr. Shapiro, were stalled in 2020 due to COVID-19. Phase I trials were continued starting mid-year 2021 and continue in 2022. New strains of Covid continue to plague Canada and the US and we cannot predict the completion of Phase I trials. We continue to monitor the status of the pandemic and will adjust our strategy accordingly in order to mitigate the impact on our research projects.

 

In addition, any significant disruption of global financial markets, reducing our ability to access capital, could negatively affect our liquidity and ability to continue operations. The exact impact is and will remain unknown and largely dependent upon future developments, including but not limited to information on the duration and spread of COVID-19, changes in customer demand, additional mitigation strategies proposed by governmental authorities (including federal, state, or local stay at home or similar orders), restrictions on the activities of our domestic and international suppliers and shipment of goods.

 

War in the Ukraine may impact the business of the Company and the financial markets in which the Company needs to raise capital.

 

Political and military events in Ukraine, including the 2022 Russian invasion of Ukraine, as well as ongoing warfare between Russia and Ukraine may have an adverse impact on our ability to grow our business.

  

For so long as the hostilities continue and perhaps even thereafter as the situation in Europe unfolds, we may see increased volatility in financial markets and a flight to safety by investors, which may make it more difficult for the Company to raise additional capital at the time when it needs to do so, or for financing to be available upon acceptable terms. We cannot predict the timing, strength, or duration of any economic slowdown, instability or recovery.

 

Moreover, retaliatory acts by Russia in response to economic sanctions or other measures taken by the international community against could include an increased number or severity of cyber-attacks from Russia or its allies. We are dependent on information technology systems, and any interruption, breach, or security lapse of those systems could adversely affect our results of operations. For example, the loss of data from any clinical trials could result in delays in research and development, and the loss, corruption, or unauthorized disclosure of our trade secrets, patents, or other proprietary information could compromise the commercial viability of our products. We may also incur additional costs in the future related to the implementation of additional security measures to protect against new or enhanced data security and privacy threats, or to comply with state, federal and international laws that may be enacted to address those threats.

 

All or any of these risks separately, or in combination could have a material adverse effect on our business, financial condition, results of operations, and cash flows.

 

We may be adversely affected by the effects of inflation.

Inflation has the potential to adversely affect our liquidity, business, financial condition and results of operations by increasing our overall cost structure. The existence of inflation in the economy has resulted in, and may continue to result in, higher interest rates and capital costs, supply shortages, increased costs of labor, components, manufacturing and shipping, as well as weakening exchange rates and other similar effects. As a result of inflation, we have experienced and may continue to experience cost increases. Although we may take measures to mitigate the effects of inflation, if these measures are not effective, our business, financial condition, results of operations and liquidity could be materially adversely affected. Even if such measures are effective, there could be a difference between the timing of when these beneficial actions impact our results of operations and when the cost of inflation is incurred.

 

5 
 

Our Company has a lack of operating history and lack of revenues from operations.   Our Company has no revenues and very limited operating history.  As of the date of this Annual Report, our most significant assets are cash and our intellectual property.  Our ability to successfully generate revenues from our intellectual property is dependent on a number of factors, including availability of funds to complete development efforts, to adequately test and refine our products, and to commercialize our products.  There can be no assurance that we will not encounter setbacks with our products, or that funding will be sufficient to bring our products to the point of commercialization.

 

We may have difficulty raising any needed additional capital.   We may have difficulty raising needed capital in the future as a result of, among other factors, our lack of revenues from operations, as well as the inherent business risks associated with our Company and present and future market conditions.  Our business currently generates no revenue from operations.  We will likely require additional funds to conduct research and development, establish and conduct non-clinical and clinical trials, secure clinical and commercial-scale manufacturing arrangements and provide for marketing and distribution.  If adequate funds are unavailable, we may be required to delay, reduce the scope of or eliminate one or more of our research, development or commercialization programs, product launches or marketing efforts, any of which may materially harm our business, financial condition and results of operations.

 

We are dependent on our key personnel, and the loss of such personnel could adversely affect our business.   We depend on the continued performance of the members of our management team and our Business and Scientific Advisory Board who have contributed to the expertise of our team and the position of our business.  If we lose the services of members of our management teams, and are unable to locate a suitable replacement in a timely manner, it could have a material adverse effect on our business.  We do not expect to obtain key man life insurance for any members of management in the foreseeable future.

 

We may experience difficulty implementing our business plan.   Our business plan is to continue with the development of the Company’s intellectual property and to develop a product for sale commercially.  We may require additional capital in order to develop our products for sale commercially.  There can be no assurance that we would be able to obtain additional capital on reasonable terms, or at all.

 

We have been and expect to be significantly dependent on our collaborative agreements for the research, development and testing of AAGP®, which exposes us to the risk of reliance on the performance of third parties.   In conducting our research and development activities, we currently rely, and expect to continue to rely, on numerous collaborative agreements with third parties such as contract research organizations, commercial partners, universities, governmental agencies and not-for-profit organizations for both strategic and financial resources.  The loss of, or failure to perform by us or our partners (who are subject to regulatory, competitive and other risks) under any applicable agreements or arrangements, or our failure to secure additional agreements for our product candidates, would substantially disrupt or delay our research and development and commercialization activities.  Any such loss would likely increase our expenses and materially harm our business, financial condition and results of operations.

 

We are a research and product development stage company that has not yet developed or sold any products.   To date, we have not yet developed nor marketed a product.  Ongoing testing of the AAGP® molecule with three amino acids joined to a monosaccharide by a gemdiflouride bond continues to show that there is significant promise in the field of medicine of preserving cells, tissue and organs from various stresses.  Tests have confirmed that the AAGP® molecule improves the harvest of cells from cryopreservation by 30% to 120%. We believe there is a market for AAGP® to preserve cells, particularly various stem cells, and we will continue testing with potential customers. At the same time, we are taking steps to improve the manufacturing process to reduce costs and improve purity and biochemical activity.

 

Even if we develop product candidates which obtain regulatory approval they may never achieve market acceptance or commercial success.   Even if we develop products and obtain FDA or other regulatory approvals, our products may not achieve market acceptance among physicians, patients and third party payors and, ultimately, may not be commercially successful.  Market acceptance of our product candidates for which we receive approval depends on a number of factors.  Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our financial results.

 

The potential widespread acceptance of therapies that are alternatives to ours may limit market acceptance of our formulations or products, even if commercialized.  Many of our targeted diseases and conditions can also be treated by other medication or technologies.  These treatments may be widely accepted in medical communities and have a longer history of use.  The established use of these competitive drugs may limit the potential for our technologies, formulations and products to receive widespread acceptance if commercialized.

 

 

6 
 

The market for our product candidates is rapidly changing and competitive, and new technologies treatments which may be developed by others could impair our ability to maintain and grow our business and remain competitive.   The pharmaceutical and biotechnology industries are subject to rapid and substantial technological change.  Developments by others may render our technologies and our product candidates noncompetitive or obsolete, or we may be unable to keep pace with technological developments or other market factors.  Technological competition from pharmaceutical and biotechnology companies, universities, governmental entities and others now existing or diversifying into the field is intense and is expected to increase.  Many of these entities have significantly greater research and development capabilities, human resources and budgets than we do, as well as substantially more marketing, manufacturing, financial and managerial resources. These entities represent significant competition for us.

 

Risks Related to Product Development and Regulation

 

Our ability to generate revenues will be dependent on our ability to develop a product that complies with legal requirements.   Although the laws and regulations of the various jurisdictions in which we may operate vary in their technical requirements and are subject to amendment from time to time, virtually all of these jurisdictions require licenses, permits, and other forms of approval.  We will have to apply for, and obtain, all requisite government licenses, registrations, findings of suitability, permits and approvals necessary for us to do business in these new markets.  We cannot offer any assurance that we will be able to obtain all necessary licenses, registrations, findings of suitability, permits, or approvals.

 

Our failure to obtain costly government approvals, including required FDA approvals, or to comply with ongoing governmental regulations relating to our technologies and product candidates could delay or limit introduction of our products and result in failure to achieve revenues or maintain our ongoing business.   Our research and development activities and the manufacture and marketing of our product candidates are subject to extensive regulation for safety, efficacy and quality by numerous government authorities in the United States and abroad.  Before receiving FDA or foreign regulatory clearance to market our proposed formulations and products, we will have to demonstrate that our formulations and products are safe and effective in the population.  Clinical trials, manufacturing and marketing of drugs are subject to the rigorous testing and approval process of the FDA and equivalent foreign regulatory authorities.  The Federal Food, Drug and Cosmetic Act and other federal, state and foreign statutes and regulations govern and influence the testing, manufacture, labeling, advertising, distribution and promotion of drugs and medical devices.  As a result, regulatory approvals can take a number of years or longer to accomplish and require the expenditure of substantial financial, managerial and other resources.

 

Conducting and completing the clinical trials necessary for FDA and/or Health Canada approval is costly and subject to intense regulatory scrutiny as well as the risk of failing to meet the primary endpoint of such trials.   We will not be able to commercialize and sell our proposed products and formulations without completing such trials.  In order to conduct clinical trials that are necessary to obtain approval by the FDA and/or Health Canada to market a formulation or product, it is necessary to receive clearance from the FDA and/or Health Canada to conduct such clinical trials.  The FDA and/or Health Canada can halt clinical trials at any time for safety reasons or because we or our clinical investigators did not follow the FDA’s and/or Health Canada requirements for conducting clinical trials.  If we are unable to receive clearance to conduct clinical trials or the trials are permanently halted by the FDA and/or Health Canada, we would not be able to achieve any revenue from such product as it is illegal to sell any drug or medical device for human consumption or use without FDA and/or Health Canada approval.

 

We could be exposed to significant drug product liability claims which could be time consuming and costly to defend, divert management attention and adversely impact our ability to obtain and maintain insurance coverage.   The testing, manufacturing, marketing and sale of our proposed products involve an inherent risk that product liability claims will be asserted against us.  Product liability insurance may prove inadequate to cover claims and/or litigation costs.  Product liability claims or other claims related to our products, regardless of their outcome, could require us to spend significant time and money in litigation or to pay significant settlement amounts or judgments.  Any successful product liability or other claim may prevent us from obtaining adequate liability insurance in the future on commercially desirable or reasonable terms.  An inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of our products and product candidates.  A product liability claim could also significantly harm our reputation and delay market acceptance of our proposed formulations and products.

 

 

7 
 

Risk Factors Related to Intellectual Property and Obsolescence

 

We rely on patents and other intellectual property to protect our business interests. We have attempted to protect our products and will attempt to protect other products through a combination of trade secrets, confidentiality agreements, patents and other contractual provisions.  Patents only provide a limited protection against infringement, and patent infringement suits are complex, expensive, and not always successful.  Although the Company believes its patents will provide significant protection, there can be no assurance that they will be issued and if they are, that they will provide enough protection.

 

Because it is difficult and costly to protect our proprietary rights, we may not be able to ensure their protection. Our commercial success will depend in part on maintaining patent protection and trade secret protection for our products, as well as successfully defending these patents against third-party challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover them.

 

The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents has emerged to date in the United States. The patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.

 

Our competitive position could be harmed if we are unable to enforce confidentiality agreements.   Our proprietary information is critically important to our competitive position and is a significant aspect of our business plan.  We generally enter into confidentiality agreements with most of our employees and consultants, and control access to, and distribution of, our documentation and other proprietary information.  Despite these precautions, we cannot assure you that these strategies will be adequate to prevent misappropriation of our proprietary information.  Therefore, we could be required to expend significant amounts to defend our rights to proprietary information in the future if a breach were to occur.

 

General Corporate Risk Factors

Insiders continue to have substantial control over the Company.  As of March 17, 2023, the Company’s directors and executive officers hold the current right to vote approximately 32.2% of the Company’s outstanding voting stock; of which 25.9% is owned or controlled, directly or indirectly by the Company CEO, Clarence Smith. In addition, the Company’s directors and executive officers have the right to acquire additional shares which could increase their voting percentage significantly. As a result, Mr. Smith acting alone, and/or many of these individuals acting together, may have the ability to exert significant control over the Company’s decisions and control the management and affairs of the Company, and also to determine the outcome of matters submitted to stockholders for approval, including the election and removal of a director, the removal of any officer and any merger, consolidation or sale of all or substantially all of the Company’s assets. Accordingly, this concentration of ownership may harm a future market price of the Company’s common stock by:

 

  · Delaying, deferring or preventing a change in control of the Company;

 

  · Impeding a merger, consolidation, takeover or other business combination involving the Company; or

 

  · Discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company.

The Company may not be able to continue as a going concern.   Our independent public accountants noted that our recurring losses from operations ($1,907,309 and $2,329,310 for the years ended December 31, 2022 and 2021, respectively) and negative net operating cash flow ($804,669 and $889,891 for the years ended December 31, 2022 and 2021, respectively) raise substantial doubt about our ability to continue as a going concern. This may hinder our future ability to obtain financing or may force us to obtain financing on less favorable terms than would otherwise be available.

 

 

8 
 

The Company is dependent upon additional financing which it may not be able to secure in the future.  As it has in the past, the Company will likely continue to require financing to address its working capital needs, continue its development efforts, support business operations, fund possible continuing operating losses, and respond to unanticipated capital requirements.  There can be no assurance that additional financing or capital will be available and, if available, upon acceptable terms and conditions.  To the extent that any required additional financing is not available on acceptable terms, the Company’s ability to continue in business may be jeopardized and the Company may need to curtail its operations and implement a plan to extend payables and reduce overhead until sufficient additional capital is raised to support further operations.  There can be no assurance that such a plan will be successful. Such a plan could have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations, liquidate and/or seek reorganization in bankruptcy.

The Company has been delinquent in filing certain income tax and information reporting returns.   The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, “Report of Foreign Bank and Financial Accounts” (“FBARs”). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs.  Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no underreported tax liabilities.  On November 30, 2017, the Company received a letter from the IRS concluding their review of the Company’s tax returns under the program and accepting the returns as filed.  No penalties have been assessed by the IRS to date, and management does not believe that the Company will incur any penalties relating to the tax years submitted under the program.

Our management is relatively inexperienced with running a public company and could create a risk of non-compliance.   Management’s inexperience may cause us to fall out of compliance with applicable regulatory requirements, which could lead to enforcement action against us and a negative impact on our stock price.

Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses and could create a risk of non-compliance.   Changing laws, regulations and standards relating to corporate governance and public disclosure have created uncertainty for public companies and significantly increased the costs and risks associated with accessing the public markets and public reporting. These corporate governance standards are the product of many sources, including, without limitation, public market perception, stock exchange regulations and SEC disclosure requirements. Our management team expects to invest significant management time and financial resources to comply with both existing and evolving standards for public companies, which will lead to increased general and administrative expenses and a diversion of management time and attention from revenue generating activities to compliance activities. Management’s inexperience may cause us to fall out of compliance with applicable regulatory requirements, which could lead to enforcement action against us and a negative impact on our stock price.

As a company with a class of securities registered pursuant to the Exchange Act the Company has significant obligations under the Exchange Act. Having a class of securities registered under the Exchange Act is a time consuming and expensive process and subjects the Company to increased regulatory scrutiny and extensive and complex regulation.  Complying with these regulations is expensive and requires a significant amount of management’s time.  For example, public companies are obligated to institute and maintain financial accounting controls and for the accuracy and completeness of their books and records.  These requirements could necessitate additional corporate spending on procedures and personnel requiring us to reallocate funds from other business objectives.

 

Risk Factors Related to Our Common Stock

The Company will face significant regulation by the SEC and state securities administrators.   The holders of shares of the Company’s common stock and preferred stock may not offer or sell the shares in private transactions or (should a public market develop, of which there can be no assurance) public transactions without compliance with regulations imposed by the SEC and various state securities administrators. To the extent that any holder desires to offer or sell any such shares, the holder must prove to the reasonable satisfaction of the Company that he has complied with all applicable securities regulations, and the Company may require an opinion of the holder’s legal counsel to that effect. Thus, there can be no assurance that the holder will be able to resell the shares or any interest therein when the holder desires to do so.

Our existing stockholders could experience further dilution if we elect to raise equity capital to meet our liquidity needs or finance a strategic transaction.   As part of our growth strategy we may desire to raise capital and or utilize our common stock to effect strategic business transactions.  Either such action will likely require that we issue equity (or debt) securities which would result in dilution to our existing stockholders.  Although we will attempt to minimize the dilutive impact of any future capital-raising activities or business transactions, we cannot offer any assurance that we will be able to do so.  If we are successful in raising additional working capital, we may have to issue additional shares of our common stock at prices at a discount from the then-current market price of our common stock.

 

 

9 
 

 

Because we have no plans to pay dividends on our common stock, investors must look solely to stock appreciation for a return on their investment in us.   We do not anticipate paying any cash dividends on our common stock in the foreseeable future.  We currently intend to retain all future earnings to fund the development and growth of our business.  Any payment of future dividends will be at the discretion of our board of directors and will depend on, among other things, our earnings, financial condition, capital requirements, level of indebtedness, statutory and contractual restrictions applying to the payment of dividends and other considerations that the board of directors deems relevant.  Investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize a return on their investment.  Investors seeking cash dividends should not purchase our common stock.

 

As our stock is not listed on a national securities exchange, trading in our shares will be subject to rules governing “penny stocks,” which will impair trading activity in our shares.   Our stock is not on a national securities exchange. Therefore, our stock is subject to rules adopted by the SEC regulating broker dealer practices in connection with transactions in “penny stocks.” Those disclosure rules applicable to “penny stocks” require a broker dealer, prior to a transaction in a “penny stock” not otherwise exempt from the rules, to deliver a standardized list disclosure document prepared by the SEC. That disclosure document advises an investor that investment in “penny stocks” can be very risky and that the investor’s salesperson or broker is not an impartial advisor but rather paid to sell the shares. The disclosure contains further warnings for the investor to exercise caution in connection with an investment in “penny stocks,” to independently investigate the security, as well as the salesperson with whom the investor is working and to understand the risky nature of an investment in this security. The broker dealer must also provide the customer with certain other information and must make a special written determination that the “penny stock” is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. Further, the rules require that, following the proposed transaction, the broker provide the customer with monthly account statements containing market information about the prices of the securities.

 

The over-the-counter market for stock such as ours is subject to extreme price and volume fluctuations. You may not be able to resell your shares at or above the public sale price. The securities of companies such as ours have historically experienced extreme price and volume fluctuations during certain periods. These broad market fluctuations and other factors, such as new product developments and trends in the industry and in the investment markets generally, as well as economic conditions and quarterly variations in our operational results, may have a negative effect on the market price of our common stock.

 

ITEM 1B.   UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2.   PROPERTIES

 

The Company’s principal executive office, for all operations during the year 2022 was at 412 Mulberry, Marietta, Oh 45750.

In January of 2023 the Company moved its executive office to109 W. Main St, Dalton, Ohio 44618.  The Company does not have a lease for its principal executive office but rents month to month. A lease on the space is held by the CFO’s company, The Guzzetta Company LLC.  The Company paid $1050 per month for the office ( $1,050 in 2021).  ProtoKinetix does not own any real property.  

 

ITEM 3.   LEGAL PROCEEDINGS

 

The Company and its management are not aware of any regulatory or legal proceedings or investigations pending involving the Company, any of its subsidiaries or affiliates, or any of their respective officers, directors or employees. 

 

ITEM 4.  MINE SAFETY MATTERS

 

Not applicable.

 

 

10 
 

PART II

 

ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock is currently quoted on OTCQB tier of the OTC Markets under the symbol “PKTX”.  The table below sets forth the high and low bid prices of the Company’s common stock during the periods indicated as reported on OTC Markets Inc. (www.otcmarkets.com).  The quotations are inter-dealer prices without retail markups, markdowns or commissions, and may not necessarily represent actual transactions.

 

2022  Low   High 
First Quarter  $0.040   $0.060 
Second Quarter   0.023    0.049 
Third Quarter   0.026    0.041 
Fourth Quarter   0.022    0.027 

 

         
2021  Low   High 
First Quarter  $0.081   $0.225 
Second Quarter   0.115    0.270 
Third Quarter   0.092    0.160 
Fourth Quarter   0.055    0.140 

 

Holders

 

As of March 17, 2023, there were approximately 115 stockholders of record of the Company’s common stock.  This does not include an indeterminate number of persons who hold our Common Stock in brokerage accounts and otherwise in “street name.”

 

Dividends

 

We have never paid cash dividends and have no plans to do so in the foreseeable future.  Our future dividend policy will be determined by our board of directors and will depend upon a number of factors, including our financial condition and performance, our cash needs and expansion plans, income tax consequences, and the restrictions that applicable laws, our current preferred stock instruments, and our future credit arrangements may then impose.

 

Adoption and Amendment of the 2017 Stock Option and Stock Bonus Plan

 

 On December 30, 2016, the Board of Directors of the Company the (“Board”) adopted the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”).  The Board adopted the 2017 Plan as it anticipates utilizing equity compensation as part of its ongoing standard corporate operations and in connection with its contemplated activities going forward.

 

On November 9, 2018, the Board amended the 2017 Stock Option and Stock Bonus Plan to increase the aggregate number of shares that may be issued under the 2017 Plan from 30,000,000 to 50,000,000 shares subject to adjustment as provided therein to continue to incentivize contractors and future employees (if any) of the Company (the amended 2017 Plan is hereinafter referred to as the “Amended 2017 Plan”).  On July 15, 2019, the Board again amended the Amended 2017 Plan to increase the aggregate number of shares that may be issued under the 2017 Plan from 50,000,000 to 89,700,000 shares. On April 6, 2020, the Board approved an amendment to the 2017 Plan to reduce the number of shares of common stock of the Company available for issuance pursuant to the 2017 Plan from 89,700,000 shares to 85,700,000 shares. On February 16, 2022, the Board approved an amendment to the 2017 Plan to increase the number of shares of common stock of the Company available for issuance pursuant to the 2017 Plan from 85,700,000 shares to 97,700,000 shares.

 

 

11 
 

The Amended 2017 Plan also provides for the ability of the Board to extend the exercise period of an option and provides for flexibility in the event of a change in control of the Company or consolidation or merger.

 

The Amended 2017 Plan is administered by the Board, or a committee appointed by the Board.  In addition to determining who will be granted options or bonuses, the committee has the authority and discretion to determine when options and bonuses will be granted and the number of options and bonuses to be granted.  The committee also may determine a vesting and/or forfeiture schedule for bonuses and/or options granted, the time or times when each option becomes exercisable, the duration of the exercise period for options and the form or forms of the agreements, certificates or other instruments evidencing grants made under the Amended 2017 Plan.  The committee may determine the purchase price of the shares of common stock covered by each option and determine the fair market value per share.  The committee also may impose additional conditions or restrictions not inconsistent with the provisions of the Amended 2017 Plan.  The committee may adopt, amend and rescind such rules and regulations as in its opinion may be advisable for the administration of the Amended 2017 Plan.

 

The committee also has the power to interpret the Amended 2017 Plan, and the provisions in the instruments evidencing grants made under it, and is empowered to make all other determinations deemed necessary or advisable for the administration of it.

 

Participants in the Amended 2017 Plan may be selected by the committee from employees, officers, consultants and advisors (including board members) of ProtoKinetix.  The committee may take into account the duties of persons selected, their present and potential contributions to the success of ProtoKinetix and such other considerations as the committee deems relevant to the purposes of the Amended 2017 Plan.

 

In the event of a change, such as a stock split, is made in the Company’s capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested bonuses and in the exercise price and in the number of shares subject to each outstanding option.  The committee also may make provisions for adjusting the number of bonuses or underlying outstanding options in the event the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of its outstanding common stock.  Options and bonuses may provide that in the event of the dissolution or liquidation of ProtoKinetix, a corporate separation or division or the merger or consolidation of ProtoKinetix, the holder may exercise the option on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the committee may provide that each option granted under the 2017 Plan shall terminate as of a date fixed by the committee.

 

The exercise price of any option granted under the Amended 2017 Plan must be no less than 100% of the “fair market value” of ProtoKinetix’s common stock on the date of grant.  Any incentive stock option granted under the Amended 2017 Plan to a person owning more than 10% of the total combined voting power of the common stock must be at a price of no less than 110% of the fair market value per share on the date of grant.

 

The exercise price of an option may be paid in cash, in shares of ProtoKinetix common stock or other property having a fair market value equal to the exercise price of the option, or in a combination of cash, shares, other securities and property.  The committee determines whether or not property other than cash or common stock may be used to purchase the shares underlying an option and shall determine the value of the property received.

 

 As of both December 31, 2022 and March 4, 2023, 97,700,000 options remain as granted under the Amended 2017 Plan.

 

 

12 
 

Securities Authorized for Issuance Under Equity Compensation Plans

 

The following table sets forth securities authorized for issuance under equity compensation plans, including but not limited to the Amended 2017 Plan and individual compensation arrangements as of December 31, 2022:

 

Plan category 

Number of securities

to be issued upon

exercise of outstanding options,

warrants and rights

  

Weighted-average

exercise price of

outstanding options, warrants and rights

  

Number of securities remaining available

for future issuance

under equity compensation plans (excluding securities

reflected in column (a))

 
    (a)    (b)    (c) 
Equity compensation plans approved by security holders   —      —      —   
Equity compensation plans not approved by security holders   107,590,000   $0.06    0 
Total   107,590,000   $0.06    0 

 

During the year ended December 31, 2022, warrants to purchase 13,300,000 shares of common stock of the Company were outstanding (see Note 6 of the notes to the financial statements).  As of the year ended December 31, 2022, there were warrants and options outstanding representing a total of 13,300,000 and 94,290,000 shares of common stock respectively to be issued upon exercise, of which: (i) options to purchase 94,290,000 shares of common stock were outstanding under the Amended 2017 Plan; and (ii) warrants outstanding to purchase 13,300,000 shares of common stock not pursuant to any plan.

 

Recent Sales of Unregistered Securities and Use of Proceeds

 

Between January 3, 2022 and February 8, 2022, the Company issued 2,136,666 shares at a price of $0.06 per share to accredited investors in a private placement for gross proceeds of $128,200. No solicitation was used in the offering. The Company relied on the exemption from registration available under Section 4(a)(2) of the 1933 Act and Rule 506(b) of Regulation D promulgated under the 1933 Act with respect to transactions by an issuer not involving any public offering.  No commissions were paid in connection with these issuances of securities.  The Company filed a Form D with the SEC on December 28, 2021, and an Amended Form D was filed on January 12, 2022 and February 25, 2022.

Between March 18, 2022 and May 11, 2022, the Company issued 7,300,000 units to accredited investors in a private placement for gross proceeds of $365,000, of which Clarence Smith purchased 1,600,000 units. Each unit consists of one common share and one warrant immediately exercisable to purchase one common share at an exercise price of $0.05 expiring March 14, 2024. No solicitation was used in the offering. The Company relied on the exemption from registration available under Section 4(a)(2) of the 1933 Act and Rule 506(b) of Regulation D promulgated under the 1933 Act with respect to transactions by an issuer not involving any public offering.  No commissions were paid in connection with these issuances of securities.  The Company filed a Form D with the SEC on April 1, 2022 and an amended Form D on May 18, 2022.

 

Between July 11, 2022 and September 30, 2022, the Company issued 7,500,000 shares of common stock to accredited investors in a private placement for gross proceeds of $225,000, of which Clarence Smith purchased 6,000,000 shares of common stock. Each share of common stock had a purchase price of $0.03. No solicitation was used in the offering. The Company relied on the exemption from registration available under Section 4(a)(2) of the 1933 Act and Rule 506(b) of Regulation D promulgated under the 1933 Act with respect to transactions by an issuer not involving any public offering.  No commissions were paid in connection with these issuances of securities. The Company filed a Form D with the SEC on July 26, 2022 and an amended Form D on October 14, 2022.

 

Between December 8, 2022 and December 27, 2022, the Company issued 3,100,000 shares of common stock to accredited investors in a private placement for gross proceeds of $77,500, of which Clarence Smith purchased 2,520,000 shares of common stock. Each share of common stock had a purchase price of $0.025. No solicitation was used in the offering. The Company relied on the exemption from registration available under Section 4(a)(2) of the 1933 Act and Rule 506(b) of Regulation D promulgated under the 1933 Act with respect to transactions by an issuer not involving any public offering.  No commissions were paid in connection with these issuances of securities. The Company filed a Form D with the SEC on December 23, 2022.

 

On December 30, 2022 the Company issued 5,450,000 shares of common stock to accredited investors in a private placement for gross proceeds of $109,000, of which Clarence Smith purchased 1,850,000 shares of common stock. Each share of common stock had a purchase price of $0.02. No solicitation was used in the offering. The Company relied on the exemption from registration available under Section 4(a)(2) of the 1933 Act and Rule 506(b) of Regulation D promulgated under the 1933 Act with respect to transactions by an issuer not involving any public offering.  No commissions were paid in connection with these issuances of securities. The Company filed a Form D with the SEC on January 6, 2023.

 

   

 

13 
 

ITEM 6.   [RESERVED]

 

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion provides information regarding the results of operations for the years ended December 31, 2022 and 2021, and our financial condition, liquidity and capital resources as of December 31, 2022 and 2021. The financial statements and the notes thereto contain detailed information that should be referred to in conjunction with this discussion.

 

The following discussion and analysis should be read in conjunction with and our historical financial statements and the accompanying notes included elsewhere in this Annual Report on Form 10-K, as well as the Risk Factors and the Cautionary Note Regarding Forward-Looking Statements included above.

 

Results of Operations

 

   For the Years Ended 
   2022   2021 
         
Operating Expenses          
Amortization  $58,450   $3,000 
General and Administrative   162,749    316,995 
Professional Fees   166,254    160,388 
Research and Development   448,873    435,872 
Share-Based Compensation   1,070,983    1,413,055 
Total operating expenses   1,907,309    2,329,310 
Loss from Operations   (1,907,309)   (2,329,310)
           
Net Loss  $(1,907,309)  $(2,329,310)

 

Revenues

 

We had no revenues for the years ended December 31, 2022 and 2021.

 

Gross profit and expenses

 

The Company’s net loss was $1,907,309 for the year ending December 31, 2022 compared to $2,329,310 for the year ending December 31, 2021.  These expenses were primarily incurred for professional fees, share-based compensation related to the operations of the Company’s business, research and development and other general and administrative expenses.  Significant changes from the prior year include:

 

  · Professional fees decreased by $5,866, year over year going to $166,254 from $160,388 as legal and auditing fees each contributed to a small increase , while accounting activity remained unchanged over prior year totals.

 

  · Share-based compensation decreased by $342,072 from $1,413,055 to $1,070,983 primarily because of a the revaluation of existing options granted.  In 2020 the Company adopted a change in accounting based on new FASB guidance for valuation of share-based payments to non-employees.   

 

  · Research and development increased slightly by $13,001 from $435,872 to $448,873 as the Company finished existing test projects and moves toward leveraging the positive study findings. Any new projects will be targeted investments  expanding the development of the AAGP® molecule through institutional collaborations and industry partnerships.

 

  · General and administrative expenses decreased throughout the year by $154,246 from $316,995 to $162,749 due to the significant decrease in spending on marketing, press releases and social media exposure. Majority of new information is currently released through updates to Company website.

 

Our expenses in 2022 were $1,907,309 which included $166,254 in professional fees. We operate the Company by hiring outside consultants to assist us with management, strategic planning, organization and daily operations.  This resulted in $1,070,983 in share-based compensation recognized based on the fair value of equity instruments granted as compensation.  These professional consulting services are related to marketing, accounting, merger opportunities as well as research development services.  The Company also incurred total research and development expenses of $448,873 and general and administrative costs of $162,749 during the year ended December 31, 2022.

 

 

14 
 

 

Liquidity and Capital Resources

 

   As at 
   December 31, 
   2022   2021 
         
Cash  $25,550   $57,568 
           
Working Capital  $(14,930)  $(9,705)

 

At December 31, 2022, we had $25,550 in cash and $26,600 in total current assets.  As of December 31, 2022, we had a working capital equity deficit position of $14,930.  Although as of the date of this Annual Report we believe we have sufficient capital to meet cash flow projections and carry forward our business objectives in the short-term, the Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities.  There can be no assurance that in the future we will be able to raise capital from outside sources in sufficient amounts to fund our business.

 

The failure to secure adequate outside funding would have an adverse effect on our plan of operation and results therefrom and a corresponding negative impact on stockholder liquidity.

 

Sources and Uses of Cash for the Years ended December 31, 2022 and 2021

 

Net Cash Used in Operating Activities

 

During the year ended December 31, 2022, net cash used in operating activities decreased $85,222 from $889,891 to $804,669 for the years ended December 31, 2021 and 2022, respectively. This decrease was predominantly due to the overall decreased spending on web marketing, news releases, and social media. Informative updates have been posted on the Company website, reducing the need news releases.

 

Net Cash Used in Investing Activities

 

During the year ended December 31, 2022, net cash used in investing activities increased by $41,064 primarily from the increase in patent application spending due to expansion of patent family. Net cash from investing activities for the year ended December 31, 2021 was $90,985.  Net cash used for investing activities for the year ended December 31, 2022 was $132,049.

 

Net Cash Provided by Financing Activities

 

During the year ended December 31, 2022, net cash provided by financing activities increased by $59,700 from $845,000 to $904,700 for the years ended December 31, 2021 and 2022 respectively. This increase was predominantly due to an increase in private placements completed.

 

Going Concern

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), which contemplate continuation of the Company as a going concern.  The history of losses and the potential inability for the Company to make a profit from selling a good or service has raised substantial doubt about our ability to continue as a going concern. In spite of the fact that the current cash obligations of the Company are relatively minimal, given the cash position of the Company, we have very little cash to operate. We intend to fund the Company and attempt to meet corporate obligations by selling common stock.  However, the Company’s common stock is at a low price and trading is not consistent.

 

Off-Balance Sheet Arrangements

 

None.

 

 

15 
 

Contractual Obligations

 

As a smaller reporting company, we are not required to provide the information required by paragraph (a)(5) of this Item.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements.

 

Our management routinely makes judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operation and/or financial condition. Our significant accounting policies are disclosed in Note 2 to the Financial Statements included in this Form 10-K.

 

While all of the significant accounting policies are important to the Company’s financial statements, the following accounting policies and the estimates derived there from have been identified as being critical.

 

Share-Based Compensation

 

The Company has granted warrants and options to purchase shares of the Company’s common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

 

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance.

 

Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

 

Intangible Assets – Patent and Patent Application Costs

 

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. The Company capitalizes its patent application costs. All other expenditures are recognized in profit or loss as incurred.

 

As at December 31, 2022, the Company does not hold any intangible assets with indefinite lives.

 

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.

 

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.

 

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at December 31, 2022.

 

Sales and Marketing

 

The Company is currently not selling or marketing any products.

 

Inflation

 

Although management expects that our operations will be influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the year ending December 31, 2022.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, we are not required to provide the information required by this item.

 

 

16 
 

ITEM 8.   FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

The information required by this Item begins on page F-1 of this Annual Report on Form 10-K and is incorporated into this part by reference. 

 

 

ITEM 9.     CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.   CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the 1934 Act is accumulated and communicated to management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Our management, under the direction of our Chief Executive Officer (who is our principal executive officer), and Chief Financial Officer (who is our principal accounting officer) has evaluated the effectiveness of our disclosure controls and procedures as required by 1934 Act Rule 13a-15(b) as of December 31, 2022 (the end of the period covered by this report). Based on that evaluation, our principal executive officer and our principal accounting officer concluded that these disclosure controls and procedures are not effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosure and are not effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

 

The Company, including its Chief Executive Officer and Chief Financial Officer, does not expect that its internal controls and procedures will prevent or detect all error and all fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

In accordance with Item 308 of SEC Regulation S-K, management is required to provide an annual report regarding internal controls over our financial reporting. This report, which includes management’s assessment of the effectiveness of our internal controls over financial reporting, is found below. Inasmuch as the Company is neither an accelerated filer nor a large accelerated filer, the Company is not obligated to provide an attestation report on the Company’s internal control over financial reporting by the Company’s registered public accounting firm.

 

Internal Control Over Financial Reporting

 

Our management is also responsible for establishing and maintaining adequate internal control over financial reporting (“ICFR”) as defined in Rules 13a-15(f) and 15d-15(f) under the 1934 Act. Our ICFR are intended to be designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.  Our ICFR are expected to include those policies and procedures that management believes are necessary that:

 

  (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
  (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures of the Company are being made only in accordance with proper authorizations of management and our directors; and
  (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

  

 

 

17 
 

 

Management recognizes that there are inherent limitations in the effectiveness of any system of internal control, and accordingly, even effective internal control can provide only reasonable assurance with respect of financial statement preparation and may not prevent or detect misstatements. In addition, effective internal control at a point in time may become ineffective in future periods because of changes in conditions or due to deterioration in the degree of compliance with our established policies and procedures.

 

As of December 31, 2022, management (with the participation of the Chief Executive Officer and the Chief Financial Officer) conducted an evaluation of the effectiveness of the Company’s ICFR based on the framework set forth in Internal Control--Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and SEC guidance on conducting such assessments by smaller reporting companies and non-accelerated filers. Based on that assessment, management (with the participation of the Chief Executive Officer and the Chief Financial Officer) concluded that, during the period covered by this report, such internal controls and procedures were not effective as of December 31, 2021.

 

Material Weaknesses Identified

 

In connection with the preparation of our financial statements for the year ended December 31, 2022, certain significant deficiencies in internal control became evident to management that, in the aggregate, represent material weaknesses, which include the following:

 

Insufficient segregation of duties in our finance and accounting functions due to limited personnel.  During the year ended December 31, 2021, we used outside services to perform all aspects of our financial reporting process, including, but not limited to, access to the underlying accounting records and systems, the ability to post and record journal entries and responsibility for the preparation of the financial statements.  This creates a lack of review over the financial reporting process that would likely result in a failure to detect errors in spreadsheets, calculations, or assumptions used to compile the financial statements and related disclosures as filed with the SEC.  These control deficiencies could result in a material misstatement to our interim or annual financial statements that would not be prevented or detected.

 

Insufficient corporate governance policies.  Although we have a code of ethics which provides broad guidelines for corporate governance, our corporate governance activities and processes are not always formally documented.  Specifically, decisions made by our Board of Directors to be carried out by management should be documented and communicated on a timely basis to reduce the likelihood of any misunderstandings regarding key decisions affecting our operations and management.

 

Plan for Remediation of Material Weaknesses

 

We intend to take appropriate and reasonable steps to make the necessary improvements to remediate these deficiencies provided that we have the resources to implement them.

 

This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting.  Management’s report is not subject to attestation by our registered public accounting firm.

 

There was no change in our internal control over financial reporting that occurred during the year ended December 31, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B.   OTHER INFORMATION

 

On February 11, 2022, the Company held its first annual stockholder meeting. The meeting was held solely by means of remote communication due to COVID-19 concerns. At the meeting, the Company: (i) elected Clarence Smith and Ed McDonough as directors of the Company; (ii) approved the amendment and restatement of the Company’s Articles of Incorporation to, among other things, increase the number of authorized shares of common stock to 500,000,000; (iii) voted, in an advisory vote, to approve the compensation of the Company’s named executive officers; (iv) voted, in an advisory vote, to conduct an advisory vote on compensation of the Company’s named executive officers every three years; and (v) approved the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the Company’s independent accounting firm for the 2022 fiscal year.

Between January 20, 2023 and February 11, 2023, the Company issued 4,000,000 shares of common stock to accredited investors in a private placement for gross proceeds of $80,000, of which Clarence Smith purchased 2,000,000 shares of common stock. Each share of common stock had a purchase price of $0.02. No solicitation was used in the offering. The Company relied on the exemption from registration available under Section 4(a)(2) of the 1933 Act and Rule 506(b) of Regulation D promulgated under the 1933 Act with respect to transactions by an issuer not involving any public offering.  No commissions were paid in connection with these issuances of securities. The Company filed a Form D with the SEC on January 6, 2023 and filed an amended Form D on February 7, 2023.

ITEM 9C.   DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

 

 

18 
 

PART III

 

ITEM 10.   DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CORPORATE GOVERNANCE

 

As of March 17, 2023, the Company’s current officers and directors consist of the following persons:

 

Name   Age   Title   Year Appointed
Clarence E. Smith     59   Chairman, Chief Executive Officer, President   February 2015
          Director   June 2014
               
Michael R Guzzetta     65   Chief Financial Officer   November 2017
               
Edward P. McDonough     70   Director   July 2015

 

Clarence E. Smith was appointed President and Chief Executive Officer for the Company on February 19, 2015 and was previously appointed a member of the Board of Directors of the Company on June 1, 2014.  Prior to joining the Company as President and CEO, Mr. Smith served and continues to serve as managing member of Tombstone Resources and Smith Equipment, LLC, a privately held company that holds operating oil and gas wells and Smith Equipment Company, a privately held company that leases out construction equipment.  In 1981, Mr. Smith started Arvilla Well Service in West Virginia which provided construction services to oil and gas companies in the Appalachian Basin.  After merging Arvilla Well Service into Arvilla Pipeline Construction Co., Inc., Mr. Smith sold the company in 2008.  Mr. Smith also purchased Arrow Oilfield Services in 2004, which was renamed Arvilla Oilfield Services, LLC and subsequently merged with Trans Energy, a publicly traded company in 2004.  Mr. Smith served as Chairman of the Board and CEO of Trans Energy, Inc. from 2005 to 2006.  Mr. Smith graduated from St. Marys High School in West Virginia in 1981.

 

Michael R. Guzzetta was appointed Chief Financial Officer of the Company on November 14, 2017.  Mr. Guzzetta is a Certified Public Accountant with a practice located in Central & Northeast Ohio providing services including business and individual taxation, non-profit accounting, corporate policy and procedure development, business organization and consulting.  Prior to opening his practice, he spent 20 years in corporate management in the communications and energy industries.  Between 2014 and 2015, Mr. Guzzetta served as Treasurer and principal financial officer of Trans Energy Inc., a publicly traded energy company, where his responsibilities included corporate banking, risk management, maintaining fiscal control, budgeting, taxation and SEC reporting.  His prior positions include Midwest Region Business Manager for a Fortune 100 company and Controller for an energy marketing company.  Mr. Guzzetta also served as an Adjunct Professor at Stark State College and taught courses in accounting, finance, business management, and economics.  He is a graduate of Walsh University where he graduated Magna Cum Laude with a BA in Accounting.  He earned his MBA from Capital University in Columbus, Ohio.  Mr. Guzzetta has been a past member of both the Ohio Society of Certified Public Accountants and the American Institute of Certified Public Accountants.  He has served on the boards of the Canton Ballet, the ALS CARE Project and the Finance Committee of Stark County Board of Developmental Disabilities.

 

Edward P. McDonough was appointed as a member of the Board of Directors of the Company on July 1, 2015.  In addition to serving as a director of the Company, Mr. McDonough is a managing shareholder and President of McDonough, Eddy, Parsons & Baylous, A.C., a certified public accountant firm in Parkersburg, West Virginia since 1985.  The firm originated in the early 1950s, employs 15 professional certified public accountants and accountants, and serves as certified public accountants for approximately 400 private corporations, firms, and individuals in various commercial, business, professional, and industrial fields.  Mr. McDonough became a Certified Public Accountant in 1978, a Certified Valuation Analyst in 1996, and a Chartered Global Management Accountant in 2012.  Since 1986, Mr. McDonough has served as a Director and Chairman of the Board of Community Bank of Parkersburg, held by Community Bankshares, Inc.  He is also a Member of the American Institute of Certified Public Accountants (AICPA), has served as a Past President and Member of the West Virginia Board of Accountancy, is a Life Member, Past Director and Past President of the West Virginia Society of Certified Public Accountants and is a Member and Past President of the Parkersburg Chapter of the West Virginia Society of CPAs.  Mr. McDonough acquired his Bachelor of Science in Business Administration with a Major in Accounting at West Virginia University in Morgantown, West Virginia in 1973.

  

 

19 
 

Family Relationships

 

There are no family relationships among any of our executive officers and directors.

 

Term of Office

 

Each director shall hold office until the next annual meeting of stockholders or until his successor shall have been elected and qualified, or until there is a decrease in the number of directors.

 

Involvement in Legal Proceedings

 

See Item 3—Legal Proceedings.

 

Corporate Governance

 

Code of Ethics

 

On July 8, 2019, the Board adopted a new Code of Business Conduct and Ethics and Whistleblower Policy (“Code of Ethics”) which replaced in its entirety the Company’s prior code of ethics. The Code of Ethics applies to all directors, officers, employees and consultants of the Company and amends and restates the Company’s prior code of ethics to update certain provisions for business and regulatory developments and to provide additional guidance and greater detail on certain issues such as conflicts of interest, reporting illegal or unethical behavior, confidentiality and use of the Company’s assets, and hedging of Company securities. The Board also approved an insider trading policy, related party transactions policy, and policy on trading blackout periods, benefit plans and SEC reporting.

 

Committees of the Board of Directors

 

The Company does not currently have a separately designated audit committee.  Instead, the Board of Directors as a whole acts as the Company’s audit committee.  Consequently, the Company does not currently have a designated audit committee financial expert.

 

The Company also does not have a separately designated compensation committee. To date, the Company has not retained an independent compensation advisor to assist the Company review and analyze the structure and terms of the Company’s executive officers.

 

Independent Directors

 

The Board of Directors has determined that Mr. McDonough is the only independent member of the Board of Directors of the Company pursuant to SEC Rule 10A-3(b)(1).

 

Business and Scientific Advisory Board

 

Our Business and Scientific Advisory Board exists to assist the Board of Directors with understanding both the regulatory and business aspects of the biopharmaceutical industry are particularly valuable for the expansion and commercialization of AAGP® applications.  The members on the board are:

 

  · Dr. Julia Levy, PhD, Chairman, Business and Scientific Advisory Board.  Dr. Levy is a founder, former President and former Chief Scientific Officer of QLT, Inc., where she and her colleagues developed the first medical treatment for macular degeneration, a leading cause of blindness among the elderly. She has received numerous awards and honorary degrees.  In her honor the Julia Levy B.C. Leadership Chair in Macular Research at the University of British Columbia was established.

 

  · Mr. Peter Jensen, former director of the Company.

 

 

20 
 

  

Delinquent Section 16(a) Reports

 

Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), requires the Company’s directors, executive officers and holders of more than 10% of the Company’s common stock to file with the Securities and Exchange Commission initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company.  To our knowledge, based solely on a review of copies of Forms 3, 4 and 5 and any amendments thereto filed with the Securities and Exchange Commission and stockholder reports from our transfer agent and written representations that no other reports were required, during the fiscal year ended December 31, 2022 our officers, directors and 10% or more stockholders complied with all Section 16(a) filing requirements applicable to them except that: Mr. Smith filed four Forms 4 late representing eight transactions not reported on a timely basis.

 

ITEM 11.      EXECUTIVE COMPENSATION

 

The following table summarizes the annual compensation paid to ProtoKinetix’s named executive officers for the two years ended December 31, 2022 and 2021:

 

Summary Compensation Table for Executive Officers

 

Name and Principal Position

Fiscal

Year

 

Salary

($)

 

Bonus

($)

 

Stock

Awards

($)

 

Option

Awards(1)

($)

 

Non-equity

Incentive

Plan

Compensation

($)

 

Nonqualified

Deferred

Compensation

Earnings

($)

 

All Other

Compensation

($)

 

Total

($)

Clarence E. Smith                                  
President & CEO

 

2022

  -     -     -     1,037,384     -     -     -     1,037,384
  2021   -     -     -     131,494     -     -     -     131,494
Michael R. Guzzetta                                                
Chief Financial Officer

 

 

2022

  60,000     -     -     405,974     -     -     -     465,974
  2021   60,000     -     -     13,149     -     -     -     73,149

 

(1)    Represents the grant date full fair value of compensation costs of stock options granted during the respective year for financial statement reporting purposes, using the Black-Scholes option pricing model. Assumptions used in the calculation of these amounts are included in the Company’s consolidated financial statements. Refer to the Outstanding Equity Awards at Fiscal Year End schedule regarding option details on an award-by-award basis.

 

Consulting Agreements

 

We have entered into consulting agreements with certain Company officers as set forth below.

 

Clarence E. Smith – Mr. Smith is Chief Executive Officer and President of the Company.  He entered into a consulting agreement with the Company dated December 30, 2016 (effective January 1, 2017) (the “2017 Smith Agreement”).

 

The 2017 Smith Agreement provides for a one-year term through December 31, 2017 and for an annual salary of $1.00.  Mr. Smith is entitled to receive a bonus payment equal to 2.5% of the aggregate value of any application sale or license of any patent rights or products effected during the term of the 2017 Smith Agreement.

 

Mr. Smith is also entitled to a termination fee if the agreement is terminated for the following two reasons:

 

  · A termination without cause:  If Mr. Smith is terminated without cause he will be entitled to a termination fee of $100,000 per year of service (including the pro-rata amount for partial years of service);

 

  · A termination upon a change of control event:  Following a change of control event he will be entitled to a termination fee equal to $100,000 per year of service (including the pro-rata amount for partial years of service) plus 2.5% of the aggregate transaction value of the change of control.

 

On September 1, 2017, Mr. Smith and the Company entered into an amendment to the 2017 Smith Agreement (the “September Amendment”), whereby the term of the agreement was extended from December 31, 2017 to December 31, 2018 and automatically renews for one-year increments under the same terms and conditions of the 2017 Smith Agreement, unless either party gives written notice to the other party at least 30 days prior to the end of such calendar year.

 

On December 7, 2022, in connection with Mr. Smith’s continued service to the Company, the Company cancelled, and concurrently replaced 32,350,000 stock options previously issued to Mr. Smith pursuant to the Company’s Amended 2017 Plan between 2021 to 2022 at exercise prices between $0.06 and $0.11 per share. The replacement options are fully vested and have a term of 6 years, exercisable at a price of $0.028 per share, expiring on December 6, 2028.

 

Please refer to “Outstanding Equity Awards at Fiscal Year-End” for a description of the option grants issued to Mr. Smith during 2022.

 

 

21 
 

Michael R. Guzzetta – Mr. Guzzetta is Chief Financial Officer of the Company.  He entered into a consulting agreement with the Company dated November 14, 2017. The consulting agreement term is from November 14, 2017 to December 1, 2018, with automatic renewal in one-year increments with both parties having a right to terminate by giving either party notice 30 days prior to the end of the term. It also provides for a monthly consulting fee of $5,000. In 2022, the Company paid Mr. Guzzetta $60,000 in consulting fees, and reimbursed The Guzzetta Company LLC $11,025 in office rent. In 2021, he received $60,000 in consulting fees and The Guzzetta Company LLC was reimbursed $12,600 for office rent of $1,050 monthly.

 

On December 7, 2022, in connection with Mr. Guzzetta’s continued service to the Company, the Company cancelled, and concurrently replaced 13,260,000 stock options previously issued to Mr. Guzzetta pursuant to the Company’s Amended 2017 Plan between 2018 to 2021 at various exercise prices between $0.06 and $0.11 per share. The replacement options are fully vested and have a term of 6 years, exercisable at a price of $0.028 per share, expiring on December 6, 2028.

 

Please refer to “Outstanding Equity Awards at Fiscal Year-End” for a description of the option grants issued to Mr. Guzzetta during 2022.

 

Outstanding Equity Awards at Fiscal Year-End

 

The following table provides information as to option awards held by each of the named executive officers of ProtoKinetix

as of December 31, 2022.

 

Name 

Number of

Securities

Underlying

Unexercised Options

(#)

Exercisable

  

Number of

Securities

Underlying

Unexercised Options

(#)

Unexercisable

  

Option

Exercise

Price

($)

  

Option

Expiration

Date

                   
Clarence E. Smith   32,350,000 (1)   —      0.028       12/06/2028
                   
Michael R. Guzzetta   13,260,000 (2)   —      0.028   12/06/2028

 

(1) Represents options cancelled, and subsequently regranted pursuant to the Amended 2017 Plan on December 7, 2022 at $0.028 per share, fully vested.
(2) Represents options cancelled, and subsequently regranted pursuant to the Amended 2017 Plan on December 7, 2022 at $0.028 per share, fully vested.

Director Compensation

The following table sets forth a summary of the compensation earned by each non-employee director who served on the Board during the fiscal year ended December 31, 2022:

 

   Director Compensation 
  

Fees

Earned or Paid in Cash

   Bonus    

Stock

Awards (1)

    

Option

Awards (2)

    

Nonequity

Incentive

Plan

Compensation

    

Nonqualified

Deferred

Compensation

Earnings

    

All Other

Compensation

    Total 
   ($)   ($)    ($)    ($)    ($)    ($)    ($)    ($) 
Edward P. McDonough     —      —      682,091    —      —      —      682,091 

 

 

  (1)    The aggregate grant date fair value of these stock awards was computed in accordance with ASC 718.

 

  (2)   

Represents the grant date full fair value of compensation costs of stock options granted during the respective year for financial statement reporting purposes, using the Black-Scholes Option Pricing Model. Assumptions used in the calculation of these amounts are included in the Company’s audited financial statements.

 

  (3)

As of December 31, 2022, Mr. McDonough held options to acquire 7,500,000 shares of the Company’s common stock, all of which were vested and exercisable and expire on December 6, 2028.

 

On or about December 30, 2016, the Company entered into a new consulting agreement with Mr. McDonough, effective January 1, 2017 (the “2017 McDonough Agreement”).

 

On September 1, 2017, the Company entered into an amendment to the 2017 McDonough Agreement, effective immediately. This new agreement is effective through December 31, 2018, but shall automatically renew for one-year increments under the same terms and conditions of the 2017 McDonough Agreement unless by stockholder vote or 30 days prior to the end of such calendar year written notice is given by either party to the other notifying them of a desire to terminate.

 

On December 7, 2022, in connection with Mr. McDonough’s continued service to the Company, the Company cancelled, and concurrently replaced 7,500,000 stock options previously issued to Mr. McDonough pursuant to the Company’s Amended 2017 Plan between 2018 to 2020 at various exercise prices between $0.06 and $0.11 per share. The replacement options are fully vested and have a term of 6 years, exercisable at a price of $0.028 per share, expiring on December 6, 2028

 

 

22 
 

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth certain information regarding our shares of common stock beneficially owned as of March 17, 2023, for (i) each stockholder known to be the beneficial owner of more than 5% of our outstanding shares of common stock (ii) each named executive officer and director, and (iii) all executive officers and directors as a group.  A person is considered to beneficially own any shares: (a) over which such person, directly or indirectly, exercises sole or shared voting or investment power, or (b) of which such person has the right to acquire beneficial ownership at any time within 60 days through an exercise of stock options, warrants or convertible debt. Shares underlying such options, warrants, and convertible promissory notes, however, are only considered outstanding for the purpose of computing the percentage ownership of that person and are not considered outstanding when computing the percentage ownership of any other person. Unless otherwise indicated, voting and investment power relating to the shares shown in the table for our directors and executive officers is exercised solely by the beneficial owner or shared by the owner and the owner’s spouse or children.

 

Name & Address of Beneficial Owner  

Amount and

Nature of

Beneficial

Ownership

   

Beneficial

Ownership

Percentage

as of

March 17, 2023 (1)

More than 5% Stockholders                
Grant Young (2)     52,301,250       14.2 %
 Alexandra Smith (3)     27,700,776       8.5 %
John & Edith Smith(4)     21,458,709        6.6 %
                 
Directors and Named Executive Officers                
Clarence E. Smith(5)     93,337,092       25.9 %
Michael R. Guzzetta(6)     13,976,369       4.1 %
Edward P. McDonough(7)     7,500,000       2.2 %
All directors and executive officers as a group:     114,813,461       32.22 %

 

  (1)    Based on 326,880,151 shares of common stock outstanding on March 17, 2023, and, with respect to each individual holder, rights to acquire common stock exercisable within 60 days of March 17, 2023.

 

  (2)    Consists of 10,021,250 shares of common stock owned by Mr. Young directly; the right to acquire 6,000,000 shares of common stock upon warrant exercise; the right to acquire 36,280,000 shares of common stock upon option exercise.

 

  (3)    Consists of 27,700,776 shares of common stock owned by Alexandra Smith directly. 

 

  (4)    Consists of 21,458,709 shares of common stock owned by John and Edith Smith JTWROS.

 

  (5)    Consists of 43,964,443 shares of common stock owned by Mr. Smith directly, 13,572,649 held by Mr. Smith’s trusts, 1,850,000 held by Mr. Smith’s retirement account, the right to acquire 32,350,000 shares of common stock upon option exercise, and the right to acquire 1,600,000 shares upon warrant exercise. 

 

  (6)    Consists of 716,369 shares of common stock owned by Mr. Guzzetta directly, and 13,260,000 shares of common stock issuable upon the exercise of stock options.

 

  (7)     Consists of 7,500,000 shares of common stock issuable upon the exercise of stock options. 

 

 

 

23 
 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

The following is a description of transactions during the last fiscal year in which the transaction involved a material dollar amount and in which any of the Company’s directors, executive officers or holders of more than 5% of the Company’s common stock had or will have a direct or indirect material interest, other than compensation which is described under “Executive Compensation.” Management believes the terms obtained or consideration that was paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in arms’ length transactions:

Pursuant to a consulting agreement with an effective date of November 14, 2017, a total of $60,000 (2020 - $60,000) was paid or accrued to the Company’s CFO. During the year ended December 31, 2022, the Company reimbursed a company controlled by the CFO a total of $11,025 (2021 - $12,600) in office rent.

On December 7, 2022, the Company cancelled and concurrently replaced 32,350,000 stock options previously issued to the Company’s CEO and a Director of the Company from 2021 to 2022. The modification incremental fair value of $80,105 was recognized in the current period. The 32,350,000 replacement options and a term of 6 years, exercisable at a price of $0.28 per share, expiring on December 6, 2028.

On December 7, 2022, the Company cancelled and concurrently replaced 13,260,000 stock options previously issued to the Company’s CFO and a Director of the Company from 2018 to 2022. The modification incremental fair value of $82,398 was recognized in the current period. The 13,260,000 replacement options granted have a term of 6 years, exercisable at a price of $0.028 per share, expiring on December 6, 2028.

 

On December 7, 2022, the Company cancelled and concurrently replaced 7,500,000 stock options previously issued to a director of the Company from 2018 to 2022. The modification incremental fair value of $24,524 was recognized in the current period The 7,500,000 replacement options granted are fully vested and have a term of 6 years, exercisable at a price of $0.028 per share, expiring on December 6, 2028.

 

On December 7, 2022, in connection with a consultant’s continued service to the Company, the Company cancelled, and concurrently replaced 36,280,000 stock options previously issued to the consultant pursuant to the Company’s Amended 2017 Plan between 2018 to 2021 at various exercise prices between $0.06 and $0.11 per share. The replacement options are fully vested and have a term of 6 years, exercisable at a price of $0.028 per share, expiring on December 6, 2028.

 

Please refer to “Recent Sales of Unregistered Securities and Use of Proceeds” for a description of the securities purchased by Mr. Smith during 2022.

 

Please refer to “Outstanding Equity Awards at Fiscal Year-End” for a description of the option grants issued to Mr. Smith and Mr. Guzzetta during 2022.

 

 

24 
 

ITEM 14.       PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Audit Fees

 

For the years ended December 31, 2022 and 2021, Davidson & Company LLP, Chartered Professional Accountants (“Davidson”) the Company’s principal accountants billed the Company $28,847 and $28,500, respectively for fees for the audit of the Company’s annual financial statements.  All amounts are in U.S. dollars.

 

Audit-Related Fees

 

For the years ended December 31, 2022 and 2021, Davidson did not provide the Company with any assurances or related services reasonably related to the performance of the audit or review of the Company’s financial statements and are not reported above under “Audit Fees.”

 

Tax Fees

 

For the years ended December 31, 2022 and 2021, Davidson billed $3,500 in 2022 and $3,500 in 2021 for professional services for tax compliance, tax advice, and tax planning.

 

All Other Fees

 

For the years ended December 31, 2021 and 2020, Davidson did not bill the Company for fees associated with the preparation and filing of the Company’s registration statements, the creation of pro forma financial statements and other related matters.

 

For the years ended December 31, 2022 and 2021, Davidson billed the Company $25,293 and $23,837 for fees for the review of the Company’s quarterly financial statements.  All amounts are in U.S. dollars.

 

Audit Committee Pre-Approval Policies

 

The Company currently does not have a formal audit committee.  The Company’s Board of Directors currently approves in advance all audit and non-audit related services performed by the Company’s principal accountants and appointed Ed McDonough as the responsible director to review all financial information of the Company and correspond with the independent auditors regarding the same.

 

 

25 
 

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENTS AND SCHEDULE

EXHIBIT INDEX

The following documents are being filed with the Commission as exhibits to this Annual Report on Form 10-K.

 

Exhibit   Description
3.1   Amended and Restated Articles of Incorporation as filed on February 16, 2022(1).
3.2   Amended and Restated Bylaws of the Company as approved on December 20, 2021(2)
4.1   Amended 2017 Stock Option and Stock Bonus Plan(3)
4.2   Amendment to Amended 2017 Stock Option and Stock Bonus Plan as approved on July 15, 2019(6)
4.3   Amendment to Amended 2017 Stock Option and Stock Bonus Plan as approved on April 6, 2020(10)
4.4   Consultant Warrant*
4.5   Form of Warrant*
4.6   Description of our Securities*
10.1   Royalty Agreement between the Company and The Governors of the University of Alberta, dated April 8, 2015(4) 
10.2   Collaborative Research Agreement between the Company and the University of British Columbia, dated May 31, 2016(5) 
10.3   Consulting Agreement between the Company and Clarence E. Smith, dated December 30, 2016(7)
10.4   Director Consulting Agreement between the Company and Edward P. McDonough, dated December 30, 2016(7)
10.5   Consulting Agreement between the Company and Grant Young, dated December 30, 2016(8)
10.6   First Amendment to Consulting Agreement between Clarence E. Smith and the Company dated September 1, 2017(9)
10.7   First Amendment to Consulting Agreement between Grant Young and the Company dated September 1, 2017(9)
10.8   First Amendment to Consulting Agreement between Edward P. McDonough and the Company dated September 1, 2017(9)
10.9   Consulting Agreement between ProtoKinetix Incorporated and Michael Guzzetta, dated November 14, 2017(11)
31.1   Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2   Certification of the Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1   Certification of the Principal Executive Officer and the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101.INS   XBRL Instance Document
101.SCH   XBRL Schema Document 
101.CAL   XBRL Calculation Linkbase Document 
101.DEF   XBRL Definition Linkbase Document 
101.LAB   XBRL Label Linkbase Document
101.PRE   XBRL Presentation Linkbase Document  
104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)*

 

26 
 

 

  1. Incorporated by reference from the Company’s Current Report on Form 8-K filed on February 14, 2022 with the SEC.

 

  2. Incorporated by reference from the Company’s Current Report on Form 8-K filed on December 23, 2021 with the SEC.
  3. Incorporated by reference from the Company’s Current Report on Form 8-K filed on November 13, 2018 with the SEC.

 

  4. Incorporated by reference from the Company’s Annual Report on Form 10-K filed on April 14, 2015 with the SEC.

 

  5. Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on August 15, 2016 with the SEC.

 

  6. Incorporated by reference from the Company’s Current Report on Form 8-K filed on July 17, 2019 with the SEC.

 

  7. Incorporated by reference from the Company’s Annual Report on Form 10-K filed on February 21, 2017 with the SEC.

 

  8. Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on November 13, 2017 with the SEC.

 

  9. Incorporated by reference from the Company’s amended Current Report on Form 8-K filed on September 12, 2017 with the SEC.

 

  10. Incorporated by reference from the Company’s Current Report on Form 8-K filed on April 10, 2020 with the SEC.

 

  11. Incorporated by reference from the Company’s Current Report on Form 8-K filed on November 15, 2017 with the SEC.

 

  * Filed herewith.

 

  ** Furnished, not filed herewith.

 


ITEM 16. Form 10-K Summary

This Item is optional and the registrant is not required to furnish this information.

 

27 
 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  PROTOKINETIX, INCORPORATED  
       
Dated: March 17, 2023 By: /s/ Clarence E. Smith  
    Clarence E. Smith  
    Principal Executive Officer  
       

 

     
       
Dated: March 17, 2023 By: /s/ Michael R. Guzzetta  
    Michael R. Guzzetta  
    Principal Financial Officer & Principal Accounting Officer 
       

 

Pursuant to the requirement of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

 

     
       
Dated: March 17, 2023 By: /s/ Clarence E. Smith  
    Clarence E. Smith  
   

Chief Executive Officer (principal executive officer)

& Chairman of the Board

 
       

 

     
       
Dated: March 17, 2023 By: /s/ Edward P. McDonough  
    Edward P. McDonough  
    Director  
       

 

 

 

 

28 
 

 

PROTOKINETIX, INC.

(A Development Stage Company)

 

 

FINANCIAL STATEMENTS

 

 

December 31, 2022

(Stated in US Dollars)

 

 

 

 

 

 
 

 

C O N T E N T S

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID #731) DAVIDSON & COMPANY LLP, VANCOUVER, BC, CANADA F-2
   
FINANCIAL STATEMENTS  
   
BALANCE SHEETS F-4
STATEMENTS OF OPERATIONS F-5
STATEMENT OF STOCKHOLDERS' EQUITY F-6
STATEMENTS OF CASH FLOWS F-8
NOTES TO FINANCIAL STATEMENTS F-9

 

 

F-1 
 

 

 

 

 

Report of Independent Registered Public Accounting Firm

 

 

To the Shareholders and Directors of

Protokinetix, Inc.

 

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Protokinetix, Inc. (the “Company”) as of December 31, 2022 and 2021, and the related statements of operations, stockholders’ equity, and cash flows for the years ended December 31, 2022 and 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years ended December 31, 2022 and 2021 in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations, requires additional working capital and has a net accumulated deficit all which raises substantial doubt about its ability to continue as a going concern. Management's plans in regards to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

 

 

F-2 
 

 

 

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Fair value of intangible assets

 

As discussed in Note 4 to the financial statements, the Company held intangible assets of $436,270 relating to patent and patent application rights.

 

We identified the estimation of the fair value of intangible assets as a critical audit matter. Subjective auditor judgment was required to evaluate management’s estimates and assumptions used to determine the fair value of the intangible assets, including the economic useful life over which the patent rights are being amortized and whether indicators of impairment were present.

 

The following are the primary procedures we performed to address this critical audit matter. We obtained management’s impairment analysis of intangible assets and assessment of impairment triggers. We assessed the consistency and reasonableness of the assumptions used by management in performing the impairment test and whether there were any changes in the expected useful life as compared to prior years. We discussed with management the plans and intent for the patents and patent applications. We reviewed the Company’s ability to fund future activities, and reviewed any available budgets for future periods. We confirmed title to ensure patent rights and patent application rights remain in good standing.

 

We have served as the Company’s auditor since 2008.

 

 

/s/ DAVIDSON & COMPANY LLP

 

 

Vancouver, Canada Chartered Professional Accountants

 

March 17, 2023

 

 

F-3 
 

 

 PROTOKINETIX, INC.

(A Development Stage Company)

BALANCE SHEETS

As of December 31, 2022

 

         
   2022   2021 
ASSETS          
Current Assets          
Cash  $25,550   $57,568 
Prepaid expenses and deposits (Note 3)   1,050    25,995 
Total current assets   26,600    83,563 
           
Intangible assets (Note 4)   436,270    362,671 
           
Total assets  $462,870   $446,234 
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current Liabilities          
Accounts payable and accrued liabilities  $41,530   $93,268 
           
Total liabilities   41,530    93,268 
Stockholders' Equity          
Common stock, $0.0000053 par value; 500,000,000 common shares authorized; 322,880,151 and 297,393,485 shares issued and outstanding for 2022 and 2021 respectively (Note 7)   1,726    1,591 
Additional paid-in capital   47,868,093    45,892,545 
Accumulated deficit   (47,448,479)   (45,541,170)
Total stockholders' equity   421,340    352,966 
Total liabilities and stockholders' equity  $462,870   $446,234 
           

Basis of Presentation – Going Concern Uncertainties (Note 1)

Commitments and Contingency (Note 9)

 

 

See Notes to Financial Statements

 

 

F-4 
 


PROTOKINETIX, INC.

(A Development Stage Company)

STATEMENTS OF OPERATIONS

For the Years Ended December 31, 2022 and 2021

 

         
   2022   2021 
         
EXPENSES          
Amortization – intangible assets (Note 4)  $58,450   $3,000 
General and administrative   162,749    316,995 
Professional fees (Note 8)   166,254    160,388 
Research and development   448,873    435,872 
Share-based compensation (Notes 5 and 8)   1,070,983    1,413,055 
           
 Operating Income (Expenses)   (1,907,309)   (2,329,310)
           
           
Net loss for the year  $(1,907,309)  $(2,329,310)
           
Net loss per common share (basic and diluted)  $(0.01)  $(0.01)
           
Weighted average number of common shares outstanding (basic and diluted)   307,392,069    291,865,922 

 

 

See Notes to Financial Statements

 

 

F-5 
 


PROTOKINETIX, INC.

(A Development Stage Company)

STATEMENT OF STOCKHOLDERS' EQUITY

For the Years Ended December 31, 2022 and 2021

 

 

                          
   Common Stock   Additional
paid-in
   Accumulated     
   Shares   Amount   capital   deficit   Total 
Balance, December 31, 2020   285,955,071   $1,531   $43,615,323   $(43,192,633)  $424,221 
                          
Fair value of share-based compensation   —            1,413,055          1,413,055 
                          
Issuance of common stock pursuant to private placement offering   7,668,572    41    569,959          570,000 
                          
Issuance of common stock pursuant to warrant exercise   3,214,286    17    274,983          275,000 
                          
Issuance of common stock pursuant to cashless option exercise   555,556    3    (3)            
                          
Extension of the terms of warrants   —            19,227    (19,227)      
                          
Net loss for the year   —                  (2,329,310)   (2,329,310)
                          
Balance, December 31, 2021   297,393,485   $1,591   $45,892,545   $(45,541,170)  $352,966 

 

 

 

See Notes to Financial Statements

 

 

F-6 
 

 

PROTOKINETIX, INC.

(A Development Stage Company)

STATEMENT OF STOCKHOLDERS' EQUITY

For the Years Ended December 31, 2022 and 2021

 

 

   Common Stock   Additional
paid-in
   Accumulated     
   Shares   Amount   capital   deficit   Total 
Balance, December 31, 2021   297,393,485   $1,591   $45,892,545   $(45,541,170)  $352,966 
                          
Fair value of share-based compensation   —            1,070,983          1,070,983 
                          
Issuance of common stock pursuant to private placement offering   25,486,666    135    904,565          904,700 
                          
Net loss for the year   —                  (1,907,309)   (1,907,309)
                          
Balance, December 31, 2022   322,880,151   $1,726   $47,868,093   $(47,448,479)  $421,340 

 

 

See Notes to Financial Statements

 

 

F-7 
 

 

 


PROTOKINETIX, INC.

(A Development Stage Company)

STATEMENTS OF CASH FLOWS

For the Years Ended December 31, 2022 and 2021

 

 

         
   2022   2021 
         
CASH FLOWS USED IN OPERATING ACTIVITIES          
Net loss for the year  $(1,907,309)  $(2,329,310)
Adjustments to reconcile net loss to cash used in operating activities:          
Amortization – intangible assets   58,450    3,000 
Fair value of compensatory options granted   1,070,983    1,413,055 
           
Changes in operating assets and liabilities:          
   Prepaid expenses and deposits   24,945    (24,945)
Accounts payable and accrued liabilities   (51,738)   48,309 
           
Net cash used in operating activities   (804,669)   (889,891)
           
CASH FLOWS USED IN INVESTING ACTIVITIES          
Purchase of intangible assets   (132,049)   (90,985)
           
Net cash used in investing activities   (132,049)   (90,985)
           
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Issuance of common stock for cash   904,700    845,000 
           
Net cash from financing activities   904,700    845,000 
           
Net change in cash   (32,018)   (135,877)
           
Cash, beginning of year   57,568    193,445 
           
Cash, end of year  $25,550   $57,568 
           
Cash paid for interest  $     $   
           
Cash paid for income taxes  $     $   
 Supplementary information – non-cash transactions:          
There were no non-cash financing or investing activities.  $     $   

 

See Notes to Financial Statements

  

F-8 
 


PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

Note 1.  Basis of Presentation – Going Concern Uncertainties

 

ProtoKinetix, Inc. (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999.  The Company is a medical research company whose mission is the advancement of human health care.

 

The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins ("AFGP") or anti-aging glycoproteins, trademarked AAGP.  During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).

 

The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.

 

The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at December 31, 2022.  These factors raise substantial doubt about the Company's ability to continue as a going concern.

 

.

 The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities.  Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective.  Management is presently engaged in seeking additional working capital through equity financing or related party loans. In addition, any significant disruption of global financial markets, reducing our ability to access capital, could negatively affect our liquidity and ability to continue operations. The exact impact is and will remain unknown and is largely dependent upon future developments, including but not limited to information on the duration and spread of COVID-19, changes in customer demand, additional mitigation strategies proposed by governmental authorities (including federal, state, or local stay at home or similar orders), restrictions on the activities of our domestic and international suppliers and shipment of goods.

 

The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and are expressed in United States dollars.

 

 

F-9 
 

 

PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

Note 2. Summary of Significant Accounting Policies (cont'd)

 

Use of Estimates

 

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity- related instruments issued, deferred income taxes and the useful life and impairment of intangible assets.

 

Cash

 

Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.

 

Fair Value of Financial Instruments

 

Financial instruments, which includes cash, accounts payable and accrued liabilities are carried at amortized cost, which management believes approximates fair value due to the short-term nature of these instruments.

 

The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:

 

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable.

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions).

 

At December 31, 2022, there were no other assets or liabilities subject to additional disclosure.

 

Income Taxes

 

The Company accounts for income taxes following the assets and liability method in accordance with the ASC 740 "Income Taxes."  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.

 

 

F-10 
 

 

PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

Note 2. Summary of Significant Accounting Policies (cont'd)

 

Intangible assets – patent and patent application costs

 

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.

 

As at December 31, 2022, the Company does not hold any intangible assets with indefinite lives.

 

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.

 

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.

 

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs at December 31, 2022.

 

Research and Development Costs

 

Research and development costs are expensed as incurred.

 

Loss per Share and Potentially Dilutive Securities

 

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 94,290,000 stock options (December 31, 2021 – 84,690,000) and 13,300,000 warrants (December 31, 2021 –12,081,143) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.

 

Share-Based Compensation

 

The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

 

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance.

 

 

F-11 
 


PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

Note 2. Summary of Significant Accounting Policies (cont'd)

 

Share-Based Compensation (cont'd)

 

Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

 

Common stock

 

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

 

Related Party Transactions

 

A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

 

F-12 
 

 

PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

Note 2. Summary of Significant Accounting Policies (cont'd)

 

Recent Accounting Pronouncements

 

 The Company has determined that other significant newly issued accounting pronouncements are either not applicable to the Company’s business or that no material effect is expected on the financial statements as a result of future adoption.

 

Note 3.  Prepaid Expenses and Deposits

 

The following summarizes the Company's prepaid expenses and deposits outstanding as at December 31, 2022 and 2021:

 

Schedule of prepaid expenses        
   2022   2021 
Rental deposit  $1,050   $1,050 
Deposit on February 11, 2022 shareholder meeting         24,945 
Total Prepaid Expenses and Deposits  $1,050   $25,995 

 

 

F-13 
 

 

   PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

Note 4. Intangible Assets

 

Intangible asset transactions are summarized as follows:

 

Intangible asset transactions            
   Patent Rights   Patent Application
Rights
   Total 
Cost               
Balance, December 31, 2020  $30,000   $261,186   $291,186 
Additions         90,985    90,985 
Balance, December 31, 2021  $30,000   $352,171   $382,171 
Additions         132,049    132,049 
Balance, December 31, 2022  $30,000   $484,220   $514,220 
Accumulated amortization               
Balance, December 31, 2020  $16,500   $     $16,500 
Amortization   3,000          3,000 
Balance, December 31, 2021  $19,500   $     $19,500 
Amortization   3,000    55,450    58,450 
Balance, December 31, 2022  $22,500   $55,450   $77,950 
                
Net carrying amounts               
December 31, 2021  $10,500   $352,171   $362,671 
December 31, 2022  $7,500   $428,770   $436,270 

 

During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the "Patent Assignment") with the Institut National des Sciences Appliquees de Rouen ("INSA") for the assignment of certain patents and all rights associated therewith (the "Patents"). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the year ended December 31, 2022, the Company recorded $58,450 (2021 - $3,000) in amortization expense associated with the Patents Rights.

 

During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the "Patent Application Rights").  In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company incurred an additional $449,220 in direct costs relating to the Patent Application Rights, $132,049 of which were incurred during the year ended December 31, 2022.

 

F-14 
 

 

   PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

Note 4. Intangible Assets (cont’d)

 

The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty from any product developed as a result of research done at the University.

 

During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled "Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells" (the "New Patent Application Rights").  In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid).  The Company incurred $2,415 in direct costs relating to the New Patent Application Rights during the year ended December 31, 2016.

 

The Company amortizes patents and licenses that have been filed over their useful lives which range between 18.5 to 20 years. The costs of provisional patents and pending applications is not amortized until the patent is filed and is reviewed each reporting period.

  

Note 5.  Stock Options

 

Pursuant to an amendment on March 15, 2022, the aggregate number of shares that may be issued under the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”) is 97,700,000 shares, subject to adjustment as provided therein. The 2017 Plan is administered by the Company’s Board of Directors, or a committee appointed by the Board of Directors, and includes two types of options. Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended, are referred to as incentive options. Options that are not intended to qualify as incentive options are referred to as non-qualified options. The exercise price of an option may be paid in cash, in shares of the Company's common stock or other property having a fair market value equal to the exercise price of the option, or in a combination of cash, shares, other securities and property.

 

As of December 31, 2022, there are 94,290,000 options granted and outstanding under the 2017 Plan.

 

F-15 
 

 

PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

Note 5.  Stock Options (cont'd)

 

Stock option transactions are summarized as follows:

 

               
   Number of
Stock Options
   Weighted Average Exercise Price   Weighted Average Remaining Life 
       $   (Years) 
Outstanding, December 31, 2020   82,650,000    0.15      
     Options cancelled   (76,100,000)   0.16      
     Options exercised   (750,000)   0.07      
     Options granted   78,890,000    0.11      
Outstanding, December 31, 2021   84,690,000    0.15    4.23 

 

   Number of
Stock Options
   Weighted Average Exercise Price   Weighted Average Remaining Life 
       $   (Years) 
Outstanding, December 31, 2021   84,690,000    0.15      
     Options cancelled   (93,540,000)   0.14      
     Options expired   (400,000)   0.06      
     Options granted   103,540,000    0.03      
Outstanding, December 31, 2022   94,290,000    0.03    6.00 

 

During the year ended December 31, 2022, the Company granted the following stock options:

 

On March 15, 2022, 10,000,000 options for shares of common stock exercisable at $0.06 per share, expiring March 14, 2030. These were cancelled On December 7, 2022 and reissued exercisable at $0.028, expiring December 6, 2028.

 

On December 7, 2022 , 93,540,000 options for shares of common stock exercisable between $0.06 and $0.11 per share, with various expiration dates were cancelled and reissued exercisable at $0.028 expiring December 6, 2028.

 

Total share-based compensation for the 103,540,000 stock options granted (2021 - 78,890,000) and vested during the year ended December 31, 2022 was $1,070,983 (2021 - $1,413,055). The fair values of the stock options granted were estimated using the Black-Scholes Option Pricing Model, based on the following weighted average assumptions:

 

Schedule of valuation assumptions for options        
   December 31, 2022   December 31, 2021 
Risk-free interest rate   3.50%   2.55%
Dividend yield   0.00%   0.00%
Expected stock price volatility   143.43%   143.56%
Expected forfeiture rate   0.00%   0.00%
Expected life   6.00 years    5.09 years 

 

The weighted-average fair value of the stock options granted during the year ended December 31, 2022 was $0.03 (December 31, 2021 - $0.10)

 

 

 

F-16 
 

PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

 

Note 5.  Stock Options (cont'd)

 

The following non-qualified stock options were outstanding and exercisable at December 31, 2022:

 

Schedule of options by exercise price            
Expiry date  Exercise Price   Number of Options
Outstanding
   Number of
Options
Exercisable
 
   $         
October 26, 2026   0.10    500,000    500,000 
 November 27, 2026   0.10    250,000    250,000 
December 6, 2028   0.028    93,540,000    93,540,000 
         94,290,000    94,290,000 

 

As at December 31, 2022, the aggregate intrinsic value of the Company's stock options is $Nil .

 

 

F-17 
 

 

PROTOKINETIX , INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

 

 

Note 6.  Warrants

 

Warrant transactions are summarized as follows:

          
   Number of
Warrants
   Weighted Average Exercise Price 
       $ 
Outstanding, December 31, 2020   10,326,857    0.19 
   Warrants granted   4,968,572    0.08 
   Warrants exercised   (3,214,286)   0.07 
Outstanding, December 31, 2021   12,081,143    0.17 
   Warrants granted   13,300,000    0.04 
   Warrants expired   (6,081,143)   0.09 
   Warrants cancelled   (6,000,000)   0.26 
Outstanding, December 31, 2022   13,300,000    0.04 

 

The following warrants were outstanding and exercisable as at December 31, 2022:

 

Schedule of outstanding and exercisable    
     
Number of Warrants   Exercise Price   Expiry Date
 1,000,000   $0.05   March 15, 2024
 200,000    0.05   March 15, 2024
 1,000,000    0.05   March 15, 2024
 600,000    0.05   March 15, 2024
 1,000,000    0.05   March 15, 2024
 500,000    0.05   March 15, 2024
 1,000,000    0.05   March 15, 2024
 2,000,000    0.05   March 15, 2024
 6,000,000    0.028   December 6, 2028
 13,300,000         

 

 In March, 2022 the Company issued 4,300,000 warrants as part of private placement transactions. On April 4, 2022 and May 12, 2022 the Company issued 1,000,000 and 2,000,000 warrants, respectively, as part of private placement transactions. On December 13, 2022, the Company cancelled 6,000,000 warrants issued July 15, 2019 with an exercise price of $0.26 in consideration for patent assignments, and expiring July 14, 2024. The Company reissued the 6,000,000 warrants with an exercise price of $0.028 and expiring December 12, 2028.

 

Total share-based compensation for the reissued warrants during the year ended December 31, 2022, was $115,537.

 

The fair values of the reissued warrants were estimated using the Black-Scholes Option Pricing Model, based on the following weighted average assumptions:

Schedule of assumptions   
  

December 31,

2022

Risk-free interest rate   3.50%
Dividend yield   0.00%
Expected stock price volatility   143.43%
Expected forfeiture rate   0.00%
Expected life   6 years 

 

The weighted-average fair value of the warrants granted during the year ended December 31, 2022 was $0.03 (December 31, 2021 - $nil)

 

 

 

F-18 
 

 

PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

 

Note 7.  Stockholders' Equity

 

The Company is authorized to issue 500,000,000 (December 31, 2021 – 400,000,000) shares of $0.0000053 par value common stock.  Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of December 31, 2022 (December 31, 2021 - $Nil).

 

During the year ended December 2022, the Company:

 

  a) Issued 5,450,000 shares of common stock (5,450,000 shares issued at $0.02) as part of a private placement for total proceeds of $109,000.
  b) Issued 3,100,000 shares of common stock (3,100,000 shares issued at $0.025) as part of a private placement for total proceeds of $77,500.
  c) Issued 7,500,000 shares of common stock (7,500,000 shares issued at $0.03) as part of a private placement for total proceeds of $225,000.
  d) Issued 2,136,666 shares of common stock (2,136,666 shares issued at $0.06) as part of a private placement for total proceeds of $128,200.
  e) Issued 7,300,000 units (each unit consisting of 1 share of common stock and 1 warrant to purchase 1 share of common stock at $0.05) as part of a private placement for total proceeds of $365,000.

 

During the year ended December 2021, the Company:

 

  a) Issued 3,528,572 units (each unit consisting of one share of common stock and one warrant to purchase one share of common stock at $0.07 per share) as part of a private placement for total proceeds of $247,000.

  b) Issued 200,000 shares of common stock at $0.12 as part of a private placement for total proceeds of $24,000.

  c) Issued 1,440,000 units (each unit consisting of one share of common stock and one warrant to purchase one share of common stock at $0.10) as part of a private placement for total proceeds of $144,000.

  d) Issued 3,214,286 shares of common stock from exercised warrants (2,214,286 shares issued at $0.07 and 1,000,000 shares issued at $0.12) for total proceeds of $275,000.

  e) Issued 555,556 shares of common stock to the Company’s CFO pursuant to a cashless exercise of 750,000 stock options.
  f) Issued 250,000 shares of common stock at $0.08 as part of a private placement for total proceeds of $20,000.
  g Issued 2,250,000 shares of common stock at $0.06 as part of a private placement for total proceeds of $135,000.
  h) Extended exercise date for warrants to purchase 1,440,000 shares of common stock issued August of 2021.  
  i) Extended exercise date for warrants to purchase 3,355,429 shares of common stock, issued December of 2020.

 

 

 

F-19 
 

 

PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

Note 8. Related Party Transactions and Balances

 

During the years ended December 31, 2022 and 2021, the Company entered into the following related party transactions:

a) Pursuant to a consulting agreement with an effective date of November 14, 2017, a total of $60,000 (2021 - $60,000) was paid or accrued to the Company's CFO. During the year ended December 31, 2022, the Company reimbursed a company controlled by the CFO a total of $11,025 (2021 - $12,600) in office rent.

b) On December 7, 2022, the Company cancelled and concurrently replaced 32,350,000 stock options previously issued to the Company’s CEO and a Director of the Company from 2021 to 2022. The modifications incremental fair value of $80,105 was recognized in the current period. The 32,350,000 replacement options granted have a term of 6 years, exercisable at a price of $0.028 per share, expiring on December 6, 2028

c) On December 7, 2022, the Company cancelled and concurrently replaced 13,260,000 stock options previously issued to the Company’s CFO of the Company from 2018 to 2022. The modifications incremental fair value of $82,398 was recognized in the current period. The 13,260,000 replacement options granted have a term of 6 years, exercisable at a price of $0.028 per share, expiring on December 6, 2028

d) On March 15, 2022, the Company granted 4,750,000 stock options to the Company’s CEO and 500,000 stock options to a Director of the Company, respectively. The 5,250,000 options granted have a term of 8 years and are exercisable at a price of $0.06 per share, expiring on March 14, 2030.

e) On March 15, 2022, the Company granted 1,500,000 stock options to the Company’s CFO. The options granted have a term of 8 years and are exercisable at a price of $0.06 per share, expiring on March 14, 2030.

f) The Company recognized $638,227 (2021 - $ 649,822) in share-based compensation during the year associated with stock options granted to key management personnel.

g) The Company recognized $638,227 including modifications (2021 - $722,822) in share-based compensation during the year associated with stock options granted to key management personnel. The total incremental fair value of stock options including modifications is $1,070,983.

As at December 31, 2022 and December 31, 2021, there were $nil balances owing to related parties.

 

F-20 
 

PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

Note 9. Commitments and Contingency

 

Commitments

 

As at December 31, 2022, the Company has the following commitments:

 

a) Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $7,000 per month for providing research and development services.

b) Entered into a consulting agreement effective April 1, 2019, whereby the Company would pay the consultant $1,500 per month minimum plus travel expenses for a term of 1 year for providing research consulting services. Agreement renews annually unless otherwise terminated by either party with at least 30 days’ notice.

Contingency

 

The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, "Report of Foreign Bank and Financial Accounts" ("FBARs"). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs.  Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no under reported tax liabilities.  On November 30, 2017, the Company received a letter from the IRS concluding their review of the Company's tax returns under the program and accepting the returns as filed.  No penalties have been assessed by the IRS to date, and management does not believe that the Company will incur any penalties relating to the tax years submitted under the program.

 

F-21 
 

PROTOKINETIX, INC.

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

December 31, 2022

 

 

Note 10.  Income Taxes

 

As a Nevada corporation, the Company is liable for taxes in the United States.  As of December 31, 2022, the Company did not have any income for tax purposes and therefore, no tax liability or expense has been recorded in these financial statements (December 31, 2021 – nil).

 

A reconciliation of income taxes at statutory rates with the reported taxes is as follows:

 

Schedule of Effective Income Tax Reconciliation        
  

 

2022

  

 

2021

 
Net loss for the year  $(1,907,309)  $(2,329,310)
           
Expected income tax recovery  $(400,535)  $(489,155)
Non-deductible expenses  $224,907   $296,742 
Adjustment to prior years provision versus statutory tax returns  $75,628   $92,414 
Change in valuation allowance   100,000   $100,000 
Total income tax expense (recovery)  $     $   

 

          

 

The Company’s deferred tax assets that have not been recognized are as follows:

 

        
Schedule of Deferred Tax Assets        
Tax benefit of net operating loss carry forward  $6,400,000   $6,300,000 
Valuation allowance  $(6,400,000)  $(6,300,000)
   $     $   

 

The Company has net operation loss carryforwards of approximately $30,500,000 (December 31, 2021 - $30,000,000) to reduce future taxable income.  The valuation allowance has not changed during the year ended December 31,2022. Tax losses expire in years starting from 2023.

 

The deferred tax asset associated with the tax loss carry forward is approximately $6,400,000 (December 31, 2021 - $6,300,000).  The Company has provided a full valuation allowance against the deferred tax asset since it is more likely than not that the asset will not be realized. 

 

Note 11. Subsequent Events

 

Subsequent to the year ended December 31, 2022, the Company:

 

  a) Issued 2,000,000 shares of common stock (2,000,000 shares issued at $0.02) to the CEO of the Company, as part of a private placement for total proceeds of $40,000.  
     

 

 

 

 

F-22 
 

 

EX-4.4 2 ex4x4.htm CONSULTANT WARRANT

Exhibit 4.4

 

 

 

WARRANT AGREEMENT

 

Neither THE WARRANT, NOR THE SHARES UNDERLYING THE WARRANT, GRANTED HEREUNDER TO WHICH THIS WARRANT AGREEMENT RELATES HAVE BEEN REGISTERED UNDER THE securities act of 1933, as amended (the “1933 Act”) OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED HEREIN) EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

________________________

The “Holder”

 

PROTOKINETIX, INCORPORATED

 

COMMON STOCK PURCHASE WARRANT

 

1.Issuance; Certain Definitions. In consideration of good and valuable consideration, the receipt of which is hereby acknowledged by PROTOKINETIX, INCORPORATED, a Nevada corporation (the “Company”), the Holder named above or registered and permitted assigns (collectively the “Holder”) is hereby granted the right to purchase at any time until 5:00 P.M., Mountain time, on December 12, 2028 (the “Expiration Date”), six million (6,000,000) fully paid and non-assessable shares of the Company’s Common Stock, $0.0000053 par value per share (the “Common Stock”), at an initial exercise price of $0.028 per share (the “Exercise Price”), subject to further adjustment as set forth herein.

 

2.Exercise of Warrants. This Warrant is exercisable in whole or in part at any time and from time to time prior to the Expiration Date. Such exercise shall be effectuated by submitting to the Company (either by delivery to the Company or by facsimile transmission as provided in Section 8 hereof) a completed and duly executed Notice of Exercise (substantially in the form attached to this Warrant) as provided in this paragraph. The date such Notice of Exercise is faxed or delivered to the Company shall be the “Exercise Date,” provided that the Holder of this Warrant tenders this Warrant to the Company within five business days thereafter. If the Holder elects to exercise only a portion of his Warrant, the Company shall issue to the Holder a new Warrant representing the remaining unexercised Warrants.

 

(a)The Notice of Exercise shall be executed by the Holder of this Warrant and shall indicate the number of shares then being purchased pursuant to such exercise. Upon surrender of this Warrant, together with appropriate payment of the Exercise Price for the shares of Common Stock purchased, the Holder shall be entitled to receive a certificate or certificates for the shares of Common Stock so purchased within ten days.

 

(b)The Holder has the option of paying the Exercise Price per share of Common Stock for the shares then being exercised either in cash or by certified or official bank check.

 

3.Reservation of Shares. The Company hereby agrees that at all times during the term of this Warrant there shall be reserved for issuance upon exercise of this Warrant such number of shares of its Common Stock as shall be required for issuance upon exercise of this Warrant (the “Warrant Shares”).

 

4.Mutilation or Loss of Warrant. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) receipt of reasonably satisfactory indemnification, and (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will execute and deliver a new Warrant of like tenor and date and any such lost, stolen, destroyed or mutilated Warrant shall thereupon become void.

 

 

1 
 

5.Rights of the Holder. The Holder shall not, by virtue hereof, be entitled to any rights of a stockholder in the Company, either at law or equity. The rights of the Holder are limited to those expressed in this Warrant and are not enforceable against the Company except to the extent set forth herein.

 

6.Protection Against Dilution and Other Adjustments.

 

(a)Adjustment Mechanism. If an adjustment of the Exercise Price is required pursuant to Section 6(b), the Holder shall be entitled to purchase such number of additional shares of Common Stock as will cause (i) the total number of shares of Common Stock that the Holder is entitled to purchase pursuant to this Warrant, multiplied by (ii) the adjusted Exercise Price per share, to equal (iii) the dollar amount of the total number of shares of Common Stock that the Holder is entitled to purchase before adjustment multiplied by the total Exercise Price before adjustment.

 

(b)Capital Adjustments. In case of any stock split or reverse stock split, stock dividend, extraordinary dividend of cash or other assets, reclassification of the Common Stock, recapitalization, merger or consolidation, sale of assets or like capital adjustment affecting the Common Stock of the Company, the provisions of this Section 6 shall be applied as if such capital adjustment event had occurred immediately prior to the date of this Warrant and the original Exercise Price had been fairly allocated to the stock resulting from such capital adjustment. A rights offering to stockholders shall be deemed a stock dividend to the extent of the bargain purchase element of the rights.

 

(c) No Adjustment for Spin Off, Merger, or Other Events. If, for any reason, prior to the exercise of this Warrant in full, the Company spins off or otherwise divests itself of substantially all of its business or operations or disposes of all or of a part of its assets in a transaction, merges with another entity the result of which the Company has been acquired by such other entity (not including a merger simply for the purpose of reincorporation), or engages in another transaction, the result of which the Common Stock is no longer registered under the Securities Exchange Act of 1934, the holder of this Warrant will be entitled to no other consideration upon the completion of such transaction; provided that the Warrant will for all purposes will be assumed by the surviving entity of such transaction and will remain outstanding and an obligation of such surviving entity. In the event of such a transaction, the Company shall give the Holder not less than 30 days’ notice of the Company’s intention to complete such transaction, and the Holder may elect whether to exercise this Warrant during that period.

 

7.Representations and Warranties of the Holder.

 

(a)Holder has received and reviewed such information about the Company’s business and proposed business, assets, financial condition, management, risks relating to the Company and the business and proposed business in which the Company conducts its operations, and such other information regarding the acquisition of the Warrant as Holder has (in consultation with such advisors as Holder has deemed appropriate) determined to be necessary or appropriate in the circumstances; and further acknowledges that Holder or its representatives have been afforded the opportunity to ask such questions as Holder or its representatives have deemed necessary.

 

(b)Holder acknowledges that it has had the opportunity to consult with its legal, financial, accounting, tax, and investment advisers regarding Holder’s personal circumstances and the advisability of Holder’s proposed receipt of the Warrant to the extent that Holder has determined such consultation to be appropriate.

 

(c)Holder has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Warrant and the shares underlying the Warrant, having been represented by advisors to the extent it deemed appropriate, and has so evaluated the merits and risks of such investment and is able to bear the economic risk of such investment and, at the present time, is able to afford a complete loss of such investment.

 

(d)Holder acknowledges that the Warrant nor any of the shares underlying the Warrant have been registered under the Securities Act of 1933, as amended (the “1933 Act”), or under any state securities or “blue sky” laws of any state of the United States, and are being offered only in a transaction not involving any public offering within the meaning of the 1933 Act and, if Holder is not a U.S. Person, the Company will rely on Rule 903 of Regulation S as an exemption from registration under the 1933 Act for the issuance of the Warrant and the shares underlying the Warrant.

 

 

2 
 

(e)If the Holder is not a U.S. Person, Holder is outside the United States when receiving and executing this Warrant Agreement and Holder is resident in the jurisdiction set out beneath the Holder’s signature to this Warrant Agreement.

 

(f)Holder has not acquired the Warrant as a result of, and will not itself engage in, any “directed selling efforts” (as defined in Regulation S under the 1933 Act) in the United States in respect of the Warrant or any shares underlying the Warrant which would include any activities undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United States for the resale of any of the Warrant or the shares underlying the Warrant.

 

(g)If Holder is not a U.S. Person, Holder acknowledges and agrees that the Warrant and the shares underlying the Warrant may not be offered or sold to a U.S. Person or for the account or benefit of a U.S. Person (other than a distributor) prior to the end of the expiration of a period of one year after the Date of Grant.

 

(h)If Holder is not a U.S. Person, Holder is not acquiring the Warrant for the account or benefit of, directly or indirectly, any U.S. Person.

 

(i)Holder is acquiring the Warrant as principal for its own account, for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof, in whole or in part, and no other person has a direct or indirect beneficial interest in such Warrant.

 

(j)Holder agrees to resell the shares underlying the Warrant only in accordance with the provisions of Regulation S, pursuant to registration under the 1933 Act, pursuant to an available exemption from registration, in accordance with applicable state or provincial securities laws, in accordance with securities laws of the International Jurisdiction (as defined below), and the Company has received an opinion of legal counsel or other evidence reasonably satisfactory to the Company that an exemption is available for such sale.

 

(k)Holder agrees not to engage in hedging transactions with regard to such securities unless in compliance with the 1933 Act.

 

(l)The Company will refuse to register any transfer of the Warrant or any shares underlying the Warrant not made in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the 1933 Act or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act.

 

(m)If Holder is not a U.S. Person, Holder acknowledges that the statutory and regulatory basis for the exemption claimed for the grant of the Warrant, although in technical compliance with Regulation S, would not be available if the offering is part of a plan or scheme to evade the registration provisions of the 1933 Act.

 

(n)Neither the Warrant nor the shares underlying the Warrant are listed on any stock exchange and no representation has been made to the Holder that that the Warrant nor the shares underlying the Warrant will become listed on any stock exchange.

 

(o)Holder is knowledgeable of, or has been independently advised as to, the applicable securities laws of the securities regulators having application in the jurisdiction in which Holder is resident (the “International Jurisdiction”) which would apply to the acquisition of the Warrant.

 

(p)Holder is receiving the Warrant pursuant to exemptions from prospectus or equivalent requirements under applicable securities laws or, if such is not applicable, Holder is permitted to receive the Shares under the applicable securities laws of the securities regulators in the International Jurisdiction without the need to rely on any exemptions.

 

 

3 
 

(q)Holder is not aware of any advertisement of the Warrant or any of the shares underlying the Warrant and is not acquiring the Warrant as a result of any form of general solicitation or general advertising including advertisements, articles, notices or other communications published in any newspaper, magazine or similar media or broadcast over radio or television, or any seminar or meeting whose attendees have been invited by general solicitation or general advertising.

 

8.Restricted Securities.

 

(a)The Holder understands that neither the Warrant nor the shares of Common Stock subject thereto and issuable upon the exercise thereof are registered under the 1933 Act, as amended, and the Company has not made any undertaking to register either the Warrant or the shares of Common Stock issuable upon exercise thereof under the 1933 Act except as hereinafter expressly provided. The Holder represents that the Warrant is being acquired by it and that, if at the time of Warrant exercise there is no effective registration statement, the Warrant may only be exercised to the extent an exemption from registration under federal and applicable state law exists for such exercise, and in such event the shares of Common Stock underlying the Warrant will be acquired by it for investment purposes and all certificates for the shares issued upon exercise of the Warrant will bear the following legends:

 

 

NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SEcurities act of 1933, as amended (the “1933 Act”), OR ANY U.S. STATE SECURITIES LAWS AND ARE “RESTRICTED SECURITIES” AS DEFINED IN RULE 144 of the 1933 ACt, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT, the availability of which is to be established by an opinion of legal counsel or other evidence reasonably satisfactory to the Company that an exemption is available for such sale AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

THE SECURITIES REPRESENTED HEREBY HAVE BEEN OFFERED IN AN OFFSHORE TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE 1933 ACT”.

(b)If there is no registration statement effective with respect to the shares underlying this Warrant at the time the Holder elects to exercise this Warrant, the Holder acknowledges and agrees that it will not be permitted to exercise this Warrant unless the Holder executes a subscription agreement satisfactory to the Company including the following representations and warranties, all of the representation and warranties set forth in Section 9 of this Warrant Agreement, together with such other representations and warranties to establish facts as the Company may deem necessary or appropriate at the time to comply with applicable securities laws:

 

(i) An investment in the Company constitutes a high degree of risk, and there can be no assurance that the Holder will receive any portion of its investment returned to it at any time. By executing this understanding, the Holder acknowledges that it understands the risks involved and it is willing and able to withstand the possible complete loss of the Holder’s investment;

 

(ii) The Holder understands that the future conduct of the Company’s business is dependent upon a number of factors and there is no assurance that the Company will be able to conduct its operations as contemplated in this Warrant Agreement or in any other information given to the Holder;

 

 

4 
 

(iii) The Holder acknowledges that it has received and reviewed such information regarding the Company, its management, its assets, financial condition, and operations, as the Holder has deemed necessary or appropriate for the purposes of considering the exercise of this Warrant. Specifically, and without limitation of the generality of the foregoing, the Holder acknowledges that it has reviewed the Company’s most recent annual report as filed with the Securities and Exchange Commission and the reports filed subsequently. The Holder further represents that it has reviewed this information regarding the Company, the subscription agreement including these representations and warranties, and other information relating to the Company, its management, its financial statements, its assets and operations as the Holder has deemed necessary with its legal, investment, tax, and financial advisors to the extent the Holder has deemed such consultation appropriate. The Holder has also consulted with such advisors with regard to the advisability of this transaction to the extent the Holder has deemed such consultation to be appropriate. The Holder acknowledges that the Company has advised it that it recommends that the Holder obtain such advice and consultation.

 

(iv) The Holder is acquiring the securities upon exercise of the Warrant for its own account and not on behalf of any other person or entity. The securities are being acquired for investment purposes and not for resale or distribution; the Holder understands that there are severe limitations on its ability to resell the securities issuable upon exercise of the Warrant, and that these limitations are established in part in federal and applicable state laws regulating the offer and sale of securities. The Holder understands that neither the Company nor any other person has any obligation to redeem or repurchase the shares at any time. The Holder’s present financial condition is such that it is unlikely that it would be necessary for the Holder to dispose of the securities which underlie the Warrant in the foreseeable future.

 

(v) The Holder represents that no part of the funds that the Holder used to exercise the Warrant will have been directly or indirectly derived from, or related to, any activity that may contravene federal, state, or international laws and regulations, including anti-money laundering laws and regulation including the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA Patriot Act) and regulations of the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC). The Holder represents that it and its affiliates are not acting directly or indirectly for or on behalf of any person, group, entity, or nation named by any Executive Order of the U.S. as a terrorist, Specially Designated National and Blocked Person (SDN) or other banned or blocked person, entity, nation, or transaction pursuant to any law, order, rule, or regulation that is enforced or administered by OFAC. The Holder further represents that it and its affiliates also are not engaged in this transaction, directly or indirectly on behalf of, or instigating or facilitating this transaction, directly or indirectly on behalf of any SDN.

 

 

9.Exercise and Transfer to Comply with the Securities Act of 1933; Registration Rights. This Warrant has not been registered under the Securities Act of 1933, as amended, (the “1933 Act”) and has been issued to the Holder for investment and not with a view to the distribution of either the Warrant or the Warrant Shares. This Warrant may not be exercised, and neither this Warrant nor any of the Warrant Shares or any other security issued or issuable upon exercise of this Warrant may be sold, transferred, pledged or hypothecated in the absence of an effective registration statement under the 1933 Act relating to such transaction or an opinion of counsel or other evidence reasonably satisfactory to the Company that registration is not required under the 1933 Act. Each certificate for the Warrant, the Warrant Shares and any other security issued or issuable upon exercise of this Warrant shall contain a legend on the face thereof, in form and substance satisfactory to counsel for the Company, setting forth the restrictions on transfer contained in this Section 7.

 

10.Notices. Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, telegraphed, telexed, sent by facsimile transmission or sent by certified, registered or express mail, postage pre-paid. Any such notice shall be deemed given when so delivered personally, telegraphed, telexed or sent by facsimile transmission, or, if mailed, two days after the date of deposit in the United States mails, as follows:

 

5 
 

 

(i)if to the Company, to:

 

ProtoKinetix, Incorporated

412 Mulberry Street

Marietta, OH 45750

Attn: President

Telephone No.: (304) 299-5070

 

(ii) if to the Holder, to the address included in the Company’s records.

 

Any party may be given notice in accordance with this Section 10 if any of the parties designates another address or person for receipt of notices hereunder.

 

11.Supplements and Amendments; Whole Agreement. This Warrant may be amended or supplemented only by an instrument in writing signed by the parties hereto. This Warrant contains the full understanding of the parties hereto with respect to the subject matter hereof and thereof and there are no representations, warranties, agreements or understandings other than expressly contained herein and therein.

 

12.Dispute Resolution and Venue.

(a) All disputes arising out of or relating to this Option Agreement and all actions to enforce this Option Agreement shall be adjudicated in the state courts of West Virginia or the federal courts sitting in Clarksburg, West Virginia. The parties hereto irrevocably submit to the jurisdiction of such courts in any suit, action or proceeding relating to any such dispute. So far as is permitted under applicable law, this consent to personal jurisdiction shall be self-operative and no further instrument or action, other than service of process or as permitted by law, shall be necessary in order to confer jurisdiction upon the undersigned in any such court.

(b) This Warrant is made under, shall be construed in accordance with, and shall be governed by the laws of the State of Colorado without regard to conflicts of laws principles.

13.Counterparts. This Warrant may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

14.Descriptive Headings. Descriptive headings of the several Sections of this Warrant are inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof.

 

IN WITNESS WHEREOF, the parties hereto have executed this Warrant on December 13, 2022.

 

PROTOKINETIX, INCORPORATED

 

 

By: ____________________________

Clarence E. Smith, President & CEO

 

 
 

NOTICE OF EXERCISE OF WARRANT

 

The undersigned hereby irrevocably elects to exercise the right, represented by the Warrant Agreement dated as of December 13, 2022 to purchase _________________ shares of the Common Stock of ProtoKinetix, Incorporated at an exercise price of $_________ per share, and tenders herewith payment in accordance with said Warrant Agreement.

 

______ CASH:$ = (Exercise Price x Exercise Shares)

 

Payment is being made by:

_ enclosed check

_ wire transfer

 

I understand that I may only exercise this Warrant if there is a registration statement relating to the exercise of this Warrant that is effective under federal, applicable state law and applicable non-U.S. law, or alternatively, if there is an exemption from registration available under federal, applicable state law, and applicable non-U.S. law (which exemption must be established to the satisfaction of ProtoKinetix, Incorporated).

 

I understand that ProtoKinetix, Incorporated may require that I provide it information regarding my financial status, state of residence, and other information necessary to determine whether the exercise is subject to an effective registration statement or to determine whether an applicable exemption is available. To the extent required by the Company to establish an exemption from registration, I will provide the Company information as to my status as an accredited investor and execute a subscription agreement in the form requested by the Company provided that form is reasonably consistent with industry custom and practice. Alternatively, I understand that I may deliver a legal opinion regarding the availability of an exemption from such registration, which legal opinion must be acceptable to ProtoKinetix, Incorporated in its reasonable discretion.

 

I understand that ProtoKinetix, Incorporated will issue the shares subject to this exercise in electronic form only and I will not receive a physical stock certificate.

 

 

Signed:________________________

 

 

Date:__________________

 

 
 

Protokinetx, Incorporated

Subscription AGREEMENT

 

THE SECURITIES BEING ACQUIRED BY THE UNDERSIGNED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 OR ANY OTHER LAWS AND ARE OFFERED UNDER EXEMPTIONS FROM THE REGISTRATION PROVISIONS OF SUCH LAWS. THESE SECURITIES CANNOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH THE RESTRICTIONS ON TRANSFER CONTAINED IN THIS SUBSCRIPTION AGREEMENT AND APPLICABLE SECURITIES LAWS.

 

This Subscription Agreement is entered for the purpose of the undersigned acquiring _____________ shares of the $0.0000053 par value common stock (the “Securities”) of ProtoKinetix, Incorporated, a Nevada corporation (the “Company”), from the Company upon exercise of the warrant granted pursuant to the Warrant Agreement (the “Warrant Agreement”) between the undersigned and the Company, dated December 13, 2022. All capitalized terms not otherwise defined herein shall be as defined in the Warrant Agreement.

 

It is understood that no grant of warrants at a time when no registration statement relating thereto is effective under the U.S. Securities Act of 1933, as amended (the “1933 Act”) can be completed until the undersigned executes this Subscription Agreement and delivers it to the Company, and that such grant or exercise is effective only in accordance with the terms of the Warrant Agreement and this Subscription Agreement.

 

In connection with the undersigned’s acquisition of the Securities, the undersigned represents and warrants to the Company as follows:

 

1.The undersigned has been provided with, and has reviewed the Warrant Agreement, and such other information as the undersigned may have requested of the Company regarding its business, operations, management, and financial condition (all of which is referred to herein as the “Available Information”).

 

2.The Company has given the undersigned the opportunity to ask questions of and to receive answers from persons acting on the Company’s behalf concerning the terms and conditions of this transaction and the opportunity to obtain any additional information regarding the Company, its business and financial condition or to verify the accuracy of the Available Information which the Company possesses or can acquire without unreasonable effort or expense.

 

3.The Securities are being acquired by the undersigned for the undersigned’s own account and not on behalf of any other person or entity.

 

4.The undersigned understands that the Securities being acquired hereby have not been registered under the 1933 Act or any state or foreign securities laws, and are, and unless registered will continue to be, restricted securities within the meaning of Rule 144 under the 1933 Act and the rules and regulations promulgated thereunder and other statutes, and the undersigned consents to the placement of appropriate restrictive legends on any certificates evidencing the Securities and any certificates issued in replacement or exchange therefor and acknowledges that the Company will cause its stock transfer records to note such restrictions.

 

5.All representations made by the Holder in the Warrant Agreement are true, accurate, and in full force and effect as of the date set forth below.

 

6.By the undersigned’s execution below, it is acknowledged and understood that the Company is relying upon the accuracy and completeness hereof in complying with certain obligations under applicable securities laws.

 

7.This Subscription Agreement binds and inures to the benefit of the representatives, successors and permitted assigns of the respective parties hereto.

 

 

 
 

8.The undersigned acknowledges that the grant of any warrants and the issuance and delivery of shares of Common Stock pursuant thereto shall be subject to the prior reasonable approval by the Company’s counsel of all legal matters in connection therewith, including compliance with the requirements of the 1933 Act and other applicable securities laws, the rules and regulations thereunder, and the requirements of any national securities exchange(s) upon which the Common Stock then may be listed.

 

9. The undersigned acknowledges understands that the shares of Common Stock to be issued hereunder are being issued under an exemption from the prospectus requirements in British Columbia and will be subject to a restrictive legend and certain restrictions on resale in accordance with the requirements of Multilateral Instrument 51-105 Issuers Quoted in the U.S. Over-the-Counter Markets, as further described in the Option Agreement.

 

10. The Warrant Agreement is incorporated herein by reference. In the event that any provision in this Subscription Agreement conflicts with ANY provision in the Warrant Agreement, the provisions of the Warrant Agreement shall govern.

 

Date: ______________, ______

______________________________

Signature of Recipient

 

Tax ID Number: __________________

 

Address: _______________________

 

______________________________

 

 

 

EX-4.5 3 ex4x5.htm FORM OF WARRANT

Exhibit 4.5

 

 

WARRANT AGREEMENT

 

Neither THE WARRANT, NOR THE SHARES UNDERLYING THE WARRANT, GRANTED HEREUNDER TO WHICH THIS WARRANT AGREEMENT RELATES HAVE BEEN REGISTERED UNDER THE securities act of 1933, as amended (the “1933 Act”) AND, UNLESS SO REGISTERED, NONE MAY BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

NOTICE IS HEREBY GIVEN THAT THIS WARRANT WAS ISSUED BY THE COMPANY AS PART OF AN “INVESTMENT UNIT” CONSISTING OF THE WARRANT AND SHARES OF THE COMPANY’S COMMON STOCK, THAT THE WARRANT IS NON-DETACHABLE FROM SUCH SHARES OF COMMON STOCK AND THEREFORE THE WARRANT MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED EXCEPT IN CONJUNCTION WITH A SIMULTANEOUS TRANSFER, SALE, ASSIGNMENT OR HYPOTHECATION OF THE SHARES OF COMMON STOCK TO WHICH THE WARRANT IS ATTACHED. ANY OTHER TRANSFER SHALL BE DEEMED BY THE COMPANY TO BE NULL AND VOID.

 

Warrant No. 2022-___

 

____________________

The “Holder”

 

 

PROTOKINETIX, INCORPORATED

 

COMMON STOCK PURCHASE WARRANT

 

1.       Issuance; Certain Definitions. In consideration of good and valuable consideration, the receipt of which is hereby acknowledged by PROTOKINETIX, INCORPORATED, a Nevada corporation (the “Company”), the Holder named above or registered and permitted assigns (collectively the “Holder”) is hereby granted the right to purchase at any time until 5:00 P.M., Eastern time, on March 14, 2024 (the “Expiration Date”), up to ________________ (_____________) fully paid and non-assessable shares of the Company’s Common Stock, US $0.0000053 par value per share (the “Common Stock”), at an exercise price of US $0.05 per share (the “Exercise Price”), subject to further adjustment as set forth herein.

 

2.       Exercise of Warrants. This Warrant is exercisable in whole or in part at any time and from time to time prior to the Expiration Date. Such exercise shall be effectuated by submitting to the Company (as provided in Section 10 hereof) a completed and duly executed Notice of Exercise (substantially in the form attached to this Warrant) as provided in this paragraph. The date such Notice of Exercise is faxed or delivered to the Company shall be the “Exercise Date,” provided that the Holder of this Warrant tenders this Warrant to the Company within five business days thereafter. If the Holder elects to exercise only a portion of his Warrant, the Company shall issue to the Holder a new Warrant representing the remaining unexercised Warrants.

 

(a)       The Notice of Exercise shall be executed by the Holder of this Warrant and shall indicate the number of Warrant Shares then being purchased pursuant to such exercise. Upon surrender of this Warrant, together with appropriate payment of the Exercise Price for the Warrant Shares purchased, the Holder shall be entitled to receive a certificate or certificates for the Warrant Shares so purchased within ten days.

 

(b)       The Holder has the option of paying the Exercise Price per share of Common Stock for the Warrant Shares then being exercised either in cash or by certified or official bank check.

 

 

1 
 

(c)       At the option of the Company, the Company may require the Holder to exercise the Warrant, in full or partially, provided that the average closing bid price of the Company’s Common Stock as reported by OTC Markets shall have been equal to or greater than $0.25 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events) for a period of three (3) consecutive trading days ending on the date preceding the date on which the Holder receives a notice from the Company in which it announces its intention to require the exercise of the Warrants. Upon Holder receipt of said notice, the Holder shall have thirty (30) calendar days to submit to the Company a completed Form of Subscription, together with a check or wire for full payment in accordance with the provisions of this Warrant. If the Company does not receive payment within said time period, this Warrant shall expire immediately and the Holder shall have no further rights hereunder.

 

3.       Reservation of Shares. The Company hereby agrees that at all times during the term of this Warrant there shall be reserved for issuance upon exercise of this Warrant such number of shares of its Common Stock as shall be required for issuance upon exercise of this Warrant (the “Warrant Shares”).

 

4.       Mutilation or Loss of Warrant. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) receipt of reasonably satisfactory indemnification, and (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will execute and deliver a new Warrant of like tenor and date and any such lost, stolen, destroyed or mutilated Warrant shall thereupon become void.

 

5.       Rights of the Holder. The Holder shall not, by virtue hereof, be entitled to any rights of a stockholder in the Company, either at law or equity. The rights of the Holder are limited to those expressed in this Warrant and are not enforceable against the Company except to the extent set forth herein.

 

6.       Protection Against Dilution and Other Adjustments.

 

(a)       Adjustment Mechanism. If an adjustment of the Exercise Price is required pursuant to Section 6(b), the Holder shall be entitled to purchase such number of additional shares of Common Stock as will cause (i) the total number of Warrant Shares that the Holder is entitled to purchase pursuant to this Warrant, multiplied by (ii) the adjusted Exercise Price per share, to equal (iii) the dollar amount of the total number of Warrant Shares that the Holder is entitled to purchase before adjustment multiplied by the total Exercise Price before adjustment.

 

(b)       Capital Adjustments. In case of any stock split or reverse stock split, stock dividend, extraordinary dividend of cash or other assets, reclassification of the Common Stock, recapitalization, merger or consolidation, sale of assets or like capital adjustment affecting the Common Stock of the Company, the provisions of this Section 6 shall be applied as if such capital adjustment event had occurred immediately prior to the date of this Warrant and the original Exercise Price had been fairly allocated to the stock resulting from such capital adjustment. A rights offering to stockholders shall be deemed a stock dividend to the extent of the bargain purchase element of the rights.

 

(c) No Adjustment for Spin Off, Merger, or Other Events. If, for any reason, prior to the exercise of this Warrant in full, the Company spins off or otherwise divests itself of substantially all of its business or operations or disposes of all or of a part of its assets in a transaction, merges with another entity the result of which the Company has been acquired by such other entity (not including a merger simply for the purpose of reincorporation), or engages in another transaction, the result of which the Common Stock is no longer registered under the Securities Exchange Act of 1934, the holder of this Warrant will be entitled to no other consideration upon the completion of such transaction; provided that the Warrant will for all purposes will be assumed by the surviving entity of such transaction and will remain outstanding and an obligation of such surviving entity. In the event of such a transaction, the Company shall give the Holder not less than 30 days’ notice of the Company’s intention to complete such transaction, and the Holder may elect whether to exercise this Warrant during that period.

 

2 
 

7.       Representations and Warranties of the Holder.

 

(a)       Holder has received and reviewed such information about the Company’s business and proposed business, assets, financial condition, management, risks relating to the Company and the business and proposed business in which the Company conducts its operations, and such other information regarding the acquisition of the Warrant as Holder has (in consultation with such advisors as Holder has deemed appropriate) determined to be necessary or appropriate in the circumstances; and further acknowledges that Holder or its representatives have been afforded the opportunity to ask such questions as Holder or its representatives have deemed necessary.

 

(b)       Holder acknowledges that it has had the opportunity to consult with its legal, financial, accounting, tax, and investment advisers regarding Holder’s personal circumstances and the advisability of Holder’s proposed receipt of the Warrant to the extent that Holder has determined such consultation to be appropriate.

 

(c)       Holder has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Warrant and the Warrant Shares, having been represented by advisors to the extent it deemed appropriate, and has so evaluated the merits and risks of such investment and is able to bear the economic risk of such investment and, at the present time, is able to afford a complete loss of such investment.

 

(d)       Holder acknowledges that neither the Warrant nor any of the Warrant Shares have been registered under the Securities Act of 1933, as amended (the “1933 Act”), or under any state securities or “blue sky” laws of any state of the United States, and are being offered only in a transaction not involving any public offering within the meaning of the 1933 Act and, if Holder is not a U.S. Person, the Company will rely on Rule 903 of Regulation S as an exemption from registration under the 1933 Act for the issuance of the Warrant and the Warrant Shares.

 

(e)       If the Holder is not a U.S. Person, Holder is outside the United States when receiving and executing this Warrant Agreement and Holder is resident in the jurisdiction set out beneath the Holder’s signature to this Warrant Agreement.

 

(f)       Holder has not acquired the Warrant as a result of, and will not itself engage in, any “directed selling efforts” (as defined in Regulation S under the 1933 Act) in the United States in respect of the Warrant or the Warrant Shares which would include any activities undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United States for the resale of any of the Warrant or the Warrant Shares.

 

(g)       If Holder is not a U.S. Person, Holder acknowledges and agrees that the Warrant and the Warrant Shares may not be offered or sold to a U.S. Person or for the account or benefit of a U.S. Person (other than a distributor) prior to the end of the expiration of a period of one year after the Date of Grant.

 

(h)       If Holder is not a U.S. Person, Holder is not acquiring the Warrant for the account or benefit of, directly or indirectly, any U.S. Person.

 

 

3 
 

(i)       Holder is acquiring the Warrant as principal for its own account, for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof, in whole or in part, and no other person has a direct or indirect beneficial interest in such Warrant.

 

(j)       Holder agrees to resell the Warrant Shares only in accordance with the provisions of Regulation S, pursuant to registration under the 1933 Act, pursuant to an available exemption from registration, in accordance with applicable state or provincial securities laws, in accordance with securities laws of the International Jurisdiction (as defined below), and the Company has received an opinion of legal counsel or other evidence reasonably satisfactory to the Company that an exemption is available for such sale.

 

(k)       Holder agrees not to engage in hedging transactions with regard to such securities unless in compliance with the 1933 Act.

 

(l)       The Company will refuse to register any transfer of the Warrant or the Warrant Shares not made in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the 1933 Act or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act.

 

(m)       If Holder is not a U.S. Person, Holder acknowledges that the statutory and regulatory basis for the exemption claimed for the grant of the Warrant, although in technical compliance with Regulation S, would not be available if the offering is part of a plan or scheme to evade the registration provisions of the 1933 Act.

 

(n)       Neither the Warrant nor the Warrant Shares are listed on any stock exchange and no representation has been made to the Holder that that the Warrant or the shares underlying the Warrant will become listed on any stock exchange.

 

(o)       Holder is knowledgeable of, or has been independently advised as to, the applicable securities laws of the securities regulators having application in the jurisdiction in which Holder is resident (the “International Jurisdiction”) which would apply to the acquisition, exercise and disposition of the Warrant and the Warrant Shares.

 

(p)       Holder is receiving the Warrant pursuant to exemptions from prospectus or equivalent requirements under applicable securities laws or, if such is not applicable, Holder is permitted to receive the Warrant under the applicable securities laws of the securities regulators in the International Jurisdiction without the need to rely on any exemptions.

 

(q)       Holder is not aware of any advertisement of the Warrant or the Warrant Shares and is not acquiring the Warrant as a result of any form of general solicitation or general advertising including advertisements, articles, notices or other communications published in any newspaper, magazine or similar media or broadcast over radio or television, or any seminar or meeting whose attendees have been invited by general solicitation or general advertising.

 

(r)       The Warrant is being granted under an exemption from the prospectus requirements in Canada and certain restrictions may apply to the resale of the Warrant and the Warrant Shares in or from a jurisdiction of Canada.

 

 

4 
 

8.       Restricted Securities.

 

(a)       The Holder understands that neither the Warrant nor the Warrant Shares are registered under the 1933 Act, as amended, and the Company has not made any undertaking to register either the Warrant or the Warrant Shares under the 1933 Act except as hereinafter expressly provided. The Holder represents that the Warrant is being acquired by it and that, if at the time of Warrant exercise there is no effective registration statement, the Warrant may only be exercised to the extent an exemption from registration under federal and applicable state law exists for such exercise, and in such event the Warrant Shares will be acquired by it for investment purposes and all certificates for the shares issued upon exercise of the Warrant will bear the following legends:

 

 

“NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SEcurities act of 1933, as amended (the “1933 Act”) AND ARE “RESTRICTED SECURITIES” AS DEFINED IN RULE 144 of the 1933 ACt, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT, the availability of which is to be established by an opinion of legal counsel or other evidence reasonably satisfactory to the Company that an exemption is available for such sale AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

[For Canadian residents:]

 

“UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [FOUR MONTHS PLUS ONE DAY] FROM THE CLOSING DATE”

 

 

(b)       If there is no registration statement effective with respect to the Warrant Shares at the time the Holder elects to exercise this Warrant, the Holder acknowledges and agrees that it will not be permitted to exercise this Warrant unless the Holder executes a subscription agreement satisfactory to the Company including all of the representation and warranties set forth in this Warrant Agreement, together with such other representations and warranties to establish facts as the Company may deem necessary or appropriate at the time to comply with applicable securities laws:

 

(i)                 An investment in the Company constitutes a high degree of risk, and there can be no assurance that the Holder will receive any portion of its investment returned to it at any time. By executing this understanding, the Holder acknowledges that it understands the risks involved and it is willing and able to withstand the possible complete loss of the Holder’s investment;

 

(ii)              The Holder understands that the future conduct of the Company’s business is dependent upon a number of factors and there is no assurance that the Company will be able to conduct its operations as contemplated in this Warrant Agreement or in any other information given to the Holder;

 

(iii)            The Holder acknowledges that it has received and reviewed such information regarding the Company, its management, its assets, financial condition, and operations, as the Holder has deemed necessary or appropriate for the purposes of considering the exercise of this Warrant. Specifically, and without limitation of the generality of the foregoing, the Holder acknowledges that it has reviewed the Company’s most recent annual report as filed with the Securities and Exchange Commission and the reports filed subsequently. The Holder further represents that it has reviewed this information regarding the Company, the subscription agreement including these representations and warranties, and other information relating to the Company, its management, its financial statements, its assets and operations as the Holder has deemed necessary with its legal, investment, tax, and financial advisors to the extent the Holder has deemed such consultation appropriate. The Holder has also consulted with such advisors with regard to the advisability of this transaction to the extent the Holder has deemed such consultation to be appropriate. The Holder acknowledges that the Company has advised it that it recommends that the Holder obtain such advice and consultation.

 

 

5 
 

(iv)             The Holder is acquiring the securities upon exercise of the Warrant for its own account and not on behalf of any other person or entity. The securities are being acquired for investment purposes and not for resale or distribution; the Holder understands that there are severe limitations on its ability to resell the Warrant Shares, and that these limitations are established in part in federal and applicable state laws regulating the offer and sale of securities. The Holder understands that neither the Company nor any other person has any obligation to redeem or repurchase the Warrant Shares at any time. The Holder’s present financial condition is such that it is unlikely that it would be necessary for the Holder to dispose of the Warrant Shares in the foreseeable future.

 

(v)               The Holder represents that no part of the funds that the Holder used to exercise the Warrant will have been directly or indirectly derived from, or related to, any activity that may contravene federal, state, or international laws and regulations, including anti-money laundering laws and regulation including the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA Patriot Act) and regulations of the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC). The Holder represents that it and its affiliates are not acting directly or indirectly for or on behalf of any person, group, entity, or nation named by any Executive Order of the U.S. as a terrorist, Specially Designated National and Blocked Person (SDN) or other banned or blocked person, entity, nation, or transaction pursuant to any law, order, rule, or regulation that is enforced or administered by OFAC. The Holder further represents that it and its affiliates also are not engaged in this transaction, directly or indirectly on behalf of, or instigating or facilitating this transaction, directly or indirectly on behalf of any SDN.

 

9.       Exercise and Transfer Restrictions

 

(a)       This Warrant has not been registered under the 1933 Act and has been issued to the Holder for investment and not with a view to the distribution of either the Warrant or the Warrant Shares. This Warrant may not be exercised, and neither this Warrant nor any of the Warrant Shares or any other security issued or issuable upon exercise of this Warrant may be sold, transferred, pledged or hypothecated in the absence of an effective registration statement under the 1933 Act relating to such transaction or an opinion of counsel or other evidence reasonably satisfactory to the Company that registration is not required under the 1933 Act. Each certificate for the Warrant and the Warrant Shares shall contain a legend on the face thereof, in form and substance satisfactory to counsel for the Company, setting forth the restrictions on transfer contained in this Section 9.

 

(b)       This Warrant was issued as part of certain “investment units” consisting of the Warrants and shares of Common Stock. The Warrants are non-detachable from the shares of Common Stock forming the other part of the investment units and may not be sold, transferred or hypothecated except in conjunction a simultaneous transfer of the shares of Common Stock to which the Warrants are attached.

 

 

6 
 

(c)       Subject to compliance with the restrictions on transfer set forth in this Section 9, each transfer of this Warrant and all rights hereunder, in whole or in part, shall be registered on the books of the Company to be maintained for such purpose, upon surrender of this Warrant at the Company’s address set forth below, together with a written assignment of this Warrant duly executed by the holder or its agent or attorney. Upon such surrender and delivery, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees and in the denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, if any. A Warrant, if properly assigned in compliance with the provisions hereof, may be exercised by the new holder for the purchase of shares underlying the Warrant without having a new Warrant issued. Prior to due presentment for registration of transfer thereof, the Company may deem and treat the registered holder of this Warrant as the absolute owner hereof (notwithstanding any notations of ownership or writing thereon made by anyone other than a duly authorized officer of the Company) for all purposes and shall not be affected by any notice to the contrary. All Warrants issued upon any assignment of Warrants shall be the valid obligations of the Company, evidencing the same rights, and entitled to the same benefits as the Warrants surrendered upon such registration of transfer or exchange.

 

10.       Notices. Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, telegraphed, telexed, sent by facsimile transmission or sent by certified, registered or express mail, postage pre-paid. Any such notice shall be deemed given when so delivered personally, telegraphed, telexed or sent by facsimile transmission, or, if mailed, two days after the date of deposit in the United States mails, as follows:

 

(i)             if to the Company, to:

ProtoKinetix, Incorporated

412 Mulberry Street

Marietta, OH 45750

Attn: CEO

Telephone No.: (304) 299-5070

 

(ii) if to the Holder, to the address included in the Company’s records.

 

Any party may be given notice in accordance with this Section 10 if any of the parties designates another address or person for receipt of notices hereunder.

 

11.       Supplements and Amendments; Whole Agreement. This Warrant may be amended or supplemented only by an instrument in writing signed by the parties hereto. This Warrant contains the full understanding of the parties hereto with respect to the subject matter hereof and thereof and there are no representations, warranties, agreements or understandings other than expressly contained herein and therein.

 

12.       Dispute Resolution and Venue.

(a)              All disputes arising out of or relating to this Warrant Agreement and all actions to enforce this Warrant Agreement shall be adjudicated in the state courts of Colorado or the federal courts sitting in the City and County of Denver, Colorado. The parties hereto irrevocably submit to the jurisdiction of such courts in any suit, action or proceeding relating to any such dispute. So far as is permitted under applicable law, this consent to personal jurisdiction shall be self-operative and no further instrument or action, other than service of process or as permitted by law, shall be necessary in order to confer jurisdiction upon the undersigned in any such court.

(b)             This Warrant is made under, shall be construed in accordance with, and shall be governed by the laws of the State of Colorado without regard to conflicts of laws principles.

 

 

7 
 

13.       Counterparts. This Warrant may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

14.       Descriptive Headings. Descriptive headings of the several sections of this Warrant are inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof.

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Warrant effective as of _________ ___, 20__.

 

PROTOKINETIX, INCORPORATED

 

 

By: ____________________________

Clarence E. Smith, President & CEO

Accepted and agreed,

 

[HOLDER NAME]

 

_________________________ 

 

 

8 
 

NOTICE OF EXERCISE OF WARRANT

 

The undersigned hereby irrevocably elects to exercise the right, represented by the Warrant Agreement dated as of ___________ ___, 20__ to purchase _________________ shares of the Common Stock of ProtoKinetix, Incorporated at an exercise price of US $_________ per share, and tenders herewith payment in accordance with said Warrant Agreement.

 

_ CASH: US $ = (Exercise Price x Warrant Shares)

 

Payment is being made by:

_        enclosed check

_        wire transfer

 

I understand that I may only exercise this Warrant if there is a registration statement relating to the exercise of this Warrant that is effective under federal, applicable state law and applicable non-U.S. law, or alternatively, if there is an exemption from registration available under federal, applicable state law, and applicable non-U.S. law (which exemption must be established to the satisfaction of ProtoKinetix, Incorporated).

 

I represent that all representations and warranties made by me in the Subscription Agreement dated _____ ____, 20__ are true and correct as of the date of this notice.

 

I understand that ProtoKinetix, Incorporated may require that I provide it information regarding my financial status, state of residence, and other information necessary to determine whether the exercise is subject to an effective registration statement or to determine whether an applicable exemption is available. To the extent required by the Company to establish an exemption from registration, I will provide the Company information as to my status as an accredited investor and execute a subscription agreement in the form requested by the Company provided that form is reasonably consistent with industry custom and practice. Alternatively, I understand that I may deliver a legal opinion regarding the availability of an exemption from such registration, which legal opinion must be acceptable to ProtoKinetix, Incorporated in its reasonable discretion.

 

I understand that ProtoKinetix, Incorporated will issue the shares subject to this exercise in electronic form only and I will not receive a physical stock certificate.

 

 

Signed:________________________

 

 

Date:__________________

 

EX-4.6 4 ex4x6.htm FORM 4.6

Exhibit 4.6

 

 

DESCRIPTION OF OUR SECURITIES

 

The following description summarizes important terms of our capital stock and our other securities. For a complete description, you should refer to our Articles of Incorporation and bylaws, forms of which are incorporated by reference to the exhibits to the annual report of which this is a part, as well as the relevant portions of the Nevada Revised Statutes (“NRS”).

 

Capital Stock

 

The Company has one class of stock: common. The Company’s Amended and Restated Articles of Incorporation authorizes the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share, and 902,670 shares of preferred stock, par value $0.0000053 per share.

 

In the discussion that follows, we have summarized selected provisions of our Certificate of Incorporation, amended and restated bylaws (the “Bylaws”), and Nevada law relating to our capital stock. This summary is not complete. This discussion is subject to the relevant provisions of Nevada law and is qualified in its entirety by reference to our Articles of Incorporation and our Bylaws. You should read the provisions of our Articles of Incorporation and our Bylaws as currently in effect for provisions that may be important to you. Please also see “Effect of Certain Provisions of Our Bylaws” below.

 

Common Stock

 

Each share of common stock has equal and identical rights to every other share for purposes of dividends, liquidation preferences, voting rights and any other attributes of the Company’s common stock. No voting trusts or any other arrangement for preferential voting exist among any of the stockholders, and there are no restrictions in our Articles of Incorporation, or Bylaws precluding issuance of further common stock or requiring any liquidation preferences, voting rights or dividend priorities with respect to this class of stock.

 

Effective February 16, 2022, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to reflect the increase in the number of authorized shares of common stock from 400,000,000 shares to 500,000,000, as approved by the stockholders on February 11, 2022. The stockholders also approved additional provisions to the Articles of Incorporation addressing officer and director liability, conflicting interest transactions, and director and officer indemnification.

 

All holders of shares of common stock are entitled to participate ratably in dividends when and as declared by the Company’s board of directors out of the funds legally available. The Company has not paid any dividends on its shares of common stock since its inception and presently anticipates that no dividends on such shares will be declared in the foreseeable future. In the event of any distribution of assets upon the dissolution and liquidation of the Company, all holders of shares of common stock are entitled to the right to receive ratably and equally all of the assets of the Company.

 

Holders of common stock have no preemptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions.

 

Warrants

 

Between March 18, 2022 and May 11, 2022, the Company issued 7,300,000 warrants as part of a unit offering, consisting of one share of common stock and one warrant. The warrants are immediately exercisable to purchase one common share at an exercise price of $0.05 expiring March 14, 2024.

 

On December 13, 2022, the Company cancelled 6,000,000 warrants issued July 15, 2019 with an exercise price of $0.26 in consideration for patent assignments, and expiring July 14, 2024. The Company reissued the 6,000,000 warrants with an exercise price of $0.028 and expiring December 12, 2028. The warrants are immediately exercisable.

 

 

 
 

Outstanding Stock Options and Warrants

 

As of December 31, 2022, there were options to acquire a total of 94,290,000 shares of common stock granted pursuant to our 2017 equity incentive plan at a weighted-average exercise price of $0.03, all of which are currently issuable upon exercise, and there were warrants to acquire a total of 13,300,000 shares of our common stock all of which are currently exercisable, at a weighted-average exercise price of $0.04.

 

Effect of Certain Provisions of Our Bylaws

 

Our Bylaws contain provisions that could have the effect of delaying, deferring, or discouraging another party from acquiring control of us. These provisions and certain provisions of Nevada law, which are summarized below, could discourage takeovers, coercive or otherwise.

 

Stockholder Meetings. Our Bylaws establish an advance notice procedure for stockholder proposals to be brought before any meeting of our stockholders, including proposed nominations of persons for election to our board of directors. At an annual or special meeting, stockholders may only consider proposals or nominations (i) specified in the notice of meeting; (ii) brought before the meeting by or at the direction of our board of directors or (iii) otherwise properly brought before the meeting by any stockholder who is a stockholder of record on the date of the giving of the notice and on the record date of the meeting and who complies with the notice procedures set forth in our Bylaws. The Bylaws do not give our Board of Directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting of our stockholders. However, our Bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of the Company.

 

Removal of Directors. Our Bylaws and Nevada law provide that any director may be removed from the Board of Directors by the vote or written consent of stockholders representing not less than two-thirds of the voting power of the issued and outstanding shares entitled to vote.

 

Filling Vacancies in the Board. Our Bylaws provide that newly created directorships resulting from any increase in the authorized number of directors or any vacancies in the Board of Directors resulting from death, resignation, retirement, disqualification, removal from office or other cause shall, unless otherwise provided by law or resolution of the Board, be filled only by a majority of the directors then in office, though less than a quorum. The directors so chosen shall hold office for a term expiring at the annual meeting of stockholders at which the term of office of the class to which they have been chosen expires.

 

No Cumulative Voting. Our Articles of Incorporation and our Bylaws do not provide for cumulative voting in the election of directors.

 

 

Nevada Anti-Takeover Statute

 

In addition, the Nevada Revised Statues contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. Nevada’s “acquisition of controlling interest” statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These “control share” laws provide generally that any person that acquires a “controlling interest” in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights. These laws will apply to the Company as of a particular date if the Company were to have 200 or more stockholders of record (at least 100 of whom have addresses in Nevada appearing on the Company’s stock ledger at all times during the 90 days immediately preceding that date) and do business in the State of Nevada directly or through an affiliated corporation, unless the Company’s Articles of Incorporation or Bylaws in effect on the tenth day after the acquisition of a controlling interest provide otherwise. These laws provide that a person acquires a “controlling interest” whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares which it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become “control shares” to which the voting restrictions described above apply. These laws may have a chilling effect on certain transactions if the Articles of Incorporation or Bylaws are not amended to provide that these provisions do not apply to the Company or to an acquisition of a controlling interest, or if the Company’s disinterested stockholders do not confer voting rights in the control shares.

 

 

 
 

Nevada’s “combinations with interested stockholders” statutes (NRS 78.411 through 78.444, inclusive) provide that specified types of business “combinations” between certain Nevada corporations and any person deemed to be an “interested stockholder” of the corporation are prohibited for two years after such person first becomes an “interested stockholder” unless the corporation’s board of directors approves the combination (or the transaction by which such person becomes an “interested stockholder”) in advance, or unless the combination is approved by the board of directors and sixty percent of the corporation’s voting power not beneficially owned by the interested stockholder, its affiliates and associates. Furthermore, in the absence of prior approval certain restrictions may apply even after such two-year period. For purposes of these statutes, an “interested stockholder” is any person who is (1) the beneficial owner, directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation, or (2) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then- outstanding shares of the corporation. The definition of the term “combination” is sufficiently broad to cover most significant transactions between a corporation and an “interested stockholder”. These laws generally apply to Nevada corporations with 200 or more stockholders of record. However, a Nevada corporation may elect in its articles of incorporation not to be governed by these particular laws, but if such election is not made in the corporation’s original articles of incorporation, the amendment (1) must be approved by the affirmative vote of the holders of stock representing a majority of the outstanding voting power of the corporation not beneficially owned by interested stockholders or their affiliates and associates, and (2) is not effective until 18 months after the vote approving the amendment and does not apply to any combination with a person who first became an interested stockholder on or before the effective date of the amendment. The Company has not made such an election in its original articles of incorporation or in its Amended and Restated Articles of Incorporation.

 

Further, NRS 78.139 also provides that directors may resist a change or potential change in control of the corporation if the board of directors determines that the change or potential change is opposed to or not in the best interest of the corporation upon consideration of any relevant facts, circumstances, contingencies or constituencies pursuant to NRS 78.138(4).

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock is Transfer Online, Inc. The transfer agent’s address is: 512 SE Salmon St, Portland, Oregon 97214. Shares of our common stock offered hereby will be issued in uncertificated form only, subject to limited circumstances.

 

Market Listing

 

Our common stock is currently quoted on the OTCQB under the symbol “PKTX”.

 

Disclosure of Commission Position on Indemnification for Securities Act of 1933 Liabilities

 

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (“Securities Act”), may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

 
 

 

EX-31.1 5 ex31x1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Clarence E. Smith, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K of ProtoKinetix, Incorporated for the year ended December 31, 2022;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

March 17, 2022   /s/ Clarence E. Smith
    Name: Clarence E. Smith
    Title:

Chief Executive Officer

(Principal Executive Officer)

 

 

 

EX-31.2 6 ex31x2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

 

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael R. Guzzetta, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K of ProtoKinetix, Incorporated for the year ended December 31, 2022;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

March 17, 2023   /s/ Michael R. Guzzetta
    Name: Michael R. Guzzetta
    Title:

Principal Financial Officer & Principal Accounting Officer 

 

 

 

 

EX-32.1 7 ex32x1.htm EXHIBIT 32.1

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ProtoKinetix, Incorporated, (the “Company”) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Clarence E. Smith, Chief Executive Officer and Principal Executive Officer of the Company and Michael R. Guzzetta, Principal Financial Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned’s knowledge and belief:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

 

 

March 17, 2023   /s/ Clarence E. Smith
    Name: Clarence E. Smith
    Title:

Chairman of the Board and
Chief Executive Officer

(Principal Executive Officer)

 

 

March 17, 2022   /s/ Michael R. Guzzetta
    Name: Michael R. Guzzetta
    Title:

Principal Financial Officer & Principal Accounting Officer 

 

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

 

 

EX-101.SCH 8 pktx-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation – Going Concern Uncertainties link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Prepaid Expenses and Deposits link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Related Party Transactions and Balances link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingency link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Prepaid Expenses and Deposits (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Basis of Presentation – Going Concern Uncertainties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Prepaid Expenses and Deposits (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Stock Options (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stock Options (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Warrants (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Warrants (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Related Party Transactions and Balances (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Commitments and Contingency (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Income Taxes (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 pktx-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 pktx-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 11 pktx-20221231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Award Type [Axis] Equity Option [Member] Antidilutive Securities [Axis] Warrant [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Patent Application Rights [Member] Related Party [Axis] Grant Young [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Technology Transfer Agreement [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Exercise Price Range [Axis] Stock Option 1 [Member] Stock Option 2 [Member] Stock Option 3 [Member] Warrant 1 [Member] Warrant 2 [Member] Warrant 3 [Member] Warrant 4 [Member] Warrant 5 [Member] Warrant 6 [Member] Warrant 7 [Member] Warrant 8 [Member] Warrant 9 [Member] Sale of Stock [Axis] Private Placement [Member] Investors [Member] Investors One [Member] Investors Two [Member] Investors Three [Member] Investors Four [Member] Investors Five [Member] Investors Six [Member] Investors Seven [Member] Investors Eight [Member] Investors Nine [Member] Chief Financial Officer [Member] Chief Executiveand Director Officer [Member] C F O [Member] Chief Executiveand Officer [Member] Director [Member] Derivative Instrument [Axis] Consultant [Member] Title of Individual [Axis] Chief Executive Officer [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current Assets Cash Prepaid expenses and deposits (Note 3) Total current assets Intangible assets (Note 4) Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable and accrued liabilities Total liabilities Stockholders' Equity Common stock, $0.0000053 par value; 500,000,000 common shares authorized; 322,880,151 and 297,393,485 shares issued and outstanding for 2022 and 2021 respectively (Note 7) Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] EXPENSES Amortization – intangible assets (Note 4) General and administrative Professional fees (Note 8) Research and development Share-based compensation (Notes 5 and 8)  Operating Income (Expenses) Net loss for the year Net loss per common share (basic and diluted) Weighted average number of common shares outstanding (basic and diluted) Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, Shares Fair value of share-based compensation Issuance of common stock pursuant to private placement offering Issuance of common stock pursuant to private placement offering, Shares Issuance of common stock pursuant to warrant exercise Issuance of common stock pursuant to warrant exercise, Shares Issuance of common stock pursuant to cashless option exercise Issuance of common stock pursuant to cashless option exercise, Shares Extension of the terms of warrants Net loss for the year Ending balance, value Ending balance, Shares Statement of Cash Flows [Abstract] CASH FLOWS USED IN OPERATING ACTIVITIES Net loss for the year Adjustments to reconcile net loss to cash used in operating activities: Amortization – intangible assets Fair value of compensatory options granted Changes in operating assets and liabilities:    Prepaid expenses and deposits Accounts payable and accrued liabilities Net cash used in operating activities CASH FLOWS USED IN INVESTING ACTIVITIES Purchase of intangible assets Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common stock for cash Net cash from financing activities Net change in cash Cash, beginning of year Cash, end of year Cash paid for interest Cash paid for income taxes  Supplementary information – non-cash transactions: There were no non-cash financing or investing activities. Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation – Going Concern Uncertainties Accounting Policies [Abstract] Summary of Significant Accounting Policies Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Prepaid Expenses and Deposits Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Stock Options Stock Options Warrants Warrants Equity [Abstract] Stockholders' Equity Related Party Transactions [Abstract] Related Party Transactions and Balances Commitments and Contingencies Disclosure [Abstract] Commitments and Contingency Income Tax Disclosure [Abstract] Income Taxes Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Cash Fair Value of Financial Instruments Income Taxes Intangible assets – patent and patent application costs Research and Development Costs Loss per Share and Potentially Dilutive Securities Share-Based Compensation Common stock Related Party Transactions Recent Accounting Pronouncements Schedule of prepaid expenses Intangible asset transactions Schedule of Share-based Compensation, Stock Options, Activity Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of options by exercise price Schedule of Stockholders' Equity Note, Warrants or Rights Schedule of outstanding and exercisable Schedule of assumptions Schedule of Effective Income Tax Reconciliation Schedule of Deferred Tax Assets Cash consideration Additional patent applications Warrant issued Fair value adjustment of warrants Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Antidilutive shares Rental deposit Deposit on February 11, 2022 shareholder meeting Total Prepaid Expenses and Deposits Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Beginning balance Additions Ending balance Beginning balance Amortization Ending balance Net carrying amounts Intangible assets Amortization of Intangible Assets Direct operating costs Intangible assets useful lives Outstanding, beginning Weighted average exercise price beginning balance Options cancelled Weighted Average Exercise Price, cancelled Options exercised Weighted Average Exercise Price, exercised Option granted Weighted Average Exercise Price, granted Outstanding, ending Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighed average exercise price ending balance Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected forfeiture rate Expected life Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Weighed average exercise price Number of outstanding Number of options exercisable Options granted Options exercisable Share based compensation exercisable per share Expiring date Share-based Payment Arrangement, Expense Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Share based compensation exercisable per share Warrant outstanding, beginning Warrant weighted average exercise price, beginning Warrant granted Warrant weighted average exercise price, granted Warrants exercised Warrant weighted average exercise price, exercised Warrants expired Warrant weighted average exercise price, expired Warrants cancelled Warrant weighted average exercise price, cancelled Warrant outstanding, ending Warrant weighted average exercise price, ending Class of Warrant or Right, Outstanding Warrant weighted average exercise price Expiry Date Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Warrants issued Number of shares cancelled Warrant exercise price Warrant expiring date Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Shares authorized Dividends declared Number of shares issued Share Price Stock Issued During Period, Value, New Issues Warrants exercised Total proceeds Option exercised Warrants to purchase Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Related Party Transaction, Amounts of Transaction Increase (Decrease) in Due from Officers and Stockholders, Current Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Modification incremental fair value option Options granted Expected term Exercisable price Option expiration date Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Share-based Payment Arrangement, Expense, after Tax Due to Related Parties, Current Research and development expense Travel and entertainment expense Travel expenses term Net loss for the year Expected income tax recovery Non-deductible expenses Adjustment to prior years provision versus statutory tax returns Change in valuation allowance Total income tax expense (recovery) Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount Deferred Tax Assets, Capital Loss Carryforwards Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Custom Element. Custom Element. Warrant Exercise Price Custom Element. Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Assets, Current Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Net Income (Loss) Attributable to Parent Shares, Outstanding Net Income (Loss) Available to Common Stockholders, Basic Increase (Decrease) in Prepaid Expenses, Other Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents StockOptionsTextBlock WarrantsTextBlock Stockholders' Equity Note Disclosure [Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Share Based Compensation Arrangement ByShare Based Payment Awards Options Outstanding Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled Warrant 13 [Member] Effective Income Tax Rate Reconciliation, Tax Credit, Amount Deferred Tax Assets, Valuation Allowance EX-101.PRE 12 pktx-20221231_pre.xml XBRL PRESENTATION FILE GRAPHIC 13 dheader.jpg GRAPHIC begin 644 dheader.jpg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end GRAPHIC 14 footer.jpg GRAPHIC begin 644 footer.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# 8$!08%! 8&!08'!P8("A *"@D) M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_ MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P 1" !@ 9T# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#ZFHHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\<^(7QBN/"G MBN[T>/1HKE8 A$K7&TG7+35V9U:L:2YIGL=%?/7_#0UU_T+ ML/\ X%'_ .)H_P"&AKK_ *%V'_P*/_Q-=/\ 9F)_E_%'/]?H=SZ%HKYZ_P"& MAKK_ *%V'_P*/_Q- _:%NR<#PY"3Z"Z/_P 31_9F)_E_%!]?H=SZ%HKP6+XY MZS,,Q^$?UJ3 MC13;2;^2W/=:*\/3XT:N_">']-8^@U-?\*BO?C9K=DF^Y\)*L8ZN+HL/T6M/ M[-Q';\48?7:/?\#W6BL#P)K[^)_"FGZQ);BW:Z4L8E;<%PQ7KWZ5OUQRBXR< M7NCIC)22:"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S1 M\1_"UQXN^,6L:?I]Y:PWHAC>.*? M2PE1B(VSC#8!P/?I72Z/\.CJ'B.XT7^W]-%W K,PC#MD)][!QQCWKT74EE\; M>1-I>^W\0:;/$]["H"_;H P_>*>Y'I^'I7)_"DK_ ,+CU;/*[;[..N,FO8EB M)N$FG9I;'FJA",HIZILYZWT/196ECTK5=,N[A(WD5;KS@9-JDX4; ,\=":E\ M/Z'J6O:!?ZEIFKV%NEC&9;FUBA9947KD +\PXZBLR*7PR^E:JEG9ZFNI/$JV MIGD61=WF)N "J,-MSSZ9J]\,5UO3?%EM?:?"\,,.3=O<*5B\C^,/[>WKC%;3 MQE'E6&.1C&#G%9RJ<]- M3[M?+6WWFL(NG4<4[:/JU?\ X!YGI]C<:C>1VMC \\\C!51!DY)X^E=MK E\ M#PWFA7TPNM3!(*+DI&".#D]NQ^-+*,QRE5$EHQ!(."F< M\CM6IH'A+4]*\17MW!K&AW%\^\LKV3@1!_F(RK#/![]J]%CT..+3K6SAGE$5 MO<"="WS' ;<%R>W;UQ2KHP36+N_2?!N R[!QA N,_@#71+&RDG=[^2,5AHQ M:LCS73_"CVR?VC9:EX?3Y@B3,DQ6)W VD O@'YAC/M5"3X6WWLM*DT[S3-;2.C2+*@.[ (^AV_AV MXHN/#,,VD0:>;NY\J ,8W+9WZU3QLD])=0^K1:U1YII'@273_#= M]X4?5M'O+5V,TZ3P3%HV'\2D-\I^7MZ'WINF?#QM.\+W&@+JVCR6FJ;)G=TE MWOR-C [_ )1T'O7KS::6NKN8SDM&H7B6,SR;#! M#;S# _>+$1R_"9[S1(- @UG2T-KXT#PWK&FG6=(NK"^<0W3312':P.% P_P K9(]\ MXKU>/0X8M7;4ED=;EMV[;P&!Z!AWV\X/7DU33PRD4%W%%>2K]I>*9RP#?O$8 M$O\ \"VC(]J;QU1JSEIO\Q?58)W2)/ >@OX9\)Z?H\LXN'M5*F11@-EB?ZUO MU%;HZ1!9I?-?G+X S^%2UPRDY26XCD+C^':Q"G/\JT;76]/NM2 M>QAFS<(7'3ABA < ]RI90?3- &G12UAQ^(K1[4W@S]C>;[/ Z\FXDW%?D7N, M@X/?KTYH VZ*P4\5Z1)):*EUN%UY6QU4[09,^6&/8MM( /?\*L:QKMEI)=;E MI&=(FN'2)"[)$#@N0.V3_ATH UJ*.V>WK2T )16)XE\0VN@6KS745S)M3S"( MHR1C>B?>Z Y<<9SC..E6M$U6+5H+B6&.6(07,UJPDP#NCG&?I0!HT5E M:AK=G87BVTQD:5MA8(A;RP[[%9L= 6X_/L*T898YXQ)"X=&Z,IR#^- $E%%1 MP31SQ[X75T)(#*JY[_3U% &S16#XB\3Z?H-S M;P7PN3)/%-,OE1%QLB 9R<>@.<=?2MBSN(KNUAN;:0203()(W7HRD9!^F#0! M-10>*P8_%FD2Z7'?PW#26\DTL";8VW,T1?S %QGY?+L_3?'FE:C8WMU;P:HJV@#2)-82Q/@@G MA64%N%)XH ZRBJUA>V^H:?;WUE()[6>-9HG3HZL,@C\#61X=\6:1XADV:=.[ M.8O/59(VC+1[BNX9'(W*1['\* .@HJ&\N$L[6:XE#E(D,AV*6; '. .2?:L> MS\1PW>MR:?%:W6Q&\K[3L_=^9Y8D*'NI"LO+8!/ YH WJ*AO+F"SM)KJZE2* MWA0R22.Q!_I0!I44R>6.WA: M6=Q'&HRSL< #ZU)0 E%07EPEG:3W,V_RX4,C;06. ,G '?BJFDZS::M%!+9& M1H;BW2ZC!7.^'?%^E:_,D5@TRRR1 M-/<10R1J^QF'KAN/7IZT =%16/;^(;"XU3[#"\C2;I(PX0^67CQO7=ZC/\ M_0UHWUU!8V8Y_>21--L/E*\:[G4OT! S[<$=: -BBJ&D7_\ :=FE MY'&4MY@'@+=70]&QVSUQUQUJ_0 5Y[!J']D>+O'FHR6UR\:0V;1[;>1_-94< M$* "6P2 =N<5Z%2T >&W&E&ZTB]?2+:^>'4=&O-/1[BV>%Y;QYPS,48 J'9V M(SV7VK?\(Z)?VOB/1X9UDSIEUJDUQ*P(#K-(#$<]]P;/_ 3Z5ZG10!DM%JTL M>IQSRVBJZLMF858.F0<%R3R+?SZ05N8E5V!D2XME4X'&XK&S>N,U=C@O+G76AEN+VQTZXNM0,$T5J MSGS_ +6CJ1Z%D'RL>,;J]HHH \\\:6KR>,+*\T8W-OKMI%" -I,%_;/*1)"_ M&,J!NSU7(/2N%TO1[J31IAI=KJ$6H6.@DV:XEC"78>=3M4X!;#?CP?2O:/$& MN6?A^P^UZDTBVXW9:.-I"H"EB2 ,X 4G-10^(;2XT"[U>!;EK:V21V4QE'8( M,G"MC\/6@#S5+.6;6+%8M4U!-&O87>VE6Q8"&XWP_NU7^$[4;!;N7KJOA7<0 M6GA^ST8V\]O=H+B9T>!D7BX8'DC!ZCIVYKLM/NEO;&VNX@1'/&LJ@]<, 1_. MJ5SJ%O;^(K&Q>&0W5Y#*T]>H\T9_%6T6\\0: D_VY+46>H+++:(S%=T:!1D _>Y&._2L M+2(-;D%C_;UE);7IG@:XAC1A%%I_V'$L8 Z#S-XVCG?C':O7-1O8[&-&DRSR M2+%$@ZN[=!_7V S5237[1/M\C-BTL#LGN">!)QE!W)&0/KQUH Q/A@LMOH4] MI>I-]MLYS#++(#^^0*/*<''/[O8#C^(-WKB]#M+F/3]%U%[>X\BTU'61+&8V M#?OGE,3;<9PPP 00.F*W/$NIQV?AJ]NIOM2_VE,UNLEM:R7#QQD%=P5 3]U2?3)K8_MJP M@FOYPJ+%;.(;BY Y:7@",<98_,H^O'7.,_5O'^B:2%^U_;SEI$<0V,LWE,A M8/L4[3R.O4^%Y'4'K7EN M@Z-'I_@G2=7O(M5EU*4_VM?3;Z'4M-MK^U\PP7$2S1[T*L5(R,J>0?:@#@]4TRWUOX6:[!X7M MKE7OH/,$,JNA>0(F4P_0G9M/;.>^:H^+=2DU[6-.BMS?66D-#-!)=):,Q6Y> M-?+^7'#*-X!.0&XZUW6@^)=.U_G37F=2A<,\+1A@'*'!(Y(92,5M\T >#:OI MLC66J$VM[,98]1\[>DC&15O8FCR._P F\J!VSBM":Q>.:YU1%O4A;7VANI)$ MED L]I,?[LGF/S"IZ M(;6R2#^T\VDDR^8(VY*)N W/_=&64'T)H ;X7FA%BNE>?=7,VGPQ12RW411I M^.AR*\FO[#4='\#2Z5PKV2YNXK2:[:.!Y'CC$TQ3KCH![G )P/3WJ6XU.T@TIM2DN$%BL7G&;MLQG M/Y4 >+ZA#J:'#J/V^X.HB-ML@=X_*B**,],X;;[]*TM?A,J7%QX9@OE MLKG3IGTX*DB[=09X\'!^Z>%]N)/>O1[GQ':642G4@]LQB-R\94L8HL@;WQ]T M9/X?@:KZ9XQTK4O$,VC6POQ?1^9GS+*6.,[" Q$C*%(R1T/- 'FMQINHWQ(JZ]G?R:OJ@OI+ZRH+J:2:M)80#S)(%#W#9P(@V=H/^T>N/3GTSCWWCK1 M+32HM1\R[N+22>2V#6MG+,=\9(8%54D %2,GB@"M\-?LEGH-M8Q)=I>BT@O+ MS[0'R9)$PQRW?*-D#H>U<+\-1-H]WI=VUK?O$+*[2^\VV2)E$AV%PF2/E;;EMIQ^==%0!YUX,OSX M:TK^R-2L[I[J"]O7D>.%G_=M,\B2\#D,'4<=\^AK2\>))XF\!^([+1TE>[CW MP^6R%"[QD,5&>H8# /0YKLZCBB2(,(UV[F+'W)ZF@#R;XCZZNIP&/3K/5G<1 M'RY([>0QDCRG;Y0N?,4< ]OG[\5FEOL-]-J+6^KM#(=0:;R5EWR+]OA,*MP2 M%V%S@<[-V*]OHH \!@:[^QI;ZI:7[>6;7[&#:2X5TU)S-A<<'9Y1_P!WI7:_ M#&Z:?Q%K#B#4HK>2UA\LWL3AW9)9U"+&\\.VWB M=;N';:V=[,-/']^%B9AC_@4I7_@-1:WI7D>-? TBQRLZ"XANI44E678' <^G MFJI&>]>@TM '%_$3(T1ⅅ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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover - USD ($)
12 Months Ended
Dec. 31, 2022
Jun. 30, 2022
Cover [Abstract]    
Document Type 10-K  
Amendment Flag false  
Document Annual Report true  
Document Transition Report false  
Document Period End Date Dec. 31, 2022  
Document Fiscal Period Focus FY  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 000-32917  
Entity Registrant Name PROTOKINETIX, INCORPORATED  
Entity Central Index Key 0001128189  
Entity Tax Identification Number 94-3355026  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 109 W Main St  
Entity Address, City or Town Dalton  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 44618  
City Area Code 330  
Local Phone Number 455-4971  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Public Float   $ 9,886,980
Entity Common Stock, Shares Outstanding 322,880,151  
Auditor Firm ID 731  
Auditor Name Davidson & Company LLP  
Auditor Location Vancouver, British Columbia, Canada  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.4
BALANCE SHEETS - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current Assets    
Cash $ 25,550 $ 57,568
Prepaid expenses and deposits (Note 3) 1,050 25,995
Total current assets 26,600 83,563
Intangible assets (Note 4) 436,270 362,671
Total assets 462,870 446,234
Current Liabilities    
Accounts payable and accrued liabilities 41,530 93,268
Total liabilities 41,530 93,268
Stockholders' Equity    
Common stock, $0.0000053 par value; 500,000,000 common shares authorized; 322,880,151 and 297,393,485 shares issued and outstanding for 2022 and 2021 respectively (Note 7) 1,726 1,591
Additional paid-in capital 47,868,093 45,892,545
Accumulated deficit (47,448,479) (45,541,170)
Total stockholders' equity 421,340 352,966
Total liabilities and stockholders' equity $ 462,870 $ 446,234
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.4
BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Common Stock, Par or Stated Value Per Share $ 0.0000053 $ 0.0000053
Common Stock, Shares Authorized 500,000,000 500,000,000
Common Stock, Shares, Issued 322,880,151 297,393,485
Common Stock, Shares, Outstanding 322,880,151 297,393,485
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.4
STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
EXPENSES    
Amortization – intangible assets (Note 4) $ 58,450 $ 3,000
General and administrative 162,749 316,995
Professional fees (Note 8) 166,254 160,388
Research and development 448,873 435,872
Share-based compensation (Notes 5 and 8) 1,070,983 1,413,055
 Operating Income (Expenses) (1,907,309) (2,329,310)
Net loss for the year $ (1,907,309) $ (2,329,310)
Net loss per common share (basic and diluted) $ (0.01) $ (0.01)
Weighted average number of common shares outstanding (basic and diluted) 307,392,069 291,865,922
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.4
STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 1,531 $ 43,615,323 $ (43,192,633) $ 424,221
Beginning balance, Shares at Dec. 31, 2020 285,955,071      
Fair value of share-based compensation 1,413,055 1,413,055
Issuance of common stock pursuant to private placement offering $ 41 569,959 570,000
Issuance of common stock pursuant to private placement offering, Shares 7,668,572      
Issuance of common stock pursuant to warrant exercise $ 17 274,983 275,000
Issuance of common stock pursuant to warrant exercise, Shares 3,214,286      
Issuance of common stock pursuant to cashless option exercise $ 3 (3)
Issuance of common stock pursuant to cashless option exercise, Shares 555,556      
Extension of the terms of warrants 19,227 (19,227)
Net loss for the year (2,329,310) (2,329,310)
Ending balance, value at Dec. 31, 2021 $ 1,591 45,892,545 (45,541,170) 352,966
Ending balance, Shares at Dec. 31, 2021 297,393,485      
Fair value of share-based compensation 1,070,983 1,070,983
Issuance of common stock pursuant to private placement offering $ 135 904,565 904,700
Issuance of common stock pursuant to private placement offering, Shares 25,486,666      
Net loss for the year (1,907,309) (1,907,309)
Ending balance, value at Dec. 31, 2022 $ 1,726 $ 47,868,093 $ (47,448,479) $ 421,340
Ending balance, Shares at Dec. 31, 2022 322,880,151      
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.4
STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
CASH FLOWS USED IN OPERATING ACTIVITIES    
Net loss for the year $ (1,907,309) $ (2,329,310)
Adjustments to reconcile net loss to cash used in operating activities:    
Amortization – intangible assets 58,450 3,000
Fair value of compensatory options granted 1,070,983 1,413,055
Changes in operating assets and liabilities:    
   Prepaid expenses and deposits 24,945 (24,945)
Accounts payable and accrued liabilities (51,738) 48,309
Net cash used in operating activities (804,669) (889,891)
CASH FLOWS USED IN INVESTING ACTIVITIES    
Purchase of intangible assets (132,049) (90,985)
Net cash used in investing activities (132,049) (90,985)
CASH FLOWS FROM FINANCING ACTIVITIES    
Issuance of common stock for cash 904,700 845,000
Net cash from financing activities 904,700 845,000
Net change in cash (32,018) (135,877)
Cash, beginning of year 57,568 193,445
Cash, end of year 25,550 57,568
Cash paid for interest
Cash paid for income taxes
 Supplementary information – non-cash transactions:    
There were no non-cash financing or investing activities.
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Basis of Presentation – Going Concern Uncertainties
12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation – Going Concern Uncertainties

Note 1.  Basis of Presentation – Going Concern Uncertainties

 

ProtoKinetix, Inc. (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999.  The Company is a medical research company whose mission is the advancement of human health care.

 

The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins ("AFGP") or anti-aging glycoproteins, trademarked AAGP.  During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).

 

The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.

 

The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at December 31, 2022.  These factors raise substantial doubt about the Company's ability to continue as a going concern.

 

.

 The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities.  Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective.  Management is presently engaged in seeking additional working capital through equity financing or related party loans. In addition, any significant disruption of global financial markets, reducing our ability to access capital, could negatively affect our liquidity and ability to continue operations. The exact impact is and will remain unknown and is largely dependent upon future developments, including but not limited to information on the duration and spread of COVID-19, changes in customer demand, additional mitigation strategies proposed by governmental authorities (including federal, state, or local stay at home or similar orders), restrictions on the activities of our domestic and international suppliers and shipment of goods.

 

The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and are expressed in United States dollars.

 

Use of Estimates

 

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity- related instruments issued, deferred income taxes and the useful life and impairment of intangible assets.

 

Cash

 

Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.

 

Fair Value of Financial Instruments

 

Financial instruments, which includes cash, accounts payable and accrued liabilities are carried at amortized cost, which management believes approximates fair value due to the short-term nature of these instruments.

 

The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:

 

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable.

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions).

 

At December 31, 2022, there were no other assets or liabilities subject to additional disclosure.

 

Income Taxes

 

The Company accounts for income taxes following the assets and liability method in accordance with the ASC 740 "Income Taxes."  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.

 

Intangible assets – patent and patent application costs

 

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.

 

As at December 31, 2022, the Company does not hold any intangible assets with indefinite lives.

 

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.

 

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.

 

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs at December 31, 2022.

 

Research and Development Costs

 

Research and development costs are expensed as incurred.

 

Loss per Share and Potentially Dilutive Securities

 

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 94,290,000 stock options (December 31, 2021 – 84,690,000) and 13,300,000 warrants (December 31, 2021 –12,081,143) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.

 

Share-Based Compensation

 

The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

 

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance.

 

Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

 

Common stock

 

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

 

Related Party Transactions

 

A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

 

Recent Accounting Pronouncements

 

 The Company has determined that other significant newly issued accounting pronouncements are either not applicable to the Company’s business or that no material effect is expected on the financial statements as a result of future adoption.

 

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Prepaid Expenses and Deposits
12 Months Ended
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Deposits

Note 3.  Prepaid Expenses and Deposits

 

The following summarizes the Company's prepaid expenses and deposits outstanding as at December 31, 2022 and 2021:

 

Schedule of prepaid expenses        
   2022   2021 
Rental deposit  $1,050   $1,050 
Deposit on February 11, 2022 shareholder meeting         24,945 
Total Prepaid Expenses and Deposits  $1,050   $25,995 

 

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Intangible Assets
12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 4. Intangible Assets

 

Intangible asset transactions are summarized as follows:

 

Intangible asset transactions            
   Patent Rights   Patent Application
Rights
   Total 
Cost               
Balance, December 31, 2020  $30,000   $261,186   $291,186 
Additions         90,985    90,985 
Balance, December 31, 2021  $30,000   $352,171   $382,171 
Additions         132,049    132,049 
Balance, December 31, 2022  $30,000   $484,220   $514,220 
Accumulated amortization               
Balance, December 31, 2020  $16,500   $     $16,500 
Amortization   3,000          3,000 
Balance, December 31, 2021  $19,500   $     $19,500 
Amortization   3,000    55,450    58,450 
Balance, December 31, 2022  $22,500   $55,450   $77,950 
                
Net carrying amounts               
December 31, 2021  $10,500   $352,171   $362,671 
December 31, 2022  $7,500   $428,770   $436,270 

 

During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the "Patent Assignment") with the Institut National des Sciences Appliquees de Rouen ("INSA") for the assignment of certain patents and all rights associated therewith (the "Patents"). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the year ended December 31, 2022, the Company recorded $58,450 (2021 - $3,000) in amortization expense associated with the Patents Rights.

 

During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the "Patent Application Rights").  In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company incurred an additional $449,220 in direct costs relating to the Patent Application Rights, $132,049 of which were incurred during the year ended December 31, 2022.

 

The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty from any product developed as a result of research done at the University.

 

During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled "Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells" (the "New Patent Application Rights").  In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid).  The Company incurred $2,415 in direct costs relating to the New Patent Application Rights during the year ended December 31, 2016.

 

The Company amortizes patents and licenses that have been filed over their useful lives which range between 18.5 to 20 years. The costs of provisional patents and pending applications is not amortized until the patent is filed and is reviewed each reporting period.

  

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Options
12 Months Ended
Dec. 31, 2022
Stock Options  
Stock Options

Note 5.  Stock Options

 

Pursuant to an amendment on March 15, 2022, the aggregate number of shares that may be issued under the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”) is 97,700,000 shares, subject to adjustment as provided therein. The 2017 Plan is administered by the Company’s Board of Directors, or a committee appointed by the Board of Directors, and includes two types of options. Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended, are referred to as incentive options. Options that are not intended to qualify as incentive options are referred to as non-qualified options. The exercise price of an option may be paid in cash, in shares of the Company's common stock or other property having a fair market value equal to the exercise price of the option, or in a combination of cash, shares, other securities and property.

 

As of December 31, 2022, there are 94,290,000 options granted and outstanding under the 2017 Plan.

 

Stock option transactions are summarized as follows:

 

               
   Number of
Stock Options
   Weighted Average Exercise Price   Weighted Average Remaining Life 
       $   (Years) 
Outstanding, December 31, 2020   82,650,000    0.15      
     Options cancelled   (76,100,000)   0.16      
     Options exercised   (750,000)   0.07      
     Options granted   78,890,000    0.11      
Outstanding, December 31, 2021   84,690,000    0.15    4.23 

 

   Number of
Stock Options
   Weighted Average Exercise Price   Weighted Average Remaining Life 
       $   (Years) 
Outstanding, December 31, 2021   84,690,000    0.15      
     Options cancelled   (93,540,000)   0.14      
     Options expired   (400,000)   0.06      
     Options granted   103,540,000    0.03      
Outstanding, December 31, 2022   94,290,000    0.03    6.00 

 

During the year ended December 31, 2022, the Company granted the following stock options:

 

On March 15, 2022, 10,000,000 options for shares of common stock exercisable at $0.06 per share, expiring March 14, 2030. These were cancelled On December 7, 2022 and reissued exercisable at $0.028, expiring December 6, 2028.

 

On December 7, 2022 , 93,540,000 options for shares of common stock exercisable between $0.06 and $0.11 per share, with various expiration dates were cancelled and reissued exercisable at $0.028 expiring December 6, 2028.

 

Total share-based compensation for the 103,540,000 stock options granted (2021 - 78,890,000) and vested during the year ended December 31, 2022 was $1,070,983 (2021 - $1,413,055). The fair values of the stock options granted were estimated using the Black-Scholes Option Pricing Model, based on the following weighted average assumptions:

 

Schedule of valuation assumptions for options        
   December 31, 2022   December 31, 2021 
Risk-free interest rate   3.50%   2.55%
Dividend yield   0.00%   0.00%
Expected stock price volatility   143.43%   143.56%
Expected forfeiture rate   0.00%   0.00%
Expected life   6.00 years    5.09 years 

 

The weighted-average fair value of the stock options granted during the year ended December 31, 2022 was $0.03 (December 31, 2021 - $0.10)

The following non-qualified stock options were outstanding and exercisable at December 31, 2022:

 

Schedule of options by exercise price            
Expiry date  Exercise Price   Number of Options
Outstanding
   Number of
Options
Exercisable
 
   $         
October 26, 2026   0.10    500,000    500,000 
 November 27, 2026   0.10    250,000    250,000 
December 6, 2028   0.028    93,540,000    93,540,000 
         94,290,000    94,290,000 

 

As at December 31, 2022, the aggregate intrinsic value of the Company's stock options is $Nil .

 

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Warrants
12 Months Ended
Dec. 31, 2022
Warrants  
Warrants

Note 6.  Warrants

 

Warrant transactions are summarized as follows:

          
   Number of
Warrants
   Weighted Average Exercise Price 
       $ 
Outstanding, December 31, 2020   10,326,857    0.19 
   Warrants granted   4,968,572    0.08 
   Warrants exercised   (3,214,286)   0.07 
Outstanding, December 31, 2021   12,081,143    0.17 
   Warrants granted   13,300,000    0.04 
   Warrants expired   (6,081,143)   0.09 
   Warrants cancelled   (6,000,000)   0.26 
Outstanding, December 31, 2022   13,300,000    0.04 

 

The following warrants were outstanding and exercisable as at December 31, 2022:

 

Schedule of outstanding and exercisable    
     
Number of Warrants   Exercise Price   Expiry Date
 1,000,000   $0.05   March 15, 2024
 200,000    0.05   March 15, 2024
 1,000,000    0.05   March 15, 2024
 600,000    0.05   March 15, 2024
 1,000,000    0.05   March 15, 2024
 500,000    0.05   March 15, 2024
 1,000,000    0.05   March 15, 2024
 2,000,000    0.05   March 15, 2024
 6,000,000    0.028   December 6, 2028
 13,300,000         

 

 In March, 2022 the Company issued 4,300,000 warrants as part of private placement transactions. On April 4, 2022 and May 12, 2022 the Company issued 1,000,000 and 2,000,000 warrants, respectively, as part of private placement transactions. On December 13, 2022, the Company cancelled 6,000,000 warrants issued July 15, 2019 with an exercise price of $0.26 in consideration for patent assignments, and expiring July 14, 2024. The Company reissued the 6,000,000 warrants with an exercise price of $0.028 and expiring December 12, 2028.

 

Total share-based compensation for the reissued warrants during the year ended December 31, 2022, was $115,537.

 

The fair values of the reissued warrants were estimated using the Black-Scholes Option Pricing Model, based on the following weighted average assumptions:

Schedule of assumptions   
  

December 31,

2022

Risk-free interest rate   3.50%
Dividend yield   0.00%
Expected stock price volatility   143.43%
Expected forfeiture rate   0.00%
Expected life   6 years 

 

The weighted-average fair value of the warrants granted during the year ended December 31, 2022 was $0.03 (December 31, 2021 - $nil)

 

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Stockholders' Equity

Note 7.  Stockholders' Equity

 

The Company is authorized to issue 500,000,000 (December 31, 2021 – 400,000,000) shares of $0.0000053 par value common stock.  Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of December 31, 2022 (December 31, 2021 - $Nil).

 

During the year ended December 2022, the Company:

 

  a) Issued 5,450,000 shares of common stock (5,450,000 shares issued at $0.02) as part of a private placement for total proceeds of $109,000.
  b) Issued 3,100,000 shares of common stock (3,100,000 shares issued at $0.025) as part of a private placement for total proceeds of $77,500.
  c) Issued 7,500,000 shares of common stock (7,500,000 shares issued at $0.03) as part of a private placement for total proceeds of $225,000.
  d) Issued 2,136,666 shares of common stock (2,136,666 shares issued at $0.06) as part of a private placement for total proceeds of $128,200.
  e) Issued 7,300,000 units (each unit consisting of 1 share of common stock and 1 warrant to purchase 1 share of common stock at $0.05) as part of a private placement for total proceeds of $365,000.

 

During the year ended December 2021, the Company:

 

  a) Issued 3,528,572 units (each unit consisting of one share of common stock and one warrant to purchase one share of common stock at $0.07 per share) as part of a private placement for total proceeds of $247,000.

  b) Issued 200,000 shares of common stock at $0.12 as part of a private placement for total proceeds of $24,000.

  c) Issued 1,440,000 units (each unit consisting of one share of common stock and one warrant to purchase one share of common stock at $0.10) as part of a private placement for total proceeds of $144,000.

  d) Issued 3,214,286 shares of common stock from exercised warrants (2,214,286 shares issued at $0.07 and 1,000,000 shares issued at $0.12) for total proceeds of $275,000.

  e) Issued 555,556 shares of common stock to the Company’s CFO pursuant to a cashless exercise of 750,000 stock options.
  f) Issued 250,000 shares of common stock at $0.08 as part of a private placement for total proceeds of $20,000.
  g Issued 2,250,000 shares of common stock at $0.06 as part of a private placement for total proceeds of $135,000.
  h) Extended exercise date for warrants to purchase 1,440,000 shares of common stock issued August of 2021.  
  i) Extended exercise date for warrants to purchase 3,355,429 shares of common stock, issued December of 2020.

 

XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions and Balances
12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
Related Party Transactions and Balances

Note 8. Related Party Transactions and Balances

 

During the years ended December 31, 2022 and 2021, the Company entered into the following related party transactions:

a) Pursuant to a consulting agreement with an effective date of November 14, 2017, a total of $60,000 (2021 - $60,000) was paid or accrued to the Company's CFO. During the year ended December 31, 2022, the Company reimbursed a company controlled by the CFO a total of $11,025 (2021 - $12,600) in office rent.

b) On December 7, 2022, the Company cancelled and concurrently replaced 32,350,000 stock options previously issued to the Company’s CEO and a Director of the Company from 2021 to 2022. The modifications incremental fair value of $80,105 was recognized in the current period. The 32,350,000 replacement options granted have a term of 6 years, exercisable at a price of $0.028 per share, expiring on December 6, 2028

c) On December 7, 2022, the Company cancelled and concurrently replaced 13,260,000 stock options previously issued to the Company’s CFO of the Company from 2018 to 2022. The modifications incremental fair value of $82,398 was recognized in the current period. The 13,260,000 replacement options granted have a term of 6 years, exercisable at a price of $0.028 per share, expiring on December 6, 2028

d) On March 15, 2022, the Company granted 4,750,000 stock options to the Company’s CEO and 500,000 stock options to a Director of the Company, respectively. The 5,250,000 options granted have a term of 8 years and are exercisable at a price of $0.06 per share, expiring on March 14, 2030.

e) On March 15, 2022, the Company granted 1,500,000 stock options to the Company’s CFO. The options granted have a term of 8 years and are exercisable at a price of $0.06 per share, expiring on March 14, 2030.

f) The Company recognized $638,227 (2021 - $ 649,822) in share-based compensation during the year associated with stock options granted to key management personnel.

g) The Company recognized $638,227 including modifications (2021 - $722,822) in share-based compensation during the year associated with stock options granted to key management personnel. The total incremental fair value of stock options including modifications is $1,070,983.

As at December 31, 2022 and December 31, 2021, there were $nil balances owing to related parties.

XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingency
12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingency

Note 9. Commitments and Contingency

 

Commitments

 

As at December 31, 2022, the Company has the following commitments:

 

a) Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $7,000 per month for providing research and development services.

b) Entered into a consulting agreement effective April 1, 2019, whereby the Company would pay the consultant $1,500 per month minimum plus travel expenses for a term of 1 year for providing research consulting services. Agreement renews annually unless otherwise terminated by either party with at least 30 days’ notice.

Contingency

 

The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, "Report of Foreign Bank and Financial Accounts" ("FBARs"). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs.  Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no under reported tax liabilities.  On November 30, 2017, the Company received a letter from the IRS concluding their review of the Company's tax returns under the program and accepting the returns as filed.  No penalties have been assessed by the IRS to date, and management does not believe that the Company will incur any penalties relating to the tax years submitted under the program.

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

Note 10.  Income Taxes

 

As a Nevada corporation, the Company is liable for taxes in the United States.  As of December 31, 2022, the Company did not have any income for tax purposes and therefore, no tax liability or expense has been recorded in these financial statements (December 31, 2021 – nil).

 

A reconciliation of income taxes at statutory rates with the reported taxes is as follows:

 

Schedule of Effective Income Tax Reconciliation        
  

 

2022

  

 

2021

 
Net loss for the year  $(1,907,309)  $(2,329,310)
           
Expected income tax recovery  $(400,535)  $(489,155)
Non-deductible expenses  $224,907   $296,742 
Adjustment to prior years provision versus statutory tax returns  $75,628   $92,414 
Change in valuation allowance   100,000   $100,000 
Total income tax expense (recovery)  $     $   

 

          

 

The Company’s deferred tax assets that have not been recognized are as follows:

 

        
Schedule of Deferred Tax Assets        
Tax benefit of net operating loss carry forward  $6,400,000   $6,300,000 
Valuation allowance  $(6,400,000)  $(6,300,000)
   $     $   

 

The Company has net operation loss carryforwards of approximately $30,500,000 (December 31, 2021 - $30,000,000) to reduce future taxable income.  The valuation allowance has not changed during the year ended December 31,2022. Tax losses expire in years starting from 2023.

 

The deferred tax asset associated with the tax loss carry forward is approximately $6,400,000 (December 31, 2021 - $6,300,000).  The Company has provided a full valuation allowance against the deferred tax asset since it is more likely than not that the asset will not be realized. 

 

XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events
12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 11. Subsequent Events

 

Subsequent to the year ended December 31, 2022, the Company:

 

  a) Issued 2,000,000 shares of common stock (2,000,000 shares issued at $0.02) to the CEO of the Company, as part of a private placement for total proceeds of $40,000.  
     
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and are expressed in United States dollars.

 

Use of Estimates

Use of Estimates

 

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity- related instruments issued, deferred income taxes and the useful life and impairment of intangible assets.

 

Cash

Cash

 

Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Financial instruments, which includes cash, accounts payable and accrued liabilities are carried at amortized cost, which management believes approximates fair value due to the short-term nature of these instruments.

 

The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:

 

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable.

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions).

 

At December 31, 2022, there were no other assets or liabilities subject to additional disclosure.

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes following the assets and liability method in accordance with the ASC 740 "Income Taxes."  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.

 

Intangible assets – patent and patent application costs

Intangible assets – patent and patent application costs

 

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.

 

As at December 31, 2022, the Company does not hold any intangible assets with indefinite lives.

 

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.

 

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.

 

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs at December 31, 2022.

 

Research and Development Costs

Research and Development Costs

 

Research and development costs are expensed as incurred.

 

Loss per Share and Potentially Dilutive Securities

Loss per Share and Potentially Dilutive Securities

 

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 94,290,000 stock options (December 31, 2021 – 84,690,000) and 13,300,000 warrants (December 31, 2021 –12,081,143) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.

 

Share-Based Compensation

Share-Based Compensation

 

The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

 

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance.

 

Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

 

Common stock

Common stock

 

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

 

Related Party Transactions

Related Party Transactions

 

A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

 The Company has determined that other significant newly issued accounting pronouncements are either not applicable to the Company’s business or that no material effect is expected on the financial statements as a result of future adoption.

 

XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Prepaid Expenses and Deposits (Tables)
12 Months Ended
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of prepaid expenses
Schedule of prepaid expenses        
   2022   2021 
Rental deposit  $1,050   $1,050 
Deposit on February 11, 2022 shareholder meeting         24,945 
Total Prepaid Expenses and Deposits  $1,050   $25,995 
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Intangible Assets (Tables)
12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible asset transactions
Intangible asset transactions            
   Patent Rights   Patent Application
Rights
   Total 
Cost               
Balance, December 31, 2020  $30,000   $261,186   $291,186 
Additions         90,985    90,985 
Balance, December 31, 2021  $30,000   $352,171   $382,171 
Additions         132,049    132,049 
Balance, December 31, 2022  $30,000   $484,220   $514,220 
Accumulated amortization               
Balance, December 31, 2020  $16,500   $     $16,500 
Amortization   3,000          3,000 
Balance, December 31, 2021  $19,500   $     $19,500 
Amortization   3,000    55,450    58,450 
Balance, December 31, 2022  $22,500   $55,450   $77,950 
                
Net carrying amounts               
December 31, 2021  $10,500   $352,171   $362,671 
December 31, 2022  $7,500   $428,770   $436,270 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Options (Tables)
12 Months Ended
Dec. 31, 2022
Stock Options  
Schedule of Share-based Compensation, Stock Options, Activity
               
   Number of
Stock Options
   Weighted Average Exercise Price   Weighted Average Remaining Life 
       $   (Years) 
Outstanding, December 31, 2020   82,650,000    0.15      
     Options cancelled   (76,100,000)   0.16      
     Options exercised   (750,000)   0.07      
     Options granted   78,890,000    0.11      
Outstanding, December 31, 2021   84,690,000    0.15    4.23 

 

   Number of
Stock Options
   Weighted Average Exercise Price   Weighted Average Remaining Life 
       $   (Years) 
Outstanding, December 31, 2021   84,690,000    0.15      
     Options cancelled   (93,540,000)   0.14      
     Options expired   (400,000)   0.06      
     Options granted   103,540,000    0.03      
Outstanding, December 31, 2022   94,290,000    0.03    6.00 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of valuation assumptions for options        
   December 31, 2022   December 31, 2021 
Risk-free interest rate   3.50%   2.55%
Dividend yield   0.00%   0.00%
Expected stock price volatility   143.43%   143.56%
Expected forfeiture rate   0.00%   0.00%
Expected life   6.00 years    5.09 years 
Schedule of options by exercise price
Schedule of options by exercise price            
Expiry date  Exercise Price   Number of Options
Outstanding
   Number of
Options
Exercisable
 
   $         
October 26, 2026   0.10    500,000    500,000 
 November 27, 2026   0.10    250,000    250,000 
December 6, 2028   0.028    93,540,000    93,540,000 
         94,290,000    94,290,000 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Warrants (Tables)
12 Months Ended
Dec. 31, 2022
Warrants  
Schedule of Stockholders' Equity Note, Warrants or Rights
          
   Number of
Warrants
   Weighted Average Exercise Price 
       $ 
Outstanding, December 31, 2020   10,326,857    0.19 
   Warrants granted   4,968,572    0.08 
   Warrants exercised   (3,214,286)   0.07 
Outstanding, December 31, 2021   12,081,143    0.17 
   Warrants granted   13,300,000    0.04 
   Warrants expired   (6,081,143)   0.09 
   Warrants cancelled   (6,000,000)   0.26 
Outstanding, December 31, 2022   13,300,000    0.04 
Schedule of outstanding and exercisable
Schedule of outstanding and exercisable    
     
Number of Warrants   Exercise Price   Expiry Date
 1,000,000   $0.05   March 15, 2024
 200,000    0.05   March 15, 2024
 1,000,000    0.05   March 15, 2024
 600,000    0.05   March 15, 2024
 1,000,000    0.05   March 15, 2024
 500,000    0.05   March 15, 2024
 1,000,000    0.05   March 15, 2024
 2,000,000    0.05   March 15, 2024
 6,000,000    0.028   December 6, 2028
 13,300,000         
Schedule of assumptions
Schedule of assumptions   
  

December 31,

2022

Risk-free interest rate   3.50%
Dividend yield   0.00%
Expected stock price volatility   143.43%
Expected forfeiture rate   0.00%
Expected life   6 years 
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Reconciliation
Schedule of Effective Income Tax Reconciliation        
  

 

2022

  

 

2021

 
Net loss for the year  $(1,907,309)  $(2,329,310)
           
Expected income tax recovery  $(400,535)  $(489,155)
Non-deductible expenses  $224,907   $296,742 
Adjustment to prior years provision versus statutory tax returns  $75,628   $92,414 
Change in valuation allowance   100,000   $100,000 
Total income tax expense (recovery)  $     $   
Schedule of Deferred Tax Assets
          

 

The Company’s deferred tax assets that have not been recognized are as follows:

 

        
Schedule of Deferred Tax Assets        
Tax benefit of net operating loss carry forward  $6,400,000   $6,300,000 
Valuation allowance  $(6,400,000)  $(6,300,000)
   $     $   
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Basis of Presentation – Going Concern Uncertainties (Details Narrative)
12 Months Ended
Dec. 31, 2015
USD ($)
shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Cash consideration $ 30,000
Additional patent applications $ 10,000
Warrant issued | shares 6,000,000
Fair value adjustment of warrants $ 25,000
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Details Narrative) - shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Warrant [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Antidilutive shares 13,300,000 12,081,143
Equity Option [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Antidilutive shares 94,290,000 84,690,000
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Prepaid Expenses and Deposits (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Rental deposit $ 1,050 $ 1,050
Deposit on February 11, 2022 shareholder meeting 24,945
Total Prepaid Expenses and Deposits $ 1,050 $ 25,995
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Intangible Assets (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Beginning balance $ 382,171 $ 291,186
Additions 132,049 90,985
Ending balance 514,220 382,171
Beginning balance 19,500 16,500
Amortization 58,450 3,000
Ending balance 77,950 19,500
Net carrying amounts 436,270 362,671
Patents [Member]    
Finite-Lived Intangible Assets [Line Items]    
Beginning balance 30,000 30,000
Additions
Ending balance 30,000 30,000
Beginning balance 19,500 16,500
Amortization 3,000 3,000
Ending balance 22,500 19,500
Net carrying amounts 7,500 10,500
Patent Application Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Beginning balance 352,171 261,186
Additions 132,049 90,985
Ending balance 484,220 352,171
Beginning balance
Amortization 55,450
Ending balance 55,450
Net carrying amounts $ 428,770 $ 352,171
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Intangible Assets (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2016
Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]        
Intangible assets $ 132,049 $ 90,985    
Amortization of Intangible Assets $ 58,450 $ 3,000    
Additional patent applications       $ 10,000
Warrant issued       6,000,000
Minimum [Member]        
Finite-Lived Intangible Assets [Line Items]        
Intangible assets useful lives 18 years 6 months      
Maximum [Member]        
Finite-Lived Intangible Assets [Line Items]        
Intangible assets useful lives 20 years      
Grant Young [Member] | Technology Transfer Agreement [Member]        
Finite-Lived Intangible Assets [Line Items]        
Additional patent applications       $ 10,000
Warrant issued       6,000,000
Patent Application Rights [Member]        
Finite-Lived Intangible Assets [Line Items]        
Intangible assets       $ 30,000
Direct operating costs     $ 2,415  
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Options (Details) - Equity Option [Member] - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Outstanding, beginning 84,690,000 82,650,000
Weighted average exercise price beginning balance $ 0.15 $ 0.15
Options cancelled (93,540,000) (76,100,000)
Weighted Average Exercise Price, cancelled $ 0.14 $ 0.16
Options exercised (400,000) (750,000)
Weighted Average Exercise Price, exercised $ 0.06 $ 0.07
Option granted 103,540,000 78,890,000
Weighted Average Exercise Price, granted $ 0.03 $ 0.11
Outstanding, ending 94,290,000 84,690,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 6 years 4 years 2 months 23 days
Weighed average exercise price ending balance $ 0.03 $ 0.15
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Options (Details 1)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3.50% 2.55%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 143.43% 143.56%
Expected forfeiture rate 0.00% 0.00%
Expected life 6 years 5 years 1 month 2 days
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Options (Details 2)
Dec. 31, 2022
$ / shares
shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Number of outstanding 94,290,000
Number of options exercisable 94,290,000
Stock Option 1 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Weighed average exercise price | $ / shares $ 0.10
Number of outstanding 500,000
Number of options exercisable 500,000
Stock Option 2 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Weighed average exercise price | $ / shares $ 0.10
Number of outstanding 250,000
Number of options exercisable 250,000
Stock Option 3 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Weighed average exercise price | $ / shares $ 0.028
Number of outstanding 93,540,000
Number of options exercisable 93,540,000
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Options (Details Narrative) - USD ($)
12 Months Ended
Dec. 07, 2022
Mar. 15, 2022
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Options exercisable     94,290,000  
Share-based Payment Arrangement, Expense     $ 103,540,000 $ 78,890,000
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture     $ 1,070,983 1,413,055
Equity Option [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Options granted     94,290,000  
Options exercisable 93,540,000 10,000,000    
Share based compensation exercisable per share $ 0.028 $ 0.028    
Expiring date Dec. 06, 2028 Dec. 06, 2028    
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture     $ 1,070,983 $ 1,413,055
Share based compensation exercisable per share     $ 0.03 $ 0.10
Equity Option [Member] | Minimum [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Share based compensation exercisable per share $ 0.06      
Equity Option [Member] | Maximum [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Share based compensation exercisable per share $ 0.11      
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Warrants (Details) - $ / shares
12 Months Ended
Mar. 15, 2022
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Warrant granted 5,250,000    
Warrant [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Warrant outstanding, beginning   12,081,143 10,326,857
Warrant weighted average exercise price, beginning   $ 0.17 $ 0.19
Warrant granted   13,300,000 4,968,572
Warrant weighted average exercise price, granted   $ 0.04 $ 0.08
Warrants exercised     (3,214,286)
Warrant weighted average exercise price, exercised     $ 0.07
Warrants expired   (6,081,143)  
Warrant weighted average exercise price, expired   $ 0.09  
Warrants cancelled   (6,000,000)  
Warrant weighted average exercise price, cancelled   $ 0.26  
Warrant outstanding, ending   13,300,000 12,081,143
Warrant weighted average exercise price, ending   $ 0.04 $ 0.17
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Warrants (Details 1)
12 Months Ended
Dec. 31, 2022
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Class of Warrant or Right, Outstanding 13,300,000
Warrant 1 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Class of Warrant or Right, Outstanding 1,000,000
Warrant weighted average exercise price | $ / shares $ 0.05
Expiry Date March 15, 2024
Warrant 2 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Class of Warrant or Right, Outstanding 200,000
Warrant weighted average exercise price | $ / shares $ 0.05
Expiry Date March 15, 2024
Warrant 3 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Class of Warrant or Right, Outstanding 1,000,000
Warrant weighted average exercise price | $ / shares $ 0.05
Expiry Date March 15, 2024
Warrant 4 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Class of Warrant or Right, Outstanding 600,000
Warrant weighted average exercise price | $ / shares $ 0.05
Expiry Date March 15, 2024
Warrant 5 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Class of Warrant or Right, Outstanding 1,000,000
Warrant weighted average exercise price | $ / shares $ 0.05
Expiry Date March 15, 2024
Warrant 6 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Class of Warrant or Right, Outstanding 500,000
Warrant weighted average exercise price | $ / shares $ 0.05
Expiry Date March 15, 2024
Warrant 7 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Class of Warrant or Right, Outstanding 1,000,000
Warrant weighted average exercise price | $ / shares $ 0.05
Expiry Date March 15, 2024
Warrant 8 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Class of Warrant or Right, Outstanding 2,000,000
Warrant weighted average exercise price | $ / shares $ 0.05
Expiry Date March 15, 2024
Warrant 9 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Class of Warrant or Right, Outstanding 6,000,000
Warrant weighted average exercise price | $ / shares $ 0.028
Expiry Date December 6, 2028
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Warrants (Details 2)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Warrants    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3.50% 2.55%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 143.43% 143.56%
Expected forfeiture rate 0.00% 0.00%
Expected life 6 years 5 years 1 month 2 days
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Warrants (Details Narrative) - $ / shares
12 Months Ended
Jul. 15, 2019
Dec. 31, 2022
May 12, 2022
Apr. 04, 2022
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Warrant [Member]              
Subsidiary, Sale of Stock [Line Items]              
Warrant exercise price   $ 0.04       $ 0.17 $ 0.19
Share based compensation exercisable per share   $ 0.03          
Warrant [Member]              
Subsidiary, Sale of Stock [Line Items]              
Warrants issued   6,000,000          
Number of shares cancelled 6,000,000            
Warrant exercise price $ 0.26 $ 0.028          
Warrant expiring date Jul. 14, 2024 Dec. 12, 2028          
Private Placement [Member]              
Subsidiary, Sale of Stock [Line Items]              
Warrants issued     2,000,000 1,000,000 4,300,000    
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]      
Shares authorized 500,000,000 400,000,000  
Common Stock, Par or Stated Value Per Share $ 0.0000053 $ 0.0000053  
Dividends declared $ 0 $ 0  
Number of shares issued 2,000,000 555,556  
Warrants to purchase   1,440,000 3,355,429
Warrant [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Warrants exercised   200,000  
Total proceeds   $ 24,000  
Equity Option [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Option exercised   750,000  
Investors [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Number of shares issued 5,450,000    
Share Price $ 0.02    
Stock Issued During Period, Value, New Issues $ 109,000    
Investors One [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Number of shares issued 3,100,000    
Share Price $ 0.025    
Stock Issued During Period, Value, New Issues $ 77,500    
Investors Two [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Number of shares issued 7,500,000    
Share Price $ 0.03    
Stock Issued During Period, Value, New Issues $ 225,000    
Investors Three [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Number of shares issued 2,136,666    
Share Price $ 0.06    
Stock Issued During Period, Value, New Issues $ 128,200    
Investors Four [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Number of shares issued 7,300,000    
Share Price $ 0.05    
Stock Issued During Period, Value, New Issues $ 365,000    
Investors Five [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Number of shares issued   3,528,572  
Share Price   $ 0.07  
Stock Issued During Period, Value, New Issues   $ 247,000  
Investors Six [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Number of shares issued   1,440,000  
Share Price   $ 0.10  
Stock Issued During Period, Value, New Issues   $ 144,000  
Investors Seven [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Number of shares issued   3,214,286  
Share Price   $ 0.12  
Stock Issued During Period, Value, New Issues   $ 275,000  
Investors Eight [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Number of shares issued   250,000  
Share Price   $ 0.08  
Stock Issued During Period, Value, New Issues   $ 20,000  
Investors Nine [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Number of shares issued   2,250,000  
Share Price   $ 0.06  
Stock Issued During Period, Value, New Issues   $ 135,000  
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions and Balances (Details Narrative) - USD ($)
12 Months Ended
Dec. 07, 2022
Mar. 15, 2022
Dec. 31, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]        
Related Party Transaction, Amounts of Transaction     $ 60,000  
Modification incremental fair value option     1,070,983  
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted   5,250,000    
Share-based Payment Arrangement, Expense, after Tax     638,227 $ 722,822
Due to Related Parties, Current     0 0
Equity Option [Member]        
Related Party Transaction [Line Items]        
Share-based Payment Arrangement, Expense, after Tax     638,227 649,822
Chief Financial Officer [Member]        
Related Party Transaction [Line Items]        
Increase (Decrease) in Due from Officers and Stockholders, Current     $ 11,025 $ 12,600
Chief Executiveand Director Officer [Member]        
Related Party Transaction [Line Items]        
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 32,350,000      
Modification incremental fair value option $ 80,105      
Options granted 32,350,000      
Expected term 6 years 8 years    
Exercisable price $ 0.028 $ 0.06    
Option expiration date Dec. 06, 2028 Mar. 14, 2030    
C F O [Member]        
Related Party Transaction [Line Items]        
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 13,260,000      
Modification incremental fair value option $ 82,398      
Options granted 13,260,000      
Expected term 6 years 8 years    
Exercisable price $ 0.028 $ 0.06    
Option expiration date Dec. 06, 2028 Mar. 14, 2030    
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted   1,500,000    
Chief Executiveand Officer [Member]        
Related Party Transaction [Line Items]        
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted   4,750,000    
Director [Member]        
Related Party Transaction [Line Items]        
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted   500,000    
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingency (Details Narrative) - USD ($)
12 Months Ended
Apr. 02, 2019
Jan. 02, 2017
Dec. 31, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]        
Research and development expense     $ 448,873 $ 435,872
Consultant [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Research and development expense   $ 7,000    
Travel and entertainment expense $ 1,500      
Travel expenses term 1 year      
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Net loss for the year $ (1,907,309) $ (2,329,310)
Expected income tax recovery (400,535) (489,155)
Non-deductible expenses 224,907 296,742
Adjustment to prior years provision versus statutory tax returns 75,628 92,414
Change in valuation allowance 100,000 100,000
Total income tax expense (recovery)
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Details 1) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Deferred Tax Assets, Gross $ 6,400,000 $ 6,300,000
Deferred Tax Assets, Valuation Allowance (6,400,000) (6,300,000)
Deferred Tax Assets, Net of Valuation Allowance
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount $ 30,500,000 $ 30,000,000
Deferred Tax Assets, Capital Loss Carryforwards $ 6,400,000 $ 6,300,000
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Number of shares issued 2,000,000 555,556
Chief Executive Officer [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Number of shares issued 2,000,000  
Share Price $ 0.02  
Stock Issued During Period, Value, New Issues $ 40,000  
XML 58 pktx_10k-123122_htm.xml IDEA: XBRL DOCUMENT 0001128189 2022-01-01 2022-12-31 0001128189 2022-06-30 0001128189 2022-12-31 0001128189 2021-12-31 0001128189 2021-01-01 2021-12-31 0001128189 us-gaap:CommonStockMember 2020-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001128189 us-gaap:RetainedEarningsMember 2020-12-31 0001128189 2020-12-31 0001128189 us-gaap:CommonStockMember 2021-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001128189 us-gaap:RetainedEarningsMember 2021-12-31 0001128189 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001128189 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001128189 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001128189 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001128189 us-gaap:CommonStockMember 2022-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001128189 us-gaap:RetainedEarningsMember 2022-12-31 0001128189 2015-01-01 2015-12-31 0001128189 2015-12-31 0001128189 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001128189 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001128189 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001128189 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001128189 us-gaap:PatentsMember 2020-12-31 0001128189 PKTX:PatentApplicationRightsMember 2020-12-31 0001128189 us-gaap:PatentsMember 2021-01-01 2021-12-31 0001128189 PKTX:PatentApplicationRightsMember 2021-01-01 2021-12-31 0001128189 us-gaap:PatentsMember 2021-12-31 0001128189 PKTX:PatentApplicationRightsMember 2021-12-31 0001128189 us-gaap:PatentsMember 2022-01-01 2022-12-31 0001128189 PKTX:PatentApplicationRightsMember 2022-01-01 2022-12-31 0001128189 us-gaap:PatentsMember 2022-12-31 0001128189 PKTX:PatentApplicationRightsMember 2022-12-31 0001128189 PKTX:PatentApplicationRightsMember 2015-01-01 2015-12-31 0001128189 PKTX:GrantYoungMember PKTX:TechnologyTransferAgreementMember 2015-12-31 0001128189 PKTX:GrantYoungMember PKTX:TechnologyTransferAgreementMember 2015-01-01 2015-12-31 0001128189 PKTX:PatentApplicationRightsMember 2016-01-01 2016-12-31 0001128189 srt:MinimumMember 2022-01-01 2022-12-31 0001128189 srt:MaximumMember 2022-01-01 2022-12-31 0001128189 us-gaap:StockOptionMember 2022-12-31 0001128189 us-gaap:StockOptionMember 2022-03-15 0001128189 us-gaap:StockOptionMember 2022-03-01 2022-03-15 0001128189 us-gaap:StockOptionMember 2022-12-07 0001128189 srt:MinimumMember us-gaap:StockOptionMember 2022-12-07 0001128189 srt:MaximumMember us-gaap:StockOptionMember 2022-12-07 0001128189 us-gaap:StockOptionMember 2022-12-01 2022-12-07 0001128189 us-gaap:StockOptionMember 2020-12-31 0001128189 us-gaap:StockOptionMember 2021-12-31 0001128189 PKTX:StockOption1Member 2022-12-31 0001128189 PKTX:StockOption2Member 2022-12-31 0001128189 PKTX:StockOption3Member 2022-12-31 0001128189 us-gaap:WarrantMember 2020-12-31 0001128189 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001128189 us-gaap:WarrantMember 2021-12-31 0001128189 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001128189 us-gaap:WarrantMember 2022-12-31 0001128189 PKTX:Warrant1Member 2022-12-31 0001128189 PKTX:Warrant1Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant2Member 2022-12-31 0001128189 PKTX:Warrant2Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant3Member 2022-12-31 0001128189 PKTX:Warrant3Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant4Member 2022-12-31 0001128189 PKTX:Warrant4Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant5Member 2022-12-31 0001128189 PKTX:Warrant5Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant6Member 2022-12-31 0001128189 PKTX:Warrant6Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant7Member 2022-12-31 0001128189 PKTX:Warrant7Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant8Member 2022-12-31 0001128189 PKTX:Warrant8Member 2022-01-01 2022-12-31 0001128189 PKTX:Warrant9Member 2022-12-31 0001128189 PKTX:Warrant9Member 2022-01-01 2022-12-31 0001128189 us-gaap:PrivatePlacementMember 2022-03-31 0001128189 us-gaap:PrivatePlacementMember 2022-04-04 0001128189 us-gaap:PrivatePlacementMember 2022-05-12 0001128189 us-gaap:WarrantMember 2019-07-01 2019-07-15 0001128189 us-gaap:WarrantMember 2019-07-15 0001128189 us-gaap:WarrantMember 2022-12-31 0001128189 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsMember 2022-12-31 0001128189 PKTX:InvestorsOneMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsOneMember 2022-12-31 0001128189 PKTX:InvestorsTwoMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsTwoMember 2022-12-31 0001128189 PKTX:InvestorsThreeMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsThreeMember 2022-12-31 0001128189 PKTX:InvestorsFourMember 2022-01-01 2022-12-31 0001128189 PKTX:InvestorsFourMember 2022-12-31 0001128189 PKTX:InvestorsFiveMember 2021-01-01 2021-12-31 0001128189 PKTX:InvestorsFiveMember 2021-12-31 0001128189 PKTX:InvestorsSixMember 2021-01-01 2021-12-31 0001128189 PKTX:InvestorsSixMember 2021-12-31 0001128189 PKTX:InvestorsSevenMember 2021-01-01 2021-12-31 0001128189 PKTX:InvestorsSevenMember 2021-12-31 0001128189 PKTX:InvestorsEightMember 2021-01-01 2021-12-31 0001128189 PKTX:InvestorsEightMember 2021-12-31 0001128189 PKTX:InvestorsNineMember 2021-01-01 2021-12-31 0001128189 PKTX:InvestorsNineMember 2021-12-31 0001128189 srt:ChiefFinancialOfficerMember 2022-01-01 2022-12-31 0001128189 srt:ChiefFinancialOfficerMember 2021-01-01 2021-12-31 0001128189 PKTX:ChiefExecutiveandDirectorOfficerMember 2022-12-01 2022-12-07 0001128189 PKTX:ChiefExecutiveandDirectorOfficerMember 2022-12-07 0001128189 PKTX:CFOMember 2022-12-01 2022-12-07 0001128189 PKTX:CFOMember 2022-12-07 0001128189 PKTX:ChiefExecutiveandOfficerMember 2022-03-01 2022-03-15 0001128189 srt:DirectorMember 2022-03-01 2022-03-15 0001128189 2022-03-01 2022-03-15 0001128189 PKTX:ChiefExecutiveandDirectorOfficerMember 2022-03-01 2022-03-15 0001128189 PKTX:ChiefExecutiveandDirectorOfficerMember 2022-03-15 0001128189 PKTX:CFOMember 2022-03-01 2022-03-15 0001128189 PKTX:CFOMember 2022-03-15 0001128189 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001128189 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001128189 PKTX:ConsultantMember 2017-01-01 2017-01-02 0001128189 PKTX:ConsultantMember 2019-04-01 2019-04-02 0001128189 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001128189 srt:ChiefExecutiveOfficerMember 2022-12-31 iso4217:USD shares iso4217:USD shares pure 0001128189 false 2022 FY 10-K true 2022-12-31 --12-31 false 000-32917 PROTOKINETIX, INCORPORATED NV 94-3355026 109 W Main St Dalton OH 44618 330 455-4971 No No Yes Yes Non-accelerated Filer true false false 731 Davidson & Company LLP Vancouver, British Columbia, Canada 9886980 322880151 25550 57568 1050 25995 26600 83563 436270 362671 462870 446234 41530 93268 41530 93268 0.0000053 0.0000053 500000000 500000000 322880151 322880151 297393485 297393485 1726 1591 47868093 45892545 -47448479 -45541170 421340 352966 462870 446234 58450 3000 162749 316995 166254 160388 448873 435872 1070983 1413055 1907309 2329310 -1907309 -2329310 -0.01 -0.01 307392069 291865922 285955071 1531 43615323 -43192633 424221 1413055 1413055 7668572 41 569959 570000 3214286 17 274983 275000 555556 3 -3 19227 -19227 -2329310 -2329310 297393485 1591 45892545 -45541170 352966 297393485 1591 45892545 -45541170 352966 1070983 1070983 25486666 135 904565 904700 -1907309 -1907309 322880151 1726 47868093 -47448479 421340 -1907309 -2329310 58450 3000 1070983 1413055 -24945 24945 -51738 48309 -804669 -889891 132049 90985 -132049 -90985 904700 845000 904700 845000 -32018 -135877 57568 193445 25550 57568 <p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zQTU5FG1n009" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1.  <span id="xdx_827_zdnCllQAQDVf">Basis of Presentation – Going Concern Uncertainties</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ProtoKinetix, Inc. (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999.  The Company is a medical research company whose mission is the advancement of human health care.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins ("AFGP") or anti-aging glycoproteins, trademarked AAGP.  During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $<span id="xdx_906_ecustom--PaymentToAcquireIntangibleAssets_pp0p0_c20150101__20151231_zgR2ADi44J7f" title="Cash consideration">30,000</span> (25,000 Euros), as well as additional patent applications for cash consideration of $<span id="xdx_90B_ecustom--AdditionalPatentApplications_iI_pp0p0_c20151231_z7d1tOTUauNf" title="Additional patent applications">10,000</span> and <span id="xdx_909_ecustom--WarrantIssued_c20150101__20151231_zeuKqfpRFdk8" title="Warrant issued">6,000,000</span> share purchase warrants with a fair value of $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20150101__20151231_zY7p3cYTqiP6" title="Fair value adjustment of warrants">25,000</span> (Note 4).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at December 31, 2022.  These factors raise substantial doubt about the Company's ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities.  Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective.  Management is presently engaged in seeking additional working capital through equity financing or related party loans. In addition, any significant disruption of global financial markets, reducing our ability to access capital, could negatively affect our liquidity and ability to continue operations. The exact impact is and will remain unknown and is largely dependent upon future developments, including but not limited to information on the duration and spread of COVID-19, changes in customer demand, additional mitigation strategies proposed by governmental authorities (including federal, state, or local stay at home or similar orders), restrictions on the activities of our domestic and international suppliers and shipment of goods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.</p> 30000 10000 6000000 25000 <p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zJWKRBpEGIyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2. <span id="xdx_825_zz0UNP6qk4bg">Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_ztUwevf75Eq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_868_z3za88Hobsh4">Basis of Presentation</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and are expressed in United States dollars.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_846_eus-gaap--UseOfEstimates_z65letlogcv" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_860_zieBtfgy8hSi">Use of Estimates</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity- related instruments issued, deferred income taxes and the useful life and impairment of intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeBur3BuMfOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86A_zrk9ybsDal38">Cash</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zARaE7pgGtvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_868_zRwvgURs4Lj8">Fair Value of Financial Instruments</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, which includes cash, accounts payable and accrued liabilities are carried at amortized cost, which management believes approximates fair value due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 1 – quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022, there were no other assets or liabilities subject to additional disclosure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zf7eCnsScTsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86F_zUkxZhNSHha9">Income Taxes</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes following the assets and liability method in accordance with the ASC 740 "Income Taxes."  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zwdvnrhHYct8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_861_zInALp17tIqb">Intangible assets – patent and patent application costs</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As at December 31, 2022, the Company does not hold any intangible assets with indefinite lives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs at December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoKBsoMfWUxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86D_zPyWMaIC2PX9">Research and Development Costs</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zudoEFxn4La1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_86A_ziX1evSvlOq1">Loss per Share and Potentially Dilutive Securities</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFx7BGsE6K6d" title="Antidilutive shares">94,290,000</span> stock options (December 31, 2021 – <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLNCTTxU2ofb" title="Antidilutive shares">84,690,000</span>) and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zcYp2SQizud5" title="Antidilutive shares">13,300,000</span> warrants (December 31, 2021 –<span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zD8ZcaJAtDkl" title="Antidilutive shares">12,081,143</span>) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zPhEwj1qDMcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_86D_zuCyJHbsaXn5">Share-Based Compensation</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_841_eus-gaap--StockholdersEquityPolicyTextBlock_zUstKmlea7If" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_863_zmsjZ8IVKdB1">Common stock</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_ecustom--RelatedPartyTransactionsPolicyTextBlock_zwgYJQzyRxH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_862_zuf7mYcio3Ad">Related Party Transactions</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqZybNiw8wSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_866_zAwSDwqFvYsa">Recent Accounting Pronouncements</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company has determined that other significant newly issued accounting pronouncements are either not applicable to the Company’s business or that no material effect is expected on the financial statements as a result of future adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_ztUwevf75Eq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_868_z3za88Hobsh4">Basis of Presentation</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and are expressed in United States dollars.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_846_eus-gaap--UseOfEstimates_z65letlogcv" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_860_zieBtfgy8hSi">Use of Estimates</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity- related instruments issued, deferred income taxes and the useful life and impairment of intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeBur3BuMfOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86A_zrk9ybsDal38">Cash</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zARaE7pgGtvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_868_zRwvgURs4Lj8">Fair Value of Financial Instruments</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, which includes cash, accounts payable and accrued liabilities are carried at amortized cost, which management believes approximates fair value due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 1 – quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2022, there were no other assets or liabilities subject to additional disclosure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zf7eCnsScTsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86F_zUkxZhNSHha9">Income Taxes</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes following the assets and liability method in accordance with the ASC 740 "Income Taxes."  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84C_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zwdvnrhHYct8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_861_zInALp17tIqb">Intangible assets – patent and patent application costs</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As at December 31, 2022, the Company does not hold any intangible assets with indefinite lives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs at December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zoKBsoMfWUxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86D_zPyWMaIC2PX9">Research and Development Costs</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zudoEFxn4La1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_86A_ziX1evSvlOq1">Loss per Share and Potentially Dilutive Securities</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFx7BGsE6K6d" title="Antidilutive shares">94,290,000</span> stock options (December 31, 2021 – <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLNCTTxU2ofb" title="Antidilutive shares">84,690,000</span>) and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zcYp2SQizud5" title="Antidilutive shares">13,300,000</span> warrants (December 31, 2021 –<span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zD8ZcaJAtDkl" title="Antidilutive shares">12,081,143</span>) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 94290000 84690000 13300000 12081143 <p id="xdx_847_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zPhEwj1qDMcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_86D_zuCyJHbsaXn5">Share-Based Compensation</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_841_eus-gaap--StockholdersEquityPolicyTextBlock_zUstKmlea7If" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_863_zmsjZ8IVKdB1">Common stock</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_ecustom--RelatedPartyTransactionsPolicyTextBlock_zwgYJQzyRxH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_862_zuf7mYcio3Ad">Related Party Transactions</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqZybNiw8wSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_866_zAwSDwqFvYsa">Recent Accounting Pronouncements</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company has determined that other significant newly issued accounting pronouncements are either not applicable to the Company’s business or that no material effect is expected on the financial statements as a result of future adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_80F_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z02NfQtPrXge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3.  <span id="xdx_825_zRE51ylbWJvb">Prepaid Expenses and Deposits</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes the Company's prepaid expenses and deposits outstanding as at December 31, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--AccountsReceivableTableTextBlock_zUZ0D1evdIU1" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Deposits (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span id="xdx_8B7_ztHLVR6Z9ylb">Schedule of prepaid expenses</span></td><td> </td> <td colspan="2" id="xdx_49A_20221231_zoeQJTDDRehc" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49D_20211231_zANrI3CLB0z3" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--DepositsAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: justify">Rental deposit</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,050</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,050</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DepositShareholderMeeting_iI_pp0p0" style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Deposit on February 11, 2022 shareholder meeting</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,945</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255); font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total Prepaid Expenses and Deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,050</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">25,995</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 8pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--AccountsReceivableTableTextBlock_zUZ0D1evdIU1" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Deposits (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span id="xdx_8B7_ztHLVR6Z9ylb">Schedule of prepaid expenses</span></td><td> </td> <td colspan="2" id="xdx_49A_20221231_zoeQJTDDRehc" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49D_20211231_zANrI3CLB0z3" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--DepositsAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: justify">Rental deposit</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,050</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">1,050</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DepositShareholderMeeting_iI_pp0p0" style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Deposit on February 11, 2022 shareholder meeting</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,945</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255); font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total Prepaid Expenses and Deposits</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,050</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">25,995</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1050 1050 24945 1050 25995 <p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_z5eUCigtpAm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4. <span id="xdx_82E_zHuEfkfSWoCf">Intangible Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible asset transactions are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zcawEUhCh06g" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_8B6_zZvsWSp9wbC1">Intangible asset transactions</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Patent Rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Patent Application <br/> Rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: justify">Balance, December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zCnFa0Qws299" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">30,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zwJnfmERuwtf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">261,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231_zMxRQaDWU5a6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">291,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Additions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPKPSMscAgWj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions"><span style="-sec-ix-hidden: xdx2ixbrl0413">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zbiQJMS63Xxd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions">90,985</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20210101__20211231_zyiuZTogAac7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions">90,985</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Balance, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zn4VLqk6rvQd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">30,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zuOzlTo8cQhb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">352,171</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231_zMREwZn9IRA7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">382,171</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Additions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVBoKBDxrYm7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions"><span style="-sec-ix-hidden: xdx2ixbrl0425">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zUBBzRwErex6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions">132,049</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20220101__20221231_zU9WnqNG6Iw1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions">132,049</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zmTysT1QpPac" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">30,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zowjrALboFig" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">484,220</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231_zkTXSNXuQLXk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">514,220</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Balance, December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zHNaDAdAFcyl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">16,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zbcD3NimJdQ9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0439">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20210101__20211231_zmkmNhtA4CNj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">16,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--Amortization_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVqTAwv5P6P2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization">3,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--Amortization_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zqhjJiGcy3fg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization"><span style="-sec-ix-hidden: xdx2ixbrl0445">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--Amortization_pp0p0_c20210101__20211231_zKQD8ejbaUn" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization">3,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Balance, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdTQm8xLCMk4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">19,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zumekyAoxJG6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0451">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20220101__20221231_ziw0UdVBdK76" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">19,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--Amortization_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjwQTViaE81i" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization">3,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--Amortization_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zmZn4mxX49Q6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization">55,450</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--Amortization_pp0p0_c20220101__20221231_zwQ6qbZO3pD9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization">58,450</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zLXP6rAutm4a" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">22,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_ziphAnYwhUBj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">55,450</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pp0p0_c20220101__20221231_zQXBRQHhFzPc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">77,950</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net carrying amounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">10,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">352,171</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_c20211231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">362,671</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">7,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">428,770</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">436,270</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the "Patent Assignment") with the Institut National des Sciences Appliquees de Rouen ("INSA") for the assignment of certain patents and all rights associated therewith (the "Patents"). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $<span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20150101__20151231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_z8OK2wzIqSx" title="Intangible assets">30,000</span> (25,000 Euros) (paid). During the year ended December 31, 2022, the Company recorded $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220101__20221231_z1HhXciN6Fhb" title="Amortization of Intangible Assets">58,450</span> (2021 - $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20211231_zVZ5wQ38tIv4" title="Amortization of Intangible Assets">3,000</span>) in amortization expense associated with the Patents Rights.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the "Patent Application Rights").  In exchange for the Patent Application Rights, the Company agreed to pay $<span id="xdx_906_ecustom--AdditionalPatentApplications_iI_pp0p0_c20151231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrantYoungMember__us-gaap--TypeOfArrangementAxis__custom--TechnologyTransferAgreementMember_zvLHX6dcQiEb" title="Additional patent applications">10,000</span> (paid) and to issue <span id="xdx_906_ecustom--WarrantIssued_c20150101__20151231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GrantYoungMember__us-gaap--TypeOfArrangementAxis__custom--TechnologyTransferAgreementMember_zRIMWCqAjd0c" title="Warrant issued">6,000,000</span> warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company incurred an additional $449,220 in direct costs relating to the Patent Application Rights, $<span id="xdx_902_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20220101__20221231_zdfBGUFsJoVk" title="Intangible assets">132,049</span> of which were incurred during the year ended December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty from any product developed as a result of research done at the University.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled "Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells" (the "New Patent Application Rights").  In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid).  The Company incurred $<span id="xdx_902_eus-gaap--DirectOperatingCosts_pp0p0_c20160101__20161231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zvPOuZ6MHvkb" title="Direct operating costs">2,415</span> in direct costs relating to the New Patent Application Rights during the year ended December 31, 2016.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company amortizes patents and licenses that have been filed over their useful lives which range between <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_za7HYToZ3Ks8" title="Intangible assets useful lives">18.5</span> to <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zlIKnGE8kXQa" title="Intangible assets useful lives">20</span> years. The costs of provisional patents and pending applications is not amortized until the patent is filed and is reviewed each reporting period. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zcawEUhCh06g" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_8B6_zZvsWSp9wbC1">Intangible asset transactions</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Patent Rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Patent Application <br/> Rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: justify">Balance, December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zCnFa0Qws299" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">30,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zwJnfmERuwtf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">261,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20210101__20211231_zMxRQaDWU5a6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">291,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Additions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPKPSMscAgWj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions"><span style="-sec-ix-hidden: xdx2ixbrl0413">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zbiQJMS63Xxd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions">90,985</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20210101__20211231_zyiuZTogAac7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions">90,985</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Balance, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zn4VLqk6rvQd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">30,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zuOzlTo8cQhb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">352,171</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20220101__20221231_zMREwZn9IRA7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">382,171</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Additions</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVBoKBDxrYm7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions"><span style="-sec-ix-hidden: xdx2ixbrl0425">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zUBBzRwErex6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions">132,049</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pp0p0_c20220101__20221231_zU9WnqNG6Iw1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions">132,049</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zmTysT1QpPac" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">30,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zowjrALboFig" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">484,220</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20220101__20221231_zkTXSNXuQLXk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">514,220</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Accumulated amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Balance, December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zHNaDAdAFcyl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">16,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zbcD3NimJdQ9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0439">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20210101__20211231_zmkmNhtA4CNj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">16,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--Amortization_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVqTAwv5P6P2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization">3,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--Amortization_pp0p0_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zqhjJiGcy3fg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization"><span style="-sec-ix-hidden: xdx2ixbrl0445">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--Amortization_pp0p0_c20210101__20211231_zKQD8ejbaUn" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization">3,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Balance, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zdTQm8xLCMk4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">19,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zumekyAoxJG6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl0451">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pp0p0_c20220101__20221231_ziw0UdVBdK76" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">19,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--Amortization_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjwQTViaE81i" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization">3,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--Amortization_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_zmZn4mxX49Q6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization">55,450</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--Amortization_pp0p0_c20220101__20221231_zwQ6qbZO3pD9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortization">58,450</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zLXP6rAutm4a" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">22,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pp0p0_c20220101__20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_ziphAnYwhUBj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">55,450</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pp0p0_c20220101__20221231_zQXBRQHhFzPc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">77,950</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net carrying amounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">10,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">352,171</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_c20211231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">362,671</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">7,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentApplicationRightsMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">428,770</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net carrying amounts">436,270</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 30000 261186 291186 90985 90985 30000 352171 382171 132049 132049 30000 484220 514220 16500 16500 3000 3000 19500 19500 3000 55450 58450 22500 55450 77950 10500 352171 362671 7500 428770 436270 30000 58450 3000 10000 6000000 132049 2415 P18Y6M P20Y <p id="xdx_80B_ecustom--StockOptionsTextBlock_z8eZdSsqMQJk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5.  <span id="xdx_82F_zIJj3BEgUrV8">Stock Options</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to an amendment on March 15, 2022, the aggregate number of shares that may be issued under the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”) is 97,700,000 shares, subject to adjustment as provided therein. The 2017 Plan is administered by the Company’s Board of Directors, or a committee appointed by the Board of Directors, and includes two types of options. Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended, are referred to as incentive options. Options that are not intended to qualify as incentive options are referred to as non-qualified options. The exercise price of an option may be paid in cash, in shares of the Company's common stock or other property having a fair market value equal to the exercise price of the option, or in a combination of cash, shares, other securities and property.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022, there are <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3S7vITibXSl" title="Options granted">94,290,000</span> options granted and outstanding under the 2017 Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock option transactions are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zVyGVtTrnrIa" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8BF_zwLisvNn3H92" style="display: none">Schedule of Share-based Compensation, Stock Options, Activity</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of <br/> Stock Options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(Years)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%">Outstanding, December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPhFc9RcDrR6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Outstanding, beginning">82,650,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zwFbPqugMmF5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price beginning balance">0.15</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">     Options cancelled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zN5lEiVpMAWa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options cancelled">(76,100,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, cancelled">0.16</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">     Options exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcXBuqMbsyyc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options exercised">(750,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, exercised">0.07</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">     Options granted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Option granted">78,890,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, granted">0.11</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSXi7yMtIGkb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding, ending">84,690,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6LtWTL2RGZf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighed average exercise price ending balance">0.15</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQz8jr6eYLuk" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term">4.23</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of <br/> Stock Options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(Years)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%">Outstanding, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsJSSHrH8M6k" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Outstanding, beginning">84,690,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znIKnWYLOJA7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price beginning balance">0.15</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">     Options cancelled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zR4hWFLEXxL2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options cancelled">(93,540,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, cancelled">0.14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">     Options expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zskQDDjGREci" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options exercised">(400,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, exercised">0.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">     Options granted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Option granted">103,540,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, granted">0.03</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4BSyGMN6pHa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding, ending">94,290,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zmr56a5w803b" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighed average exercise price ending balance">0.03</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4bkDiK0AiB9" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term">6.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_z35Fn1qi7Pu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2022, the Company granted the following stock options:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 15, 2022, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220315__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQO6E2TIDwgh" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number">10,000,000</span> options for shares of common stock exercisable at $0.06 per share, expiring March 14, 2030. These were cancelled On December 7, 2022 and reissued exercisable at $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220315__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPIej7mNvd3k" title="Share based compensation exercisable per share">0.028</span>, expiring <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220301__20220315__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM6fB35RQPyk" title="Expiring date">December 6, 2028</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On December 7, 2022 , <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221207__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCUQIlmNRejb" title="Options exercisable">93,540,000</span> options for shares of common stock exercisable between $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221207__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zsQtTrmQo00i" title="Share based compensation exercisable per share">0.06</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221207__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zowYGYOanhNa" title="Share based compensation exercisable per share">0.11</span> per share, with various expiration dates were cancelled and reissued exercisable at $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221207__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsLZPxIyBmc5" title="Share based compensation exercisable per share">0.028</span> expiring <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221201__20221207__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkPtDrlhUxCi" title="Expiring date">December 6, 2028</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total share-based compensation for the <span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231_zaHTNSDJlsFe" title="Share-based Payment Arrangement, Expense">103,540,000</span> stock options granted (2021 - <span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231_zE10VZnM5Pe9" title="Share-based Payment Arrangement, Expense">78,890,000</span>) and vested during the year ended December 31, 2022 was $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKA8HvZ5BmY2" title="Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture">1,070,983</span> (2021 - $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZ9bqbOlVqj1" title="Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture">1,413,055</span>). The fair values of the stock options granted were estimated using the Black-Scholes Option Pricing Model, based on the following weighted average assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zPRQBPsSA1l4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options (Details 1)"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt">Sch<span style="font-family: Times New Roman, Times, Serif">edule of valuation assumptions for options</span></span></td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left; text-indent: 0.05in">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zA1x1w2Am748" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate">3.50</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231_zyyyhh6YMSD3" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate">2.55</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; text-indent: 0.05in">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220101__20221231_zkkmuyL30kUg" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate">0.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210101__20211231_zNh175cph8y6" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate">0.00</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0.05in">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zyEkQ5ksRFCb" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate">143.43</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20211231_z6XWemZvea6k" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate">143.56</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; text-indent: 0.05in">Expected forfeiture rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--ExpectedForfeitureRate_dp_c20220101__20221231_zzEII4HrD9M" title="Expected forfeiture rate">0.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--ExpectedForfeitureRate_dp_c20210101__20211231_zRowrYfXHTmj" title="Expected forfeiture rate">0.00</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0.05in">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymenstAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zPTAMMAgNb3b" title="Expected life">6.00</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymenstAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z7BSPvbhdYFd" title="Expected life">5.09</span> years</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AE_zAL9oKNL8cDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The weighted-average fair value of the stock options granted during the year ended December 31, 2022 was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTY6vISzQrK3" title="Share based compensation exercisable per share">0.03</span> (December 31, 2021 - $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCSn9WgTZdt5" title="Share based compensation exercisable per share">0.10</span>)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following non-qualified stock options were outstanding and exercisable at December 31, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_ziSyvYnCSvF" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options (Details 2)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zsPIUv1OiNY6">Schedule of options by exercise price</span></td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Expiry date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options <br/> Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> Options <br/> Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 11pt; text-align: center">$</td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%">October 26, 2026</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption1Member_z5LLWBAClH5i" style="width: 12%; text-align: right" title="Weighed average exercise price">0.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption1Member_pdd" style="width: 12%; text-align: right" title="Number of outstanding">500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption1Member_pdd" style="width: 12%; text-align: right" title="Number of options exercisable">500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td> November 27, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption2Member_pdd" style="text-align: right" title="Weighed average exercise price">0.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption2Member_pdd" style="text-align: right" title="Number of outstanding">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption2Member_pdd" style="text-align: right" title="Number of options exercisable">250,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">December 6, 2028</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption3Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighed average exercise price">0.028</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption3Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding">93,540,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption3Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options exercisable">93,540,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font-size: 11pt; padding-bottom: 2.5pt"> </td><td style="font-size: 11pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 11pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 11pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231_zcA0JdG4p3Pc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding">94,290,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231_z1VEU2YWfxli" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">94,290,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zxqyYUK3ALQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As at December 31, 2022, the aggregate intrinsic value of the Company's stock options is $Nil .</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 94290000 <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zVyGVtTrnrIa" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8BF_zwLisvNn3H92" style="display: none">Schedule of Share-based Compensation, Stock Options, Activity</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of <br/> Stock Options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(Years)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%">Outstanding, December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPhFc9RcDrR6" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Outstanding, beginning">82,650,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zwFbPqugMmF5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price beginning balance">0.15</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">     Options cancelled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zN5lEiVpMAWa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options cancelled">(76,100,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, cancelled">0.16</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">     Options exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcXBuqMbsyyc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options exercised">(750,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, exercised">0.07</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">     Options granted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Option granted">78,890,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, granted">0.11</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSXi7yMtIGkb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding, ending">84,690,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6LtWTL2RGZf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighed average exercise price ending balance">0.15</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQz8jr6eYLuk" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term">4.23</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of <br/> Stock Options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(Years)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%">Outstanding, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsJSSHrH8M6k" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Outstanding, beginning">84,690,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_znIKnWYLOJA7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price beginning balance">0.15</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">     Options cancelled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zR4hWFLEXxL2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options cancelled">(93,540,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, cancelled">0.14</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">     Options expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zskQDDjGREci" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options exercised">(400,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, exercised">0.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">     Options granted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Option granted">103,540,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, granted">0.03</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4BSyGMN6pHa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding, ending">94,290,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zmr56a5w803b" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighed average exercise price ending balance">0.03</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4bkDiK0AiB9" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term">6.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 82650000 0.15 76100000 0.16 750000 0.07 78890000 0.11 84690000 0.15 P4Y2M23D 84690000 0.15 93540000 0.14 400000 0.06 103540000 0.03 94290000 0.03 P6Y 10000000 0.028 2028-12-06 93540000 0.06 0.11 0.028 2028-12-06 103540000 78890000 1070983 1413055 <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zPRQBPsSA1l4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options (Details 1)"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt">Sch<span style="font-family: Times New Roman, Times, Serif">edule of valuation assumptions for options</span></span></td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left; text-indent: 0.05in">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zA1x1w2Am748" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate">3.50</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231_zyyyhh6YMSD3" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate">2.55</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; text-indent: 0.05in">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220101__20221231_zkkmuyL30kUg" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate">0.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210101__20211231_zNh175cph8y6" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate">0.00</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0.05in">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zyEkQ5ksRFCb" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate">143.43</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20211231_z6XWemZvea6k" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate">143.56</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left; text-indent: 0.05in">Expected forfeiture rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--ExpectedForfeitureRate_dp_c20220101__20221231_zzEII4HrD9M" title="Expected forfeiture rate">0.00</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--ExpectedForfeitureRate_dp_c20210101__20211231_zRowrYfXHTmj" title="Expected forfeiture rate">0.00</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0.05in">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymenstAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zPTAMMAgNb3b" title="Expected life">6.00</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymenstAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_z7BSPvbhdYFd" title="Expected life">5.09</span> years</span></td><td style="text-align: left"> </td></tr> </table> 0.0350 0.0255 0.0000 0.0000 1.4343 1.4356 0.0000 0.0000 P6Y P5Y1M2D 0.03 0.10 <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_ziSyvYnCSvF" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock Options (Details 2)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zsPIUv1OiNY6">Schedule of options by exercise price</span></td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Expiry date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options <br/> Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> Options <br/> Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="vertical-align: bottom; font-size: 11pt; text-align: center">$</td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%">October 26, 2026</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption1Member_z5LLWBAClH5i" style="width: 12%; text-align: right" title="Weighed average exercise price">0.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption1Member_pdd" style="width: 12%; text-align: right" title="Number of outstanding">500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption1Member_pdd" style="width: 12%; text-align: right" title="Number of options exercisable">500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td> November 27, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption2Member_pdd" style="text-align: right" title="Weighed average exercise price">0.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption2Member_pdd" style="text-align: right" title="Number of outstanding">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption2Member_pdd" style="text-align: right" title="Number of options exercisable">250,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">December 6, 2028</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption3Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighed average exercise price">0.028</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption3Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding">93,540,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20221231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--StockOption3Member_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options exercisable">93,540,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font-size: 11pt; padding-bottom: 2.5pt"> </td><td style="font-size: 11pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 11pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 11pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; font-size: 11pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231_zcA0JdG4p3Pc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding">94,290,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20221231_z1VEU2YWfxli" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">94,290,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.10 500000 500000 0.10 250000 250000 0.028 93540000 93540000 94290000 94290000 <p id="xdx_805_ecustom--WarrantsTextBlock_z41F81JXDST" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6.  <span id="xdx_827_z9GyhbSLPsjc">Warrants</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Warrant transactions are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlock_z0u80mZKiFRf" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zY7pGsxwp3G3" style="display: none">Schedule of Stockholders' Equity Note, Warrants or Rights</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of <br/> Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">Outstanding, December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqdJv2Wxtdf2" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Warrant outstanding, beginning">10,326,857</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWkdBOzbrzSe" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Warrant weighted average exercise price, beginning">0.19</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">   Warrants granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuMy3itX8oh6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant granted">4,968,572</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNdtg1LdbOg4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, granted">0.08</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">   Warrants exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrT0zURHUjfl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants exercised">(3,214,286</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLMrhhVOSq25" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, exercised">0.07</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif">Outstanding, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4v5Tz2o1xTf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant outstanding, beginning">12,081,143</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ986H5FWLNl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, beginning">0.17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">   Warrants granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zntd6wdEu1Sd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant granted">13,300,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq3RQA5Kq0v5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, granted">0.04</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">   Warrants expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjPsBCdHN9oh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants expired">(6,081,143</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z0U6p6sRzQs1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, expired">0.09</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">   Warrants cancelled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3zy0s9oDAX5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants cancelled">(6,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2x7vJvVMp92" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, cancelled">0.26</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfDnl1giEaC3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant outstanding, ending">13,300,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6zSUlQl1nib" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, ending">0.04</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z29zpzI7iCXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">The following warrants were outstanding and exercisable as at December 31, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zcyNBFd82Nc3" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details 1)"> <tr style="vertical-align: bottom"> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zq5GyZ8aESEe">Schedule of outstanding and exercisable</span></td><td> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif"> </td><td> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant1Member_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right" title="Class of Warrant or Right, Outstanding">1,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant1Member_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"><span id="xdx_907_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant1Member_zJuXrbUxKtCi" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant2Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">200,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant2Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant2Member_znYLHC0AOceh" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant3Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">1,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant3Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant3Member_zIiwbRpBWsF4" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant4Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">600,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant4Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant4Member_zUee6bZcJbE" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant5Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">1,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant5Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant5Member_zu8RJX3jtVgf" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant6Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant6Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant6Member_zUkcLFpfwUDf" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant7Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">1,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant7Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant7Member_zDbCWdSgJSe6" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--AwardTypeAxis__custom--Warrant8Member_zKS28fpfiOEa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightsExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--Warrant8Member_zacLUHn7FpI3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant8Member_z4jX7RvIJMz3" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--AwardTypeAxis__custom--Warrant9Member_zv0lLWNxYad2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">6,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightsExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--Warrant9Member_zLsNLenIUQMj" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Warrant weighted average exercise price">0.028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span id="xdx_90C_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant9Member_ztIB00ZAZhmb" title="Expiry Date">December 6, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">13,300,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p id="xdx_8AF_zLlLKDhMMA8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: #333333"> In March, 2022 t</span>he Company issued <span id="xdx_903_ecustom--WarrantsIssued_iI_c20220331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zz5zF31lyfzi" title="Warrants issued">4,300,000</span> warrants as part of private placement transactions. On April 4, 2022 and May 12, 2022 the Company issued <span id="xdx_908_ecustom--WarrantsIssued_iI_c20220404__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zW23fuKNLacj" title="Warrants issued">1,000,000</span> and <span id="xdx_908_ecustom--WarrantsIssued_iI_c20220512__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWgHEBJnzcP8" title="Warrants issued">2,000,000</span> warrants, respectively, as part of private placement transactions. On December 13, 2022, the Company cancelled <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20190701__20190715__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2fDNla0JDle" title="Number of shares cancelled">6,000,000</span> warrants issued July 15, 2019 with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20190715__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zknC4g65RN95" title="Warrant exercise price">0.26</span> in consideration for patent assignments, and expiring <span id="xdx_905_ecustom--WarrantExpiringDate_dd_c20190701__20190715__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZZYMQX2mLk8" title="Warrant expiring date">July 14, 2024</span>. The Company reissued the <span id="xdx_906_ecustom--WarrantsIssued_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7OgjU1fpISe" title="Warrants issued">6,000,000</span> warrants with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjJk2PvvwQK7" title="Warrant exercise price">0.028</span> and expiring <span id="xdx_902_ecustom--WarrantExpiringDate_dd_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zARvdZ9Y72Hb" title="Warrant expiring date">December 12, 2028</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total share-based compensation for the reissued warrants during the year ended December 31, 2022, was $115,537.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair values of the reissued warrants were estimated using the Black-Scholes Option Pricing Model, based on the following weighted average assumptions:</p> <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionTableTextBlock_zqi5sdNjkuHe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details 2)"> <tr style="vertical-align: bottom"> <td style="display: none; padding-bottom: 1pt; vertical-align: bottom; text-align: center">Schedule of assumptions</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="padding-bottom: 1pt; vertical-align: bottom; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: bottom; text-align: center"><b> </b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>December 31,</b></p> <p style="margin-top: 0; margin-bottom: 0"><b>2022</b></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left; text-indent: 0.05in">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zUXyJO5wfa5f" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate">3.50</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0.05in">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220101__20221231_z8nWxHzk67Cg" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate">0.00</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0.05in">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zu42ACkwRKB4" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate">143.43</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0.05in">Expected forfeiture rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--ExpectedForfeitureRate_dp_c20220101__20221231_ziGR19Gxxp8b" title="Expected forfeiture rate">0.00</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0.05in">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymenstAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zR1YcTPRlM83" title="Expected life">6</span> years</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zuGCWPww1mMa" style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average fair value of the warrants granted during the year ended December 31, 2022 was $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBmRjem84qcd" title="Share based compensation exercisable per share">0.03</span> (December 31, 2021 - $nil)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlock_z0u80mZKiFRf" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zY7pGsxwp3G3" style="display: none">Schedule of Stockholders' Equity Note, Warrants or Rights</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of <br/> Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">$</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">Outstanding, December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqdJv2Wxtdf2" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Warrant outstanding, beginning">10,326,857</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWkdBOzbrzSe" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Warrant weighted average exercise price, beginning">0.19</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">   Warrants granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuMy3itX8oh6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant granted">4,968,572</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNdtg1LdbOg4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, granted">0.08</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">   Warrants exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrT0zURHUjfl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants exercised">(3,214,286</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLMrhhVOSq25" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, exercised">0.07</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif">Outstanding, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4v5Tz2o1xTf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant outstanding, beginning">12,081,143</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ986H5FWLNl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, beginning">0.17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">   Warrants granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zntd6wdEu1Sd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant granted">13,300,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq3RQA5Kq0v5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, granted">0.04</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">   Warrants expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjPsBCdHN9oh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants expired">(6,081,143</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z0U6p6sRzQs1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, expired">0.09</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">   Warrants cancelled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3zy0s9oDAX5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants cancelled">(6,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2x7vJvVMp92" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, cancelled">0.26</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfDnl1giEaC3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant outstanding, ending">13,300,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6zSUlQl1nib" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price, ending">0.04</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10326857 0.19 4968572 0.08 3214286 0.07 12081143 0.17 13300000 0.04 6081143 0.09 6000000 0.26 13300000 0.04 <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zcyNBFd82Nc3" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details 1)"> <tr style="vertical-align: bottom"> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B9_zq5GyZ8aESEe">Schedule of outstanding and exercisable</span></td><td> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif"> </td><td> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Expiry Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant1Member_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right" title="Class of Warrant or Right, Outstanding">1,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant1Member_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"><span id="xdx_907_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant1Member_zJuXrbUxKtCi" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant2Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">200,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant2Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant2Member_znYLHC0AOceh" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant3Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">1,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant3Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant3Member_zIiwbRpBWsF4" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant4Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">600,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant4Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant4Member_zUee6bZcJbE" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant5Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">1,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant5Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant5Member_zu8RJX3jtVgf" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant6Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">500,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant6Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant6Member_zUkcLFpfwUDf" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231__us-gaap--AwardTypeAxis__custom--Warrant7Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">1,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightsExercisePrice_c20221231__us-gaap--AwardTypeAxis__custom--Warrant7Member_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant7Member_zDbCWdSgJSe6" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--AwardTypeAxis__custom--Warrant8Member_zKS28fpfiOEa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">2,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightsExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--Warrant8Member_zacLUHn7FpI3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant weighted average exercise price">0.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant8Member_z4jX7RvIJMz3" title="Expiry Date">March 15, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--AwardTypeAxis__custom--Warrant9Member_zv0lLWNxYad2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">6,000,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightsExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--Warrant9Member_zLsNLenIUQMj" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Warrant weighted average exercise price">0.028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span id="xdx_90C_ecustom--ExpiryDateOfWarrant_dd_c20220101__20221231__us-gaap--AwardTypeAxis__custom--Warrant9Member_ztIB00ZAZhmb" title="Expiry Date">December 6, 2028</span></td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20221231_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Class of Warrant or Right, Outstanding">13,300,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> 1000000 0.05 March 15, 2024 200000 0.05 March 15, 2024 1000000 0.05 March 15, 2024 600000 0.05 March 15, 2024 1000000 0.05 March 15, 2024 500000 0.05 March 15, 2024 1000000 0.05 March 15, 2024 2000000 0.05 March 15, 2024 6000000 0.028 December 6, 2028 13300000 4300000 1000000 2000000 6000000 0.26 2024-07-14 6000000 0.028 2028-12-12 <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionTableTextBlock_zqi5sdNjkuHe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details 2)"> <tr style="vertical-align: bottom"> <td style="display: none; padding-bottom: 1pt; vertical-align: bottom; text-align: center">Schedule of assumptions</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"> </td> <td colspan="3" style="padding-bottom: 1pt; vertical-align: bottom; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: bottom; text-align: center"><b> </b></td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>December 31,</b></p> <p style="margin-top: 0; margin-bottom: 0"><b>2022</b></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left; text-indent: 0.05in">Risk-free interest rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20221231_zUXyJO5wfa5f" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate">3.50</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0.05in">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220101__20221231_z8nWxHzk67Cg" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate">0.00</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0.05in">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20221231_zu42ACkwRKB4" title="Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate">143.43</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0.05in">Expected forfeiture rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--ExpectedForfeitureRate_dp_c20220101__20221231_ziGR19Gxxp8b" title="Expected forfeiture rate">0.00</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0.05in">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymenstAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zR1YcTPRlM83" title="Expected life">6</span> years</td><td style="text-align: left"> </td></tr> </table> 0.0350 0.0000 1.4343 0.0000 P6Y 0.03 <p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxVxTtXwaR64" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7.  <span id="xdx_820_zOPKubhuYn1f">Stockholders' Equity</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue <span id="xdx_903_ecustom--CommonStockSharesAuthorizeds_c20221231_pdd" title="Shares authorized">500,000,000</span> (December 31, 2021 – <span id="xdx_900_ecustom--CommonStockSharesAuthorizeds_c20211231_pdd" title="Shares authorized">400,000,000</span>) shares of $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20221231_pdd" title="Common Stock, Par or Stated Value Per Share">0.0000053</span> par value common stock.  Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. <span id="xdx_908_eus-gaap--DividendsReceivable_iI_pp0p0_do_c20221231_zGcdfFvWbcI2" title="Dividends declared"><span id="xdx_90F_eus-gaap--DividendsReceivable_iI_pp0p0_do_c20211231_zN7X4AFmFt31" title="Dividends declared">No</span></span> dividends have been declared or paid as of December 31, 2022 (December 31, 2021 - $Nil).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the year ended December 2022, the Company:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 26px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsMember_zETs0ZlVXWgd" title="Number of shares issued">5,450,000</span> shares of common stock (5,450,000 shares issued at $<span id="xdx_90E_eus-gaap--SharePrice_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsMember_pdd" title="Share Price">0.02</span>) as part of a private placement for total proceeds of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsMember_pp0p0" title="Stock Issued During Period, Value, New Issues">109,000</span>. </span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsOneMember_zyo9dvjaENUl" title="Number of shares issued">3,100,000</span> shares of common stock (3,100,000 shares issued at $<span id="xdx_90F_eus-gaap--SharePrice_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsOneMember_pdd" title="Share Price">0.025</span>) as part of a private placement for total proceeds of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsOneMember_zbPWypQJfu6h" title="Stock Issued During Period, Value, New Issues">77,500</span>.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsTwoMember_pdd" title="Number of shares issued">7,500,000</span> shares of common stock (7,500,000 shares issued at $<span id="xdx_906_eus-gaap--SharePrice_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsTwoMember_z3ztDyR0OmUl" title="Share Price">0.03</span>) as part of a private placement for total proceeds of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsTwoMember_zPX2nPQGcfrk" title="Stock Issued During Period, Value, New Issues">225,000</span>. </span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsThreeMember_zWDRktrYNO8d" title="Number of shares issued">2,136,666</span> shares of common stock (2,136,666 shares issued at $<span id="xdx_90F_eus-gaap--SharePrice_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsThreeMember_zf7NDyUnTlZf" title="Share Price">0.06</span>) as part of a private placement for total proceeds of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsThreeMember_zzTgc1bWlqJ3" title="Stock Issued During Period, Value, New Issues">128,200</span>. </span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsFourMember_zTMmQj3YLuca" title="Number of shares issued">7,300,000</span> units (each unit consisting of 1 share of common stock and 1 warrant to purchase 1 share of common stock at $<span id="xdx_902_eus-gaap--SharePrice_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsFourMember_zCvGOZmaE3Q7" title="Share Price">0.05</span>) as part of a private placement for total proceeds of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsFourMember_zb0agJnB8Wr7" title="Stock Issued During Period, Value, New Issues">365,000</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the year ended December 2021, the Company:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 26px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsFiveMember_zBImcEAEbxF" title="Number of shares issued">3,528,572</span> units (each unit consisting of one share of common stock and one warrant to purchase one share of common stock at $<span id="xdx_907_eus-gaap--SharePrice_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsFiveMember_zktB3O3SQat1" title="Share Price">0.07</span> per share) as part of a private placement for total proceeds of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsFiveMember_zSmNJAIqHYZi" title="Stock Issued During Period, Value, New Issues">247,000</span>.</span></td></tr> </table> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"/> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 26px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_907_ecustom--WarrantExercised_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYa9bEVb6vRl" title="Warrants exercised">200,000</span> shares of common stock at $0.12 as part of a private placement for total proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zzQjCKOmvsPf" title="Total proceeds">24,000</span>.</span></td></tr> </table> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"/> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 26px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsSixMember_zpp23WxWahS6" title="Number of shares issued">1,440,000</span> units (each unit consisting of one share of common stock and one warrant to purchase one share of common stock at $<span id="xdx_900_eus-gaap--SharePrice_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsSixMember_zKpxif0SjJwc" title="Share Price">0.10</span>) as part of a private placement for total proceeds of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsSixMember_zhuERQaJSyH" title="Stock Issued During Period, Value, New Issues">144,000</span>.</span></td></tr> </table> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"/> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 26px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsSevenMember_z1KicQY2kazi" title="Number of shares issued">3,214,286</span> shares of common stock from exercised warrants (2,214,286 shares issued at $0.07 and 1,000,000 shares issued at $<span id="xdx_902_eus-gaap--SharePrice_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsSevenMember_zvtLDKG3yaMj" title="Share Price">0.12</span>) for total proceeds of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsSevenMember_zrmGLQBUMJoh" title="Stock Issued During Period, Value, New Issues">275,000</span>. </span></td></tr> </table> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"/> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 26px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231_zqnuWpYeY1Vl" title="Number of shares issued">555,556</span> shares of common stock to the Company’s CFO pursuant to a cashless exercise of <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Option exercised">750,000</span> stock options.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsEightMember_zNZNYaagpyXk" title="Number of shares issued">250,000</span> shares of common stock at $<span id="xdx_906_eus-gaap--SharePrice_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsEightMember_z0i9Zsynm2U5" title="Share Price">0.08</span> as part of a private placement for total proceeds of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsEightMember_zxRFc9ph81x6" title="Stock Issued During Period, Value, New Issues">20,000</span>.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsNineMember_z3wgohj0wrY4" title="Number of shares issued">2,250,000</span> shares of common stock at $<span id="xdx_90A_eus-gaap--SharePrice_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsNineMember_zGiMFUMbnqVi" title="Share Price">0.06</span> as part of a private placement for total proceeds of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorsNineMember_z7sOeV1ivr7e" title="Stock Issued During Period, Value, New Issues">135,000</span>.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extended exercise date for warrants to purchase <span id="xdx_90E_ecustom--ClassOfWarrantOrRightOutstandings_iI_c20211231_zzxNAoPUQBGh" title="Warrants to purchase">1,440,000</span> shares of common stock issued August of 2021.  </span></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extended exercise date for warrants to purchase <span id="xdx_90E_ecustom--ClassOfWarrantOrRightOutstandings_iI_c20201231_zRpqqJChcZoh" title="Warrants to purchase">3,355,429</span> shares of common stock, issued December of 2020.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 500000000 400000000 0.0000053 0 0 5450000 0.02 109000 3100000 0.025 77500 7500000 0.03 225000 2136666 0.06 128200 7300000 0.05 365000 3528572 0.07 247000 200000 24000 1440000 0.10 144000 3214286 0.12 275000 555556 750000 250000 0.08 20000 2250000 0.06 135000 1440000 3355429 <p id="xdx_80C_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zEsmmtP8Q4oa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 8. <span id="xdx_825_zp7JrIoLs0M1">Related Party Transactions and Balances</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt">During the years ended December 31, 2022 and 2021, the Company entered into the following related party transactions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">a) Pursuant to a consulting agreement with an effective date of November 14, 2017, a total of $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pp0p0_c20220101__20221231_zKHyfoXVIpx2" title="Related Party Transaction, Amounts of Transaction">60,000</span> (2021 - $60,000) was paid or accrued to the Company's CFO. During the year ended December 31, 2022, the Company reimbursed a company controlled by the CFO a total of $<span id="xdx_90D_eus-gaap--IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefFinancialOfficerMember_zHKdMuX4KzO9" title="Increase (Decrease) in Due from Officers and Stockholders, Current">11,025</span> (2021 - $<span id="xdx_90E_eus-gaap--IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent_pp0p0_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefFinancialOfficerMember_zrkIIWJ3NO02" title="Increase (Decrease) in Due from Officers and Stockholders, Current">12,600</span>) in office rent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 12pt 0; text-align: justify">b) On December 7, 2022, the Company cancelled and concurrently replaced <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20221201__20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveandDirectorOfficerMember_zMItr9lWRou5" title="Number of shares cancelled">32,350,000</span> stock options previously issued to the Company’s CEO and a Director of the Company from 2021 to 2022. The modifications incremental fair value of $<span id="xdx_90E_ecustom--ModificationIncrementalFairValueOption_pp0p0_c20221201__20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveandDirectorOfficerMember_z18FA69RHkx" title="Modification incremental fair value option">80,105</span> was recognized in the current period. The <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGranted_c20221201__20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveandDirectorOfficerMember_zkcakGJsMND6" title="Options granted">32,350,000</span> replacement options granted have a term of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221201__20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveandDirectorOfficerMember_zl8q905fntC2" title="Expected term">6</span> years, exercisable at a price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveandDirectorOfficerMember_zMFHFEBwIG5c" title="Exercisable price">0.028</span> per share, expiring on <span id="xdx_904_ecustom--OptionsExpirationDate_dd_c20221201__20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveandDirectorOfficerMember_zW6tjBpZhBEa" title="Option expiration date">December 6, 2028</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 12pt 0; text-align: justify">c) On December 7, 2022, the Company cancelled and concurrently replaced <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20221201__20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CFOMember_ziLPHeQ0vur3" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations">13,260,000</span> stock options previously issued to the Company’s CFO of the Company from 2018 to 2022. The modifications incremental fair value of $<span id="xdx_90D_ecustom--ModificationIncrementalFairValueOption_pp0p0_c20221201__20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CFOMember_zqpbn7RDM5ul" title="Modification incremental fair value option">82,398</span> was recognized in the current period. The <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGranted_c20221201__20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CFOMember_zo9FzjzCrgha" title="Options granted">13,260,000</span> replacement options granted have a term of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221201__20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CFOMember_zw3jftZ7JyIl" title="Expected term">6</span> years, exercisable at a price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CFOMember_zII3IKYqz55k" title="Exercisable price">0.028</span> per share, expiring on <span id="xdx_903_ecustom--OptionsExpirationDate_dd_c20221201__20221207__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CFOMember_zquJomutMEma" title="Option expiration date">December 6, 2028</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 12pt 0; text-align: justify">d) On March 15, 2022, the Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220301__20220315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveandOfficerMember_zdcMNFDJGsa3" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted">4,750,000</span> stock options to the Company’s CEO and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220301__20220315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zDhl4iWrCUdi" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted">500,000</span> stock options to a Director of the Company, respectively. The <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220301__20220315_z135hQrDj5W5" title="Option granted">5,250,000</span> options granted have a term of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220301__20220315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveandDirectorOfficerMember_zKhgbKDJ2Yc4" title="Expected term">8</span> years and are exercisable at a price of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveandDirectorOfficerMember_zYwjhKgkuPl8" title="Options exercisable price">0.06</span> per share, expiring on <span id="xdx_90F_ecustom--OptionsExpirationDate_dd_c20220301__20220315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveandDirectorOfficerMember_zP6jyOZBftW8" title="Option expiration date">March 14, 2030</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 12pt 0; text-align: justify">e) On March 15, 2022, the Company granted <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220301__20220315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CFOMember_zDljE3N33Lph" title="Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted">1,500,000</span> stock options to the Company’s CFO. The options granted have a term of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220301__20220315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CFOMember_zG0IJQon5xm2" title="Expected term">8</span> years and are exercisable at a price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CFOMember_z9hqzZXKuRY2" title="Exercisable price">0.06</span> per share, expiring on <span id="xdx_901_ecustom--OptionsExpirationDate_dd_c20220301__20220315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CFOMember_zjRiHPiZVFLf" title="Option expiration date">March 14, 2030</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">f) The Company recognized $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpenseNetOfTax_pp0p0_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQqLuyGM78b4" title="Share-based payment arrangement, expense, after tax">638,227</span> (2021 - $ <span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpenseNetOfTax_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQ2CQx97UW8e" title="Share-based payment arrangement, expense, after tax">649,822</span>) in share-based compensation during the year associated with stock options granted to key management personnel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 12pt 0; text-align: justify">g) The Company recognized $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpenseNetOfTax_pp0p0_c20220101__20221231_z7MVKrkwWIfe" title="Share-based Payment Arrangement, Expense, after Tax">638,227</span> including modifications (2021 - $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpenseNetOfTax_pp0p0_c20210101__20211231_zW6FZ7jEuzR7" title="Share-based Payment Arrangement, Expense, after Tax">722,822</span>) in share-based compensation during the year associated with stock options granted to key management personnel. The total incremental fair value of stock options including modifications is $<span id="xdx_900_ecustom--ModificationIncrementalFairValueOption_pp0p0_c20220101__20221231_zghqhyUhE3df" title="Modification incremental fair value option">1,070,983</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 12pt 0; text-align: justify">As at December 31, 2022 and December 31, 2021, there were $nil balances owing to related parties. <span id="xdx_90B_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20221231_zx1bIhRe3m37" title="Due to Related Parties, Current"><span id="xdx_904_eus-gaap--DueToRelatedPartiesCurrent_iI_pp0p0_c20211231_z0B7axYMfdeb" style="display: none" title="Due to Related Parties, Current">0</span></span></p> 60000 11025 12600 32350000 80105 32350000 P6Y 0.028 2028-12-06 13260000 82398 13260000 P6Y 0.028 2028-12-06 4750000 500000 5250000 P8Y 0.06 2030-03-14 1500000 P8Y 0.06 2030-03-14 638227 649822 638227 722822 1070983 0 0 <p id="xdx_80F_eus-gaap--CommitmentsDisclosureTextBlock_zoBZgYXfgwld" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 9. <span id="xdx_821_z5wqnpgmHsbj">Commitments and Contingency</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Commitments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As at December 31, 2022, the Company has the following commitments:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">a) Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20170101__20170102__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_zM8aOQfVlaW9" title="Research and development expense">7,000</span> per month for providing research and development services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">b) Entered into a consulting agreement effective April 1, 2019, whereby the Company would pay the consultant $<span id="xdx_90F_eus-gaap--TravelAndEntertainmentExpense_pp0p0_c20190401__20190402__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_zji56omDFfs8" title="Travel and entertainment expense">1,500</span> per month minimum plus travel expenses for a term of <span id="xdx_900_ecustom--TravelExpensesTerm_dtY_c20190401__20190402__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_zV6st7M26Pmb" title="Travel expenses term">1</span> year for providing research consulting services. Agreement renews annually unless otherwise terminated by either party with at least 30 days’ notice.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Contingency</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, "Report of Foreign Bank and Financial Accounts" ("FBARs"). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs.  Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no under reported tax liabilities.  On November 30, 2017, the Company received a letter from the IRS concluding their review of the Company's tax returns under the program and accepting the returns as filed.  No penalties have been assessed by the IRS to date, and management does not believe that the Company will incur any penalties relating to the tax years submitted under the program.</p> 7000 1500 P1Y <p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zLmG2AZtQR6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10.  <span id="xdx_827_zu6KLHmDDiZ9">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As a Nevada corporation, the Company is liable for taxes in the United States.  As of December 31, 2022, the Company did not have any income for tax purposes and therefore, no tax liability or expense has been recorded in these financial statements (December 31, 2021 – nil).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">A reconciliation of income taxes at statutory rates with the reported taxes is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zepQqORnI17h" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B2_zTEFsqHRVdDb">Schedule of Effective Income Tax Reconciliation</span></td><td> </td> <td colspan="2" id="xdx_497_20220101__20221231_zdDWccaEFok6" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_490_20210101__20211231_z3D3gQ8uEHa3" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2021</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-bottom: 1pt">Net loss for the year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(1,907,309</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(2,329,310</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_pp0p0_di_zpgWILphMqp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected income tax recovery</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(400,535</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(489,155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-deductible expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">224,907</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">296,742</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Adjustment to prior years provision versus statutory tax returns</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">75,628</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">92,414</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total income tax expense (recovery)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_z2mPjXoGzfOa" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zbME4uGXte1j" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8BE_zSOjgdfh7PSl" style="display: none">Schedule of Deferred Tax Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company’s deferred tax assets that have not been recognized are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of Deferred Tax Assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Tax benefit of net operating loss carry forward</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredTaxAssetsGross_c20221231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Deferred Tax Assets, Gross">6,400,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsGross_c20211231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Deferred Tax Assets, Gross">6,300,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20221231_zU40k0OlZFO3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax Assets, Valuation Allowance">(6,400,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20211231_zVvvYzYbbHY2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax Assets, Valuation Allowance">(6,300,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsNet_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax Assets, Net of Valuation Allowance"><span style="-sec-ix-hidden: xdx2ixbrl1014">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsNet_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax Assets, Net of Valuation Allowance"><span style="-sec-ix-hidden: xdx2ixbrl1016">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_z79yU0l2gYLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company has net operation loss carryforwards of approximately $<span id="xdx_904_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_c20220101__20221231_pp0p0" title="Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount">30,500,000</span> (December 31, 2021 - $<span id="xdx_902_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_c20210101__20211231_pp0p0" title="Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount">30,000,000</span>) to reduce future taxable income.  The valuation allowance has not changed during the year ended December 31,2022. Tax losses expire in years starting from 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The deferred tax asset associated with the tax loss carry forward is approximately $<span id="xdx_904_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pp0p0_c20221231_zklW0kZftmej" title="Deferred Tax Assets, Capital Loss Carryforwards">6,400,000</span> (December 31, 2021 - $<span id="xdx_906_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pp0p0_c20211231_ziVVzVoeVUB8" title="Deferred Tax Assets, Capital Loss Carryforwards">6,300,000</span>).  The Company has provided a full valuation allowance against the deferred tax asset since it is more likely than not that the asset will not be realized. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b/></p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zepQqORnI17h" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B2_zTEFsqHRVdDb">Schedule of Effective Income Tax Reconciliation</span></td><td> </td> <td colspan="2" id="xdx_497_20220101__20221231_zdDWccaEFok6" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_490_20210101__20211231_z3D3gQ8uEHa3" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2021</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left; padding-bottom: 1pt">Net loss for the year</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(1,907,309</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">(2,329,310</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_pp0p0_di_zpgWILphMqp2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected income tax recovery</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(400,535</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(489,155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-deductible expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">224,907</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">296,742</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Adjustment to prior years provision versus statutory tax returns</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">75,628</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">92,414</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total income tax expense (recovery)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -1907309 -2329310 400535 489155 224907 296742 75628 92414 100000 100000 <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zbME4uGXte1j" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8BE_zSOjgdfh7PSl" style="display: none">Schedule of Deferred Tax Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company’s deferred tax assets that have not been recognized are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of Deferred Tax Assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Tax benefit of net operating loss carry forward</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DeferredTaxAssetsGross_c20221231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Deferred Tax Assets, Gross">6,400,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--DeferredTaxAssetsGross_c20211231_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Deferred Tax Assets, Gross">6,300,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20221231_zU40k0OlZFO3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax Assets, Valuation Allowance">(6,400,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20211231_zVvvYzYbbHY2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax Assets, Valuation Allowance">(6,300,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsNet_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax Assets, Net of Valuation Allowance"><span style="-sec-ix-hidden: xdx2ixbrl1014">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsNet_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax Assets, Net of Valuation Allowance"><span style="-sec-ix-hidden: xdx2ixbrl1016">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 6400000 6300000 6400000 6300000 30500000 30000000 6400000 6300000 <p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zSeKyNpfhOkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 11. <span id="xdx_82C_zXBcd4yeX0x3">Subsequent Events</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Subsequent to the year ended December 31, 2022, the Company:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 26px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zvHzFRC5idH8" title="Number of shares issued">2,000,000</span> shares of common stock (<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231_zPNBEieEfnF3" title="Number of shares issued">2,000,000</span> shares issued at $<span id="xdx_904_eus-gaap--SharePrice_iI_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zdcpRZr9rgch" title="Share Price">0.02</span>) to the CEO of the Company, as part of a private placement for total proceeds of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zAWqcHy7OBIg" title="Stock Issued During Period, Value, New Issues">40,000</span>.  </span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> </table> 2000000 2000000 0.02 40000 EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

"CRTKZ?[9RKWIZ>VG2G"FD7IE(EKFQ- M74B'K_7MJ:UJ)3->5.2GZ^7RU6DA=3F[>,>_7=<7[TSCYK=5WCVVDG)=.%*JTVI:C5]OWL [?M=J;Z//@HZR,>:.OOR2O9\M22.5J]21"(E_]^I*Y3E)@AY_!J&S M;D]:&']NI7_BP^,P&VG5ES\[GXE,;663NR]F_W<5#L0*IB:W_%?L M_;TO7\U$VEAGBK 8&A2Z]/_E0S!$M.!\>63!.BQ8L]Y^(];RHW3RXEUM]J*F MNR&-/O!1>364TR5YY<;5N*JQSEW<>&\(LQ4W^K;46YW*THG+-#5-Z71Y*ZY- MKE.MK#AI/SU[=^JP-0DX3<,V'_PVZR/;K-;BLRG=SHJ?RDQE0P>+E3?-TJ M_F$]*?&C2A?B;#47Z^5Z/2'OK#/$& M1=-;6\E4O9\A7*RJ[]7LXOOO5J^6/TYH^Z+3]L64](L/TFI+3KLFV:63!/$Q M)2?%C"LY*EO\ME,(H=04E2P?R4I;7P5;<-6\^"JBO:R<+LT@FYW8)+(:$R M-9E1%N0V]@#N5^_))PN1,8/]I@W MT[S)!LZQY+%[F3<=#LBI[O$YSI!+'RD@KB8(@!]5-J=J:+R*,E7#RP;LH M(2T:J[9-#D]LO>DTE-(UPP/R-6B@O-6;7 6W30;-JRYH7DT&S96TN[% F5PU M'B@D2O ?( S\Y;&P;@%)UY.6^ 1;B]_A4<;\IPX'O_1^'#/4 MI-!Q0WW#3M&O$8[F8K_3Z:[%(^($MIMWMDPJ^2@9'T0=:5HWZB"N$2ZIK&M- MX>HH8A&%_\&7U%C7"H](::-RC5#&PJJJS4/ _I;4OV?UL\;[ ."U.PA[[E1= M)*5T<%=@#D1M= (?MVTB*I0DQUK/,+W8 :MZL">''%4UM6VD9\[+FRMQOEZ* M6639SUYV3U0?.Q*TLW!4A"/\%9]H3C$.&VJ4^7JU^%'\VAO@3=4C* M[!W:A@1%\AUE*_*$SL@ :0MNU.YYU.Q[>&ULZ.2$-U(,L4&=Q%(LMFC,DM PA!YN'Q=3L9((ZI[X0 M> ;H.(':6Q4;9,>V_IZ35['-GOZ41ACZVELGB<]FF\T?5$; (3++-(F%)7OL M3O+I><>GYY-\^HM/<;]1BALCSLG5X\09BQP02,7BD? *05(?& O9$4B+G@ R:@"2@SOI M\ WNK)VDT@R[5,8R&GDG=$"=K!21BB+OZ6Z'#I\+-#N$&.(F/JBGO:9HS/FI[+A#W*B=Z@C;F7E.V[DZ# M?0">7IUY$J6&.1W66BYI^2)5?KC;.O8.JFF9DZ_FL1F@"M^E"^%+:ESNX]F[ MM99E..3'IT!]DE\)J$&K#/3-)74)1@RK:BX%J+CW/QF& RX;(Z.,4"URNLDER>M.1TYO_04X'Q71'VQ4. M5@93AX^$<^\++I1&V6QRNV-L]LTZ)$]T&$2BV9?V:7_0EN'D.FK[?)PE7J(] M(9U"7>GR("^8.--*^UD MSO%M2IR3BR$ D;J0M,:!54S8.$5I"IT"NB6*26B.K&PRW;,#L2C%\5%<@FF\ G[B4)#O@&78!>N=HQEEH%6#<4RJ@)NW,<+@PXJF8'3]&2)>J[T':0YP4-"6#36M:&QWD. K2=*T([JXS0\DUUZCX 2+\SR! MHC?4?+Z/_D; =FN$_)P*EFH.FH"V(6LF1!>_]\'$XP@D$ M1UV3HH"E:GAPVIVT?D :*63";.@8W8Y%UF0F6BW[\?]R,A=]04*@/L]WJ=1% MF(J#X.I8LID6.)YMIG<1@\M9=#DJ.P+=LX%?1IL ^FD3P5!9*0$9PF*BRYC3_"7HF7D\G[SAD60&4!S1B"S _ M)OBD.UC#/<^&SP^TE+@:V< /_*O(>EEK/=M9;Y%0X:+\&!OG>?-BOGZSG"^7 M2W'^8OXJ?%R=S<^6X>-ZOCQ?S5IR,ND>9(]N"S+3#?D,#+C"L54GKDD.>BP'DI]'P?$/\ M5S-.B?4YB>1,S*0?#3]\$]D2Q P"LR3<1Z(!Y7EX$$)NS0\%>FK M8!^U_;Y=0@L>:;,O'\CO$C=%R'%ND5RA7-B*WY4OY\$V/%'CK.R7T&VM/CD5 M(IE\;#U['Y:UW# $ -WEG= ['2F 1KD _%$_)\?]/)0]9)8P%6#/!T0>[-<- MO89P]RKR "^V.TTU2"9Y>^%9_+F7,# Z[5>:\GF/'^!$/?@:AH>[M\9D'ON= M7FSC-HH*7[9TLU>&S^L?+75?L%S@T5 "Y]8P!NK,UX9/,1-U_!X_-"D:EFS' MD1P>?T4BR(?'SJX'$S\/ FI(LC\:ZPK_'-"7Z<3O.R@W]^P>KR1<&+JXB1AW-!W_A?8-8IAA\B2*! MD(D+RM%[((.\G+0]8(LD/YW[-CR) ^[D)Y1/L<.WEHSB73J';/T BFCF86!]-4;B #=\1,1>Z9(QIT2(9#H ^[ MH,";[ MOMSN1]*Z =3.PKX%SKG&>B)Q@;#M?T#3+Z,Z]84"M'EIP8M&A)FV X;]%9$ M;7*(9#3QE]P7\W2C#<5O@$BXH7],$+:?T\TG^IX/35ON=RBTD3.BMQ3X@?8V MYPD_/Y6(GG5RY<6A#V[+5*HM6WMH'W36?IH;4*YMQQGM'!60'/HGOK\=:87! M2L+7MKZ_@.\-"D_%C[O,)M>W(:VU3QMBL?RD;0K+_:L[J^EW=[Z@MSYXYZTV MI:&G T>?O$^+/(;HZ7V>5.E17<+H\5.ZR)M)J?;D44_F@_>H!H*Y@]:\FL9O M8<(0$5'8M2LK-I1#:>3)C(BM2WK62S-^ "4T4-'\/#'33R-D>+DFFB7)S%/: MN ]/HS<:"X5<3.]M6D_#_N7&[M?NW=!+_T9D?[M_L?0S4CD*"I&K+98N%Z_A MN=J_J^F_.%/Q^Y$;XYPI^.-.2>"9;L#UK4%7&;[0!MT;LQ?_!5!+ P04 M" ![B'%6O^T+!I " "M!0 &0 'AL+W=OXU$!U63+]9X9";2=!'.P> M'OBF,.XA3,<5V^ CFF_54ELI[%!R7J(DKB1H7$^":7P]&SI]K_"=XY;V[N B M62GU[(0O^22('"$4F!F'P.SQ@G,4P@%9&K];S*!SZ0SW[SOT.Q^[C67%".=* M_."Y*2;!90 YKEDMS(/:?L8VGI'#RY0@_X5MHWMQ$4!6DU%E:VP9E%PV)WMM M\[!GN*(]&V[_;_ X269,W1R);=C%-CR&GC[:V13O,]9B+GBN1JU/<>T!IDVKGQ'<4?("X'XVBW=EK.PWL?-[A2M=V+T#< MUABH8!H+)7*;_=(V.)<;.#VY3.+D!I)A_VHXZCTIAWZ\B=]\)J/^U=4(#B4X MW!NA$O7&+PJ"3-72--/4O7:[:-J,X)MZL\CNF=YP22!P;4VCLXM1 +I9#HU@ M5.4'P^1>T4[/^U4F8G. ?=AD[_ 5!+ P04 " ![B'%69>,# MW@0# !T!P &0 'AL+W=O! *6@)7%'!D83UU)M'5XO$^CN';Q3VJF,C6\E*B%^V MX <8LR,CXW3"]0TH;V+5;^D=7NZEE113<"/:=%GH[ M]3(/%; F.Z8?Q/XS-/6DEI<+IMP7[6O?-/90OE-:E$VP45!27K?DI9F'3D 6 MG@C 30!VNNM$3N4MT60VD6*/I/4V-&NX4EVT$4>Y791'+QX\0G>)R&*/64,$5Z@MZ7?4I4SH782T(_Y M2FEI]LS/8_-09TF.9['GZ$I5)(>I9PZ* OD,WNSB+!J&USTU)(<:DCYZ=\6( ME8V,3*Z(V^3JF-A>W'&QO3D&2Z*!:^0.L$)-;UY5C.;$';4GH0D;W BE!PO" M",_!1V8IH5R!;)1GZ4#:TU=M9@7A3494,79QF.\#4:A_XX M2YOF-#?JR2G$CY2OG&UK_C6@V.*@L;0F=QAM@?FL4YEG#4 M>"CU$.RON/KCA:5NU=70IM;VIE;\RR"M [F_UH(W79L@L-#._L+ M4$L#!!0 ( 'N(<59/VFVCX@, ,H* 9 >&PO=V]R:W-H965T^'*ES0=W,BK8$I]1_UH\2MJYC96$9Y@K+G*0 MN!C;T_[-+#+RI< 7CEO56H.)9"[$B]G\G(QMSP#"%&-M+#!Z;? 6T]08(AA_ MUC;MQJ51;*\/UG\L8Z=8YDSAK4B_\D2OQO;0A@07;)WJ)[']">MX0F,O%JDJ MG["M93T;XK72(JN5"4'&\^K-=G4>WJ+@UPI^B;MR5**\8YI-1E)L01IILF86 M9:BE-H'CN2G*LY9TRDE/3YZUB%_@H3 I4G#QF[[?86_01#HH[0W> M$NFY "OUX+RZ(<>-*EB,8YNZ7Z'XWD>>+U^:!VZ.&9Y3#0G#Q=7D=/W*I%+(Q0U0EB# M,D+A4<*[:B26DN4&YM70&5XW;OK=J/HP#)SH*!Y"T/,'_W]V3G"%YWDIN\=39# H!N4#]>!XU\?Q2'JT:J#/V'#G_!?\F=6 M]NXCV],?1,-TRV1RTKQ?6+HNVQJFBOY*=6R_EY<@?,:=AEE*"G^<(U@GGE<) M!@W*3>.;M7S37Q9$M;9.LW=29.N)JY M6W=$T03S!/8G.YZW3!?-]PN@KB7-4ZS?[S MM?BJ+Q,LEWM(3!K^QN@C]P_L:;Y8[ZR'6 NS\:.RI)'A(26JIEW]MCZ)355Y M_ZHMYMXAQ5B',^W1_ P SPD !D !X M;"]W;W)K&ULG5;;IT;<*_W'N#@.#6? #@Z@SB&SSWU- ML$;H9QW$90L1_0 BC."SJ/16P7658_XM@$_Q]$%%AZ NHU'$*\PF$(<>1$$4 MC>#%?9*QQ8M?2/)4;JWE]+2E:8ES5;,,%RYQ7J'SN+>\QAXL=2FICN'Y$F7&%<"-YALY;Y^]&*\VJG%<;#VAKT9IV MVQM &'AQE'JSY R"2?C!Z;UMS$# 4^]#.O.2LXCDP>PHQ\Y1#N]B+PJG7C1+ MX;U1.AOW&4(8><$L],)I;'R>/?<9QEXAOPY ME.U;WM"4"OT$=*BA$_9E?&OJDL!G)K,MA(DMV]2)CC5[)CO:GI*FK[9,7FT9 MC4*6@P#69!I,SZC39/A_:B1:UO;)70M,#P/YN MZ<6%TBB0?"WH8.XFQD'_AEO^#U!+ P04 " ![B'%61=CU&X # A" M&0 'AL+W=OM7$&I1)( V MDFCY*[$-.!_%]M B2++MH>B!ED86MQ*I)2D[V5^_0])6O8#KM!=K*,V\><-Y M''JVE>J[K@ ,>6YJH>=A94Q[&<=-K+9!2.#A@O_9,^[?3@(F"0_":"[ M .IX^T2.Y2TS;#%3CS66P0VCK$^0[FVL/0G\"DE'R4PE2:W(D"BO\#Q,BI)T;WQ*[I2<1; MR"_(((T(32@]@3?H"QTXO,&KA9);KO-:ZDX!^;I<::-0&M^.U>P1L^.(]KA< MZI;E, _Q/&A0&P@7[]ZDH^3J!-^LYYN=0E\\XO$KNAJ(+,E=68)3+SFHX@%R M*7)>G5@75"1,->1,-? M%M$ME* 4;K9MXU)K,/J8:$X"OBZ:(UF"IPJ"&]FT3+RXVL97V@Y.[V7XP_G<+P?[9?"KS8P/QG8# M:NTN)Z0E.V'\!._?]O??TH_]'^[^\OS(U)JC6FLH,32Y&&,;E;^0_,+(UET" M*VGP2G%FA76NEG4R!:>"F%-/V@L+:Z"4.3%5@R 2)QK,LBR9_CU$H=;]( ZV"P]\45BW$*:]BBUP MBO:QFFB:A0U*SDN4ABL)&N?]8!#?#+MNO]_PC>/:[(S!.9DI]>PFG_-^$#E! M*#"S#H'1984C%,(!D8Q?&\R@H72%N^,M^IWW3EYFS.!(B2>>VZ(?7 >0XYPM MA7U0ZT^X\=-V>)D2QO_#>K,W"B!;&JO*33$I*+FLK^QED\-.0?+^0$&R*4B\ M[IK(JQPSR]*>5FO0;C>AN8&WZJM)')?NH4RMIKNM.5HX&R,-!8&OC"MF98_X:("0OC:%D:VB8'$4<8W8)K?@"DBANP^-T#&?O MSL$4C/P=@6\U>;4\?.L _%>]8)+_\3%=N&2,$CRO4V,R?QTCQ7K')9,99P*F MM(ATG*V![X.9L9H.Y(]]B=4"KO8+<"_IC:E8AOV@A)WHMLC]JX: M>U?'T-,1,P5DY(KGJ+V)?0IKC+;'<&_]*FU%].N%JSW4[8:Z?91ZD.?<$5)4 M%24E+;"J$CSS*LP^&>TW,N+#,CJ-C,Y1&4_N-!,Y-V:).?S=>W1J_AJHL\/? MB:+#"KJ-@NY1!7>,:U@QL41@^4]J >[0N+.TKJ7MU=)]DT72?JLDW&D4)>J% M;X>&'OA2VKIG-*M-QQW4C>;_]KI=WS.]X-* P#F51I==XM9U"ZPG5E6^[XAQ5D3V*2+D @ MGPD !D !X;"]W;W)K&ULQ59M;]HP$/XK5B9- MF[0VKPVT@TA -ZW2NJ&BK1^J?3#)D5A-[-1V2/GWLQW(2 O1)B&-#\1V[A[? M\_@NOE'-^*/( "1Z+G(JQE8F97EEVR+.H,#BG)5 U9L5XP66:LI36Y0<<&*< MBMSV'">T"TRH%8W,VIQ'(U;)G%"8B@VA^A07DJNW1/G) M:-&<'F(KM" I)2L28RK1)(Y9126A*9JSG,0$!'IW#1*37*!OF'.LU7^/SI#( M, 0WR. M?/<#\AS/.Q#0[._=W9YP_%99W^ %1_#NM4I*RH=;*); ?QV2J!=!%_"5*'$, M8TM5J "^!BMZ^\8-G8^'Z)T(K$,V:,D&!MT_ED8Z"\ZFJIX2-&.%^L8(;,IT MHD5(0=6]1,L-VK>;XXU9GM28)^CAJX)$-Q(*<5"JX)12G0BL(]5%*]5%;UY, M5%DE)*]T ?543P,2&A#]*5Y'KN\[^C>RU_M<#AAZSM!U [\U[,09MG&&O7%^ M>JJ(W*#OI3G'OBSNQ?G7HSD16(?RH*4\^,]9/#BE5"<"ZT@U;*4:GB*+AZ^2 M\S+P+@]D\6O#81!V#9LX[;V[K@">FA9 ('-=-7=%N]IV&1-SN;Y8GZKNHVD6 M_L TK+?@-02P,$% @ >XAQ5C_6MJ*- @ M 8 !D !X;"]W;W)K M&ULK55=;],P%/TK5D!HD\KRT:9C(XVTM4SP@*@V M!@^(!S>Y;:PYW<<^X]Q_9-LE7Z 0L PW:EK'#B M%<;4E[Z/60$EQS-50T5?EDJ7W-!4KWRL-?#<@4KI1T$P]DLN*B]-W-I*'WN' K5H6Q"WZ:U'P%=V#NZ[FFF=^QY**$"H6J MF(;EQ+L*+Z>QC7($M""1DQC)P>FU@"E):(BKC M1\OI=2DM<'_\R'[CM).6!4>8*OE5Y*:8>&\\EL.2KZ6Y5=OWT.IQ!69*HGNR M;1-[?NZQ;(U&E2V8*BA%U;SYKO5A#Q".G@!$+2!Z+F#8 H9.:%.9DS7CAJ>) M5ENF;32QV8'SQJ%)C:CL+MX935\%X4PZUU!SD;-W.SH7",AXE;,9U J%078R M \.%Q%/VFMW?S=C)R]/$-Y36@OVL37'=I(B>2#&#[(P-PP&+@BCJ@4^?#P\/ MX3Z)[11'G>+(\0V?Y%N"UI"SJ4*# S;EM3!8DUSV#BT:U#T!OPTEB6O45?S1#O[6L;XL:GO&> MOFAT,8K[!<:=P/BHP,_*6G_TBF1S83HVK79A;*4--RPX)^*Z!M 'U?*F4>)[9S=3^J]#=02P,$ M% @ >XAQ5ES/,:-\! #A< !D !X;"]W;W)K&ULM9A=;]LV%(;_"J$-0PNLD4A]6,YL W:RH@&:(6C0[6+8!2W1ME!) M]$@Z;O?K1TJ*9(DT[33NC2W)AR_?5[D%C@KG=FD>O; 9A.Z$WE6 MD@<&^*XH,/NV(#G=3QWH/#_XE*TW0CUP9Y,M7I-'(CYO'YB\/ZN_KY*7R2PQ)SQ0>" 9,<%+9K&TD&1E?4W_MH4XJ !C(XT0$T#-&QPK >_:>!7 MB=;.JK1NL<"S":-[P%2T5%,756VJUC*;K%3#^"B8_#63[<3LKA2X7&?+G( Y MYT1P\.:6")SE_"UX!SX_WH(W/[^=N$)VI1JX22.[J&71$5F(P#TMQ8:#W\N4 MI'T!5WILC:)GHPMD5;PER17PX:\ >0@9#-V M?93O8 KT(O[]4<:#.T$*_H^I>K5X8!974_>:;W%"IHZ5IYL<(CN0X/!WF MH8>A,81QU(;U'(:MP]#J<)ZFF5HQN,E9W30ZZ!+ZR O& V=ZV-@;QZ'96-0: MBZS&Y,PX4;=(ZS:$ 4+>P)T>-BAOS]ZHM3=Z_,6?CUMGXE0,[UGH=C<::-SVJ7]R> M.>AU*[YGM?>'_'.08,:^*9.XH+M2&.=&(W/8?^!':#2T:8B38=&Q]P\>H E: MC3Y@04JUF-Z38DF8<2&U2[QT);V46C]AU"6,?B14&O5+U>)":OU:='R%5FR= MM_PT&L/IJ[VAI\+Z'COV03O\K&BQMS77#Q@'XO5"_?PZ2Z'PT0@3D??4,$347US'4.A':)G MC+!.2(0,U=/#;+#J4 KM+#T;5@:D&EP:D.H==8DZI"([4FM2@?EVFV=)-=*@ MVA#;V647?>EZ?2FU?@DZ6"/X(]F%+LKQ2ZGU:]%Q'%G9>-ZRU&CT9G1HV!49 MXE!T?%N$.L(B.V&M]$(Z,HT[(T.<96N$.K0B.UI/+TR-0._O:6S8'1GB!G7N M6^SHB.QT/&^4K1HO^!=P :%^GAUDD1VRIP"&#-O44-]IV7OYC@0Z B,[@<]X MEW2Z&E.P]O,=*72<1G9.GXO!1N;P#"5 \4C;LQGBC)/"/3A9+ A;5P>N'"3* M0'UVUSYM#W7GU5'FX/D"7M_41[.=3'U2?(^9G$<J@/0*?_0]02P,$% @ >XAQ5C=, M)'VS! HB$ !D !X;"]W;W)K&ULM9K_;YM& M&,;_E1.;IE9:"X>-8V>V)2?0+5(S14V[:JKVPP5>VZC N7?G.)GVQ^_X$C V MOH;MS2\QX'L_=SP//GAR3'=TB23,VNMU.; $) MW\TL:CT=^!"OUBH_8,^G&[:"6U"?-C="[]DU)8I3R&3,,R)@.;,6]#QPBX*B MQ1\Q[.3>-LE/Y8[SK_G.532SG'Q$D$"H<@33'_=P"4F2D_0XOE50J^XS+]S? M?J*_*TY>G\P=DW#)D\]QI-8S:VR1")9LFZ@/?/<;5"?DY;R0)[+X2W9EVY%K MD7 K%4^K8CV"-,[*3_90";%70,^:!8G$CR.Q."Y3:^)F_(IUN?O/KQ]=16NM.\U ZK#B[*#MP3'5"7 M7/-,K24)L@BB-L#6HZV'[#X-^<(U$GT(WY(!_9FXCNMV#.CR^>6TH]Q_=CD= M=90'SR_W#&(,:O\&!6]P@ODD3<>>LZ!DL>M!HYST,@WCJZOD$BPEI"C6LB16<@H MBG,164(V3$&F"-MLDC@LE.U4TUZZ3V(R$O@ICPGQ,6( $:]DPJ6V8O.2CQP33(4R8CPD+D& MAZC3/-T[ M_1X^R%;"OCMWF1%]?QJH-!^5%F#1VF:XC1GN2\Y@%1W+)TR:CTH+L&AMGYJ,2XT! M[;_,8F:@ZY2S6*/Y*-N(9<@R&(E -(\:1AG.LRH>HE*\U%I 1:M[5P3I*GWHC,=9A*^1*7Y MJ+0 B];VJH:1Z5YJ/2 M BQ:>^FK"?1NST#?Y8:9T=<-5)J/2@LJVN'_\4_,5FX3TUUS3/=C :$B? /Y M$JA^W VY/*$U:EA'I?D5;5\==T@/EHL"K#Y+J>V]M>@4Q*IX"4!J_;:9*M=X MZZ/UBP:+8GG]X/@%/0_*UP4:3/GVPC43JSB3)(&E1CIOS_0)BO*%@')'\4VQ MXGW'E>)IL;D&%H'(&^COEYRKIYV\@_JUC/F_4$L#!!0 ( 'N(<5:T\ @U MV@, (8- 9 >&PO=V]R:W-H965T3#! UB;.V@?+OSW9""&!2I%T> MB.W,?/[FB^T9#[>,OXH5@$1O69J+D;.2LKAW71&M(*/BCA60JS<+QC,J59%[@9C3)G7!HQF8\'+*U3),<9AR)=991OIM RK8C!SO[@>=D MN9)ZP V'!5W""\A_BQE7/;=&B9,,.1XFA&D$$D-0=5C U-(4XVD>/RH0)UZ3NW8;._1_S3!JV#F5,"4 MI5^36*Y&3M]!,2SH.I7/;/L75 %U-5[$4F'^T;:R]1P4K85D6>6L&&1)7C[I M6R5$PP$'%QQ(Y4!.'$CW@D.G*IHD MUY_Q17+U-E%^,GR1+'I%7PJMJ4!_/("D22H^HEOT^&.=R%WU"GU[@FP._+MZ M\1MRD5A1#F+H2D5! [E1-=VDG(Y'QEO(8??M;0:+/$C+QW29P.;]OGU_O^GM1T A&CMK6 M O@&G/#W#SCP/MG$^45@1U+YM51^&WKX92V%I'FJ:0NYQ D, MCCZ7-F'?#P:>^@W=33,&1U2[-=5N*]6OYC10GXIN@*O3#<$;\"@1 M@ J>1'!@KXZ4E.81V*(HI^@WR'EWN'L2P3M&1^R#FGW0+G2UNR/-+$U/MUW) M+CB3[G;0Z?H6D2V6O0![EU7NU3Q[UZD\KE1^W*L\TRK?M ?0LRGGGW"W&@5V MVOV:=O\J>?=KPLJN?RZ:[UG$M=CU6A;PH.8X^#EI6\D/+*IYP0ESJU'/._IA M>Q38.V0K[PJMT5*=I=+.M0)H*H@]^T*VF/;Z_<%EM7$CJ^*?T[LM FQ3LG-* MWF:%+PE,#L3)]85(SF3;N 3VY%LL3P[O(^Y'E(M;DU/5:Z=7YEKY^>Y M]F9?^*A&,^ZSK_<,NB+6Y_M452]-#-L;MZ=@$?3G%E6NA+;]5^.^M6YO5689S&Q5M!GQI M"GV5P=@ZEV5M6(_6EXFQ*:%/QB?ZDF$JY0-,>4-YHEPE;8%26"A([ZZG4B\O MB_ZR(UEAZN8YDZH*-\V5NB@!UP;J_8(QN>_H">JK5_@_4$L#!!0 ( 'N( M<59E^*B9[P( $<) 9 >&PO=V]R:W-H965T9-&U21[X@L XB 6VU/E1#H'7/)KD0BR3.; /EW\]V0@HL9'V8 MU!>PG7M.SCF1?3W<,[X1":*$ERS-Q-J9M2 MJZ=4X62XD"S:P(]"9RK@TQU*0E,![N>A+16]+K*CBFI24GE7J%P/GE@N$P'W M>8SQ.8&M=-7BO*.XB=?*>(=1!WSW!CS'\QH$3=\.=UOD^'56ON'SWY)54SXE MO-L,U_OQ5A0DPI&E-IQ OD,K_/C!#9QO3=[^$]F9TV[MM-O&'BX2PO&+WAXQ M3%FFC@Q!S*X;\/@&'@CE\$S2+<)8J#.B3.T& MYE1LX($CPF,N44F7,"<2F^(L-7XU&O5IM N=CN/WAO;N-*?&*J_W6G:60*]. MH/=>"=R_%.H,4_5W=$=CS..K 9027>?4VX7[UI(SYT'M/'AWY\\L59PIE8>K MWH._/JO;Z?I=_\)_O @)@?1=.+8)STI0[XVK5I MQ+:Y+#M O5K?!L:F"5ZL3]0MH6SJKS3E%>.)\#5572O%E:)T.GVU&7C9MLN) M9(7I?$LF51\UPT3==)#K O5\Q9@\3O0+ZKM3^ =02P,$% @ >XAQ5J55 MB, E P /0X !D !X;"]W;W)K&ULQ5=M;YLP M$/XK%INF3>H"=EX:.H+4M)M6:=VB5EL_5/O@P"6Q"IC93M)*^_&S@0!5"&J[ M1,V'8!O?<\_A.S\Z;\W%G5P *'0?1XD<60NETA/;EL$"8BH[/(5$OYEQ$5.E MIV)NRU0 #3.C.+*)XPSLF++$\KUL;2)\CR]5Q!*8""27<4S%PQ@BOAY9V-HL M7+'Y0ID%V_=2.H=K4#_3B= SNT0)60R)9#Q! F8CZQ2?C+%K#+(=OQBL96V, M3"A3SN_,Y"(<68YA!!$$RD!0_5C!&4210=(\_A2@5NG3&-;'&_0O6? ZF"F5 M<,:C&Q:JQ<@:6BB$&5U&ZHJOOT(14-_@!3R2V3]:YWN/^Q8*EE+QN##6#&*6 MY$]Z7WR(FD&7[# @A0')>.>.,I;G5%'?$WR-A-FMT#92L.;37900(US*+(#ZAR"#NKB(T0< M0M!;9".YH )D\7@,:&N>)5E2DB69A^XNL@;HXU@?0H@F]$$GAT*G0M!D#F9\ M5,1QA#[?@PB8!#01+ !T97:@VV\:#ETHB.7OINARW[UFWZ8Z3F1* QA9.OTE MB!58_KLW>.!\:HFL6T;6;4/WOR_C*0C$9TA7CE0T"5DR;R*9PPPR&%-Q*]_M M$=?1/\]>-1#HE01Z3R50Y +DWY!.(V@BTGLFD7Y)I-]*I)Z0"*/;2S#$&@^L M%>B%!S8H:0Y>,14'!XCLN(SLN/4 ;LQ%IJ.B*Q#Z7M[D : T"^!OK;*;J.?@ MPUI>.!W,\* M@KIT3"9OW!E"O=;63#A>[O0)@-^OV,<[69F):C[!C]?U!+ P04 " ![ MB'%6N1DH-<<$ !>( &0 'AL+W=OUE;:[U50S^S#:!T,,1,V%L4VATG[X MM9,T%QI=G^W_PL8_SZ?ICL9A0F[YTCL MXICRYVL6I?N9A:V7!Y_#]4;J!_9\NJ5K]L#DE^T]5W=V20G"F"4B3!/$V6IF M7>%+WW6T0V;Q-61[4;M&>BB+-'W4-[?!S')TCUC$EE(CJ/IZ8C-[ M ;7*-K5C_?J%_ELV>#68!17L)HW^#@.YF5EC"P5L17>1_)SN?V?%@(::MTPC MD?U%^]QV-+'09!_U3L-I2S3]=JF@3H)HU5[A TFWU7*GC) MFJGY+-'B&=7M[NES]OAJ3WF OOVAD.A6LEC\TS*>Z[S]07O[.H==BBU=LIFE MDI1@_(E9\U]^PI[S:UMH(&$$$N8#P1I!')1!')CH\Y>IQPZ,+T-!%Q%KBX01 MTC42D#"2P[P,II>EI_EDX$X<]9G:3W65@5IMJ#PL51X:5*OLQH:[R@X)(UZ+["-G,NX?B>Z]FAEX@/O. M<-BN^:C4?&34W/^^"^5SL6:C;WFKZ-G*X20L((),P'@C6",2Z#,7[G M-7@,&41(&(&$^4"P1A G91 G9ZW!:Q4R>;Q/S:-@!'2- B2,3,Y=?X%:;2B, MG:K.<"#V.06E,9S6)>VFQ1([^:=I2>>^.08M84!H!I?E0M&8H MJY(8FVMB@%0V:DL7WO&>"+0*!J7Y4+1F"*I"&!M+-$/.HX>W+)>^<\T%(9E$9 :3X4K7D25E74KKFB_O&<5S1PM/G!1SG/W(VN M(0"E^5"T/ 1V[1PU9GR='6 +)>XND?D99?FT/"2_RHZ&CYX3?.GG1]T5)C]Y MOZ-\'28"16RED,[%2&V!>'Z8G=_(=)N=UBY2*=,XN]PP&C"N#=3[59K*EQO= M0/DO!?/_ %!+ P04 " ![B'%6;>EY3RP$ #(%@ &0 'AL+W=OR$V-^;)@]VD! ^HGM(Y94-90D1\I1M3;YG0,(L*(E-V[(\,R%1:BSG M6=LS6\[I0<11"L\,\4.2$/;V"#$]+0QLG!L^1MN=4 WF9G,FG!8T?AS%(K=PI@:*(0-.<3B M(SW]#D5"8Z47T)AGW^B4]YW,#!0"Q"5 .QV!-A%@-T, M\#H"G"+ &3J"6P2X&9D\E8R#3P19SAD](:9Z2S5UD,',HF7Z4:KN^XM@\FHD MX\3R,V&,I(*CGWP0)(KYS^@.O4,FXCO"@,]-(0=17.K=>2>[TD "T,N%!S8$8SECS]@S_JEC:U. M,5^36(V[6W)W^]3/A8ZVZKM9ESFX7,#+!-1Z>5R.[;$E/W/S6&72.]"M3#2) MU9B,2R;C04R^/$&R!M9:3;T*MU:33C%?DUB-G%>2\_[GI]C3R5VGF*])K,9] M4G*?#*I8Z6"X(&D8I=OW: W;*$WE81O'7KU;.4ZN5@AL6U.,7:>^1/@M'2W' M]J;C2=FQEO^TS'\Z*/]3YF=D49$C,.G/$+P""R(.:,^B +[!I'>,6YGD8M-* MJM8(3QH\6CO-VEG,2A:S_[JB]PKOM]GRQ=?%J MEIZ[WX.D?XA;F11J]1MKN0T@[;VF'3@JUA4/P<'+]-L3[A6Y.6&=:GZA5BV5 M.\?&KCWU.N#8%SBVGEKIA]<[R,WP=*KYA5JCJB96[8,[.%[L.NYUI=4BVT>L M@Y)6RUVHU8K":WW+Z!JWCN;BJ/$P2SV@Q+K1Z333JT*M41*S)K;OX;GQQ73C M0:Z;HX"D <1Q!QBMQKM0:]14V\M+U[AU.!=?C7OMX_":ZH>GU3T7:O6JLKTF MN._AB_'%&.-_X8PA^VTEI-47XQ:_V^Z-VGHV+72=P,4:8TW>N(>*5F>,VUSO MM3GZAH'.:9B5+;X$V#;;*I5+"#VD(M]**UO+[=B';!.RT;Y2V[39UN%%)M_C M?2),_F?@*(:-E+1&$[D2L'S;-#\1=)]M)*ZI$#3)#G= 0F"J@[R^H52<3]0 MY>;U\A]02P,$% @ >XAQ5LEBR-6H! ;2( !D !X;"]W;W)K&ULQ9IK;]LV%(;_"J$-PP9TD7CQ+;,-Y-)B!18L:+#U M0[$/C$3;0B71(^DX ?;C1U&*J"(V+=NEG0^Q+CSO.8?BJP>P.5YS\54N&%/@ M.<\*.0D62BTOPU#&"Y93><&7K-!W9ESD5.E3,0_E4C":F* \"U$4]<.&(W+,M*)5W'O[5HT.0L ]O'K^H?3/.ZF4)6DR"80 2 M-J.K3'WBZ]]9W5"OU(MY)LU_L*[&#D8!B%=2\;P.UA7D:5%]TN=Z(EH!&&T) M0'4 ,G57B4R5MU31Z5CP-1#E:*U6'IA63;0N+BW*I_*@A+Z;ZC@U_4R%H(62 MX.=;IFB:20!_&8=**Y?WP[A6N:Y4T!85B, =+]1"@O=%PI)O!4)=4E,7>JWK M&CD5;UE\ 3!\!U"$$/@1A$ NJ&"R_G!DP$WGV&3 6S(\E$*_7NLGFH ;GNME M+JE9*%?EC,R97GH*/+Z ]KA[^F(N7ZVI2,"7/[0D^*A8+O_9-&=5?K(Y?VFW M2[FD,9L$VD^2B2<63'_Z ?:CWQS=D:8[XE*?WF142L!GH'[ @ M@+/<._+E2 M4M$B28OYIJHKW;[1+3W]-(481^7?.'S:4%&OJ:CGK.BU$ B^W+'\D8F-<^;4 M.'#.^DV%_3.OB+Z'[@9-=P-/*V+P=D5$C@4Q; H:=EH0:_/FU'-)GYC0) #L MF8DXE0PL11HS\%_+_IO*J[(,6^5%%U%OL+ME "S^R?NH#OW""R#2)/%JJ% MVQY"#@M!"S'HI,AW,U&=IIN+H*40=&-HAX]V1'2D$42.C>2D \D(8LDY M):$\D(8LD=!HDH7V0A"R2T%%(VA'= MV4G8(@EW0U+?Z22WR($+#5LDX7,C"?M $K9(PKZ0A-\BJ>]TDF42.0V3ZC00?FLE--Q2H*42.8I*.Z)O66S6.^@;-PTW M/<>PM0,@9V)N]CE($/-5H:K- ,W59B_%5;6#P ZO-F)HZ\[30H*,S71H=#'0 MCA+5WH;J1/&EV4_PR)7BN3E<,)HP40[0]V>3,D&SPV3Z/U!+ P04 M" ![B'%6HX-1T^P" ]"0 &0 'AL+W=O^(+ .(@%=M3Y40E1KGTUR(5:=.+,-E'\_VX$4 M6$C[,*DOB3_N.3GG1K[7PRT7SS)#5/"2LT*.G$RI\MIU99)A3F2'EUCHG247 M.5%Z*E:N+ 62U()RY@:>%[DYH843#^W:3,1#OE:,%C@3(-=Y3L1N@HQO1X[O M'!;F=)4IL^#&PY*L\ '5[W(F],RM65*:8R$I+T#@OIP,3;@$>*6WDT M!N-DP?FSF=RE(\T!HC5;*K*T;HD@\%'P+PD1K-C.PN;%H[886 MYB\^**%WJ<:I^(D(00HEXR[R9YE4K$$%UC\ .YYH3() M/XL4TU,"5TNJ=04'79.@E?$&DPZ$_A4$7A T")J^'^ZWR GK-(66+WPC34VI MJ9#=9J0YA=>R) F.''W,)(H-.O'G3W[D_6BR]9_(3DQV:Y/=-O;X(2,"OYE# MD<*4Y[I02&+/VMB87Z$^O H6.SB.FY&=71YOB4BOX)90 8^$K1'&4E>&TN#E M%V!NZF^,\-48%O=>PDPST MZ@ST/BH#/U]*7;ET_ W=T!2+]&("*HF^=^SMS'UKR(GSJ'8>?;CS1\XT)Z-J M=]%[],]O]3O=L!N>^6\.ZT7-.>C7.>BWYJ 6JIOC$JE:"P1Q06C_[9_4&G(B M<% +'+Q/(*/+1E7M\ AV2$13#9NV WL5$'S(396' %*RDTT5QSWJ1#F*E6W0 M$A*^+E15_.O5^@XPMJWO;'VB[P95*W^EJ2X6]T2L:"&!X5)3>IV^/@RB:M;5 M1/'2]KL%5[I[VF&F[S7W*N#A/S@?K&%/\%4$L#!!0 ( 'N(<5;D MQW,JL00 *$D 9 >&PO=V]R:W-H965TQ#O-_'(D_*'+ Z9ZR9[XA1*#7(B_YS-@(L;TS39YL2('Y@&Y)*>^L M*"NPD*=L;?(M(SBM1$5N.I;EF07.2F,^K:X]L?F4[D2>E>2)(;XK"LR^?2 Y MW<\,VWB[\#E;;X2Z8,ZG6[PF"R+^WCXQ>6:VE#0K2,DS6B)&5C/CWKZ+[9$2 M5!'_9&3/CXZ1>I0EI<_JY&,Z,RR5$I8)Q(QA?*I@T@DG5NW5W5'WI8X'G4T;WB*EH25,'E2$JM>S" MK%3>70@F[V92)^9?,&.X%!S]ZA.!LYRC3^J*,M1OZ'?T,S(1WV!&^-04LCDE M,I,&_5"CG3-HVT&/M!0;CH(R)6D78,H\VV2=MV0_.%KBG[M\@.S1#7(L^[8O M(;W<)\D #6TE=YP>N:^7/^)OR';.J@.]^G[+!LARS\K#]QIGVMRCRQ_=[I'' ME\LM34<.6]<-*YZK=QWZ^DB*)6'_]F3T04M00_H=W^*$S PY9G/"7H@Q_^4G MV[/^Z#,&),R'A 60L! 2%D'"8B!8QVUNZS:WH@_/N&VQ6_(LS>2G^08M<$X0 M7:&%H,DS^OJ7#$4?!2EXKP==2 ]"PGQ(6 )"R%A$20L!H)U/#AJ/3BZ:,0C MKX0E&2=HR[*$]'E.R[G6^U?>]I^WZA)E#5##M%"2WDLH/C:N+>F $OY9BT):R>:?5Y M0LN_UA->GR>&)YZ ;#& A(60L @2%@/!.AX;MQX;_^\9E99PK8L@83XD+("$ MA9"P"!(6 \$Z;INT;IO\H!G5!-*#D# ?$A9 PD)(6 0)BX%@'0_>MAZ\O63$ MXRCC?'=:7JC-I@5<:[8:YAU]-CVK^COYUX+>+TK46"GD"[+S#L"72'/8$1Z(/$4+3:!N;1?HB"L'6U-T8N MZ^BN%/76B/9JN__FOMIU8A["Z\T[CYBMLY*CG*RDU!J,9:*LW@]3GPBZK797 M+*D0M*@.-P2GA*D >7]%J7@[40VTNY+FWP%02P,$% @ >XAQ5K*XE' W M" AD\ !D !X;"]W;W)K&ULM9Q=;]LV%(;_ M"N$-6PNDL45*LI,E!IJPQ0*L:=#TXZ+8A6HSL5!9="793O?K1WW$-"6&%>-# M7R26S/.2?"61YY%IG6UY]CU?,%:@AV62YN>#15&L3H?#?+9@RR@_YBN6BD_N M>+:,"K&9W0_S5<:B>16T3(9X- J'RRA.!].S:M]--CWCZR*)4W:3H7R]7$;9 MSPN6\.WYP!L\[O@0WR^*K:*[MDM*SZM;C*Q-=RIS.,E2_.8IRAC=^># MU]XI#8,RH"KQ.6;;?.\]*KORC?/OY<;5_'PP*EO$$C8K2HE(_-NP2Y8DI9)H MQX]&=+"KLPSMD^(#W_[-F@Y5 M#9SQ)*_^HFU=-A USM9YP9=-L-A>QFG]/WIHC-@+\,(G G 3@-L!_A,!I D@ M?0/\)L"OG*F[4OE HR*:GF5\B[*RM% KWU1F5M&B^W%:'O?;(A.?QB*NF-X6 M?/9]P9,YR_(_T9L?Z[CXB5Y05D1QDJ/K*,NB\L"\1*_0IUN*7OS^\FQ8B'K+ MZ.&LJ>.BK@,_48>'T3N>%HL1$$71NECP+/ZO?=[5UM428251#I&;:3!J7F?#S;XOW9*^ MOB0U-NN9G0YVG0Z,G;[DRZ483:NK^@C=1!GBF=B*"G%Z?8Z2-4,W3.PHK='9 M48N/]^TX)NS5*&R9T;,<-3;VF5:$.RM"HQ4TWL1SELYS,0W,$M%A[0E0:P1[ M/6D?^%^6H,9V/+.7XUTOQ\9>7J^7W\01Y7_NCUNQ39 \MF<:X?>\PBU@9Z3PQEK2L1JE;5&BRMP49K M/O(B2M JXS/&YKG6%J. M2VX,U5A7^,*4*6J*S+9]8Q9W[1AC/>KBOM,HYE9 MR-H=T,P62DTU4>:VGN]V0 -*4AMK(=4HE)IJK&9ZJ) ?W63Q M3 M*3?1DGW*/1[CM""@20*FI=Q E$V!C8ES?^417U7F"Z#J+T_ORYDC,YT?U MK9(C=,VV=0%M\M;H[Z=;WNBD>QZ9VV'K&I2:ZII,][$YW9>3P'LQ5IDF K.0 M[6@%JD:AU%03)1A@['0BP*#8 *I&H=14:R5=8#-=6$P$C9)RH\;3W1 S5VEM MD MRP)(<<(_;XD]/!$VTY[5F@J#M"6C*#Z6F>B)3?FQ.^0^?"H+.5# N4_BV M:9#80*'45-,D#N"^./!QR\TS 2@2@*I1*#751(D$V"T28% D %6C4&JJM1() M,!@2X"X2U #>N8!!D0!*335((@$^" FP%@E(VQ%0)(!24[^&ETA '",!Z2(! MQD'W/#*WP_I;=A=(0"02D+Y(\'&1,3,4F*6LURJ 0@&4FFJCA +B%@H(*!2 MJE$H-=7:O?4U8%! NE" /1**5_L2AETHXP(*B(0"&-F K.2[7 %JD:A MU%07)1/X;IG !V4"4#4*I:9:*YG !V,"LY*UBYJO'0(\"<:XO8[KYO>7S M!S&!.=K:%"UAC$?*RVL;Y (1?(D(OF-$,.M;6]@%#NR/-3]/<($(OD0$OR\B MW,8/YGD!E!! U2B4FFJB) 3?+2'XH(0 JD:AU%1K)2'X8(1@5K)VL>_O"Z"J M50V2A. ?1 CF:&M3=+S1F0=< $(@ 2%P# AF?5O+ LVR)%^S#!RJ5M4U"0A! M7T"X91MF7@ANEK(V")00H-14&R4A!&X)(0 E!% U"J6F6BL)(0 C!+.2M8L: M0L">CR>=GU>Z((1 $D)P$"&8HZU-T1&"UV8FJ#I51_9^?>L8"]):C&5^G1?W4K]W>W/ M4&OMO_!.+^M'PDF9^@EU[Z+L/DYSE+ [(3DZ'HL.9/5#W^J-@J^JQZ!]XT7! ME]7;!8OF+"L+B,_O."\>-\H*=H_>F_X/4$L#!!0 ( 'N(<5:;D?'M)P< M !0[ 9 >&PO=V]R:W-H965TF&\:_IDE*!GN,H22\Z2R%6Y[U>ZB]I3-(SMJ*)_&7!>$R$ M_,H?>^F*4Q)D07'4PY8U[,4D3#JS:;;MCL^F;"VB,*%W'*7K.";\Y8I&;'/1 ML3NO&SZ&CTNA-O1FTQ5YI/=4?%[=Q"'2?Z7/!>)V JPAP<"_FQ9XESB2"S*6<;Q%5K25,?LNQGT3)?8:).E'O!Y:^AC!.SCS0B M@@;HCG#Q@CYQDJ0DDS!%) G0%8E(XM,4O7&I(&&4HO>$H<_W+GKS MZ]MI3\A=4<">7W3KYMWB ]W:&-VR1"Q3Y"4!#71 3QY#>2#X]4"NL)'H4O\, M6:,NPA;&-3LT-X??$GZ&[,'!<+=![XY],-QK'FX;DN&4JCH9SVFK*OKREVR* M;@2-TW]K]O,JY_;KN:IJG:5/M#/[[1=[:/U>EW)(F L)\X!@ MFCC]4IR^B7Y8G"ZZC-DZ$2EBB^WM=3H9NVBK$R3,S6&##*9N4T^SH27_37M/ MVP( =:D),"@%&!@%N&5!N A]DET08>)S*N]\@D1H04*.GDBTIHBM#F7>R&Z; M>4B8F\.&6YFWK9$U&3L[N0?J5,O]L,S]T)C[^R7A])VZM0=HSF(YWDES'2[E M;25YS)1 #R]HN]T=>?R4P\(IDDW*J4;-9:NE*12K8N\9R4G[2*R M$)2C3^2Y3@1C)VU%@(2YHSU%A\X8X]'.Y3/:*W CC,?JMO]4D]UQF=VQ,;NN M+#J"H>V;0TCEZ3Q?^4; MY\H=5]X+Y7YZ;^6CWD4VEU0TY]P7BSX@5JCT%I M+BC-@Z+I0E4^VAZ>JGB!VF!0F@M*\Z!HND257[:;&^;3/.NX9GQ!0[&6>Y]5 M0#EB"WG61UJK_+[#=;!3\]!B;CZRUJI"TCPHFJYJY=-MLU'_OJ>'!7R[;H\M MVQKLYA_4CH/2/"B:GO_*Y]MFHY]?#BEZ//R[YS)1;NQWFRX\S#:O$>M\P=$T_-7 MF6ML-M?%C9&6-ST4R"%1;1+-H&SZ%5G#+E(3L./:4]9,R*>/^QG L6K/7%#G M#$73,U\Y9VRT?;,YND8?C#[ #&@[R 2EN: T#XJF2U$Y9-P_D0_ H"X8E.:" MTCPHFBY1Y:FQV5/_[WP KIDI=G#--/WZA\QS4[X+2/"B:GN?*[V*S MWSWN \SQ)A]@CC3Y %!'"T73,UPY6GQDZKJ1#Y@T] &31CX U*E"T?2UCI53 M=:GM>F>)K,\9FKKU(-.48/2/"B:KL_6.NZ3+>2& M7=_2<$]8,^4$_H)FAXAQ5O@HI"A3 P 6@\ M !D !X;"]W;W)K&ULM9==;],P%(;_BA40&A(L M'_W<:"-M31!##$T;@XN)"R\Y;2,2.]ANN_U[CITLM%L65LGT M9[+AXI=< BAR5^1,3IVE4N6QZ\ID"065A[P$AD_F7!1485-[0+6C&G'!BQBY$..$KE6<,+@21JZ*@XOX4YI1)F//^1I6HY=<8. M26%.5[FZY)M/4)]GH'D)SZ7Y))MJ[@ G)RNI>%&+<0=%QJIO>E?[L"7P^\\( M@EH0O%30JP6]QX+A,X)^+>B_=(5!+3!'=ZNS&^,BJF@X$7Q#A)Z---TP[ALU M^I4Q?4^NE,"G&>I4..-%D2D,O)*$LI3,.%,96P!+[LE!!(IFN21?J1!4!_0M M>4^NKR)R\/KMQ%6XO(:X2;U45"T5/+.4'Y!SI"\EB5D*Z2[ Q7TWFP\>-G\: M=!)/2G%(O. ="3S_J&5#LV[Y9\H:^:CM/-WR"))#TO.U/ A:Y/'+Y7Z'&;TF MDCW#ZSW+F^-(2DZ!84N1BYPR$F4RR;E<"2 W7_ Q.5-0R)\MNSVMZ/UVNDY7 MQ[*D"4P=S$<2Q!J<\,TK?^A]:#/>)BRR"8LMP79"U&]"U.^BAY=(I")9FC@3N,.]+: M+)W'?L-B$115L8&#ZYV@=]OOC\:@W<=?;AK=,ZPW& MHZ"9MF/EH+%RT&DEYBF)OP44S;LYA^(61.NE[H3LZYY-6&03%EN"[41BV$1B M^%_SSM!FB&S"(INPV!)L)T2C)D0CZWFGD[AO6$9/]S8/>ZT^YN@:+$Q&TT&@7^BV+_L'C]QR!\\=FC6N>R^M]LF++8$V['[J+'[ MZ"5VU^9*@HX7;19W4WQRC^](V^7MU.WKNDU8; E6N>YN%1$%B(6IWB1)^(JI MZB]Y,]H4B">F+GHT'F'A6-5Y?S%5U7E.Q2)CDN0P1Z1W.,+[+JI*KNHH7II2 MY98K+'Q,XAQ5A%QC/H\ M P 8PD !D !X;"]W;W)K&ULK5;?;]LV$/Y7 M"*T84F")).J'K:.EL:95(C:3LY+_O49)5QV'4 IL? M+)*Z^_A]I^,=%PNJ[(":J:N1 ,;%;LY([Z:);NY/I0K2Z*CG<2:+:NF;R\18J<5@ZOG-<^%CN M"FT6W'31L!W<@_[1/ 5RD-W*D1XZW=!)Q#=D5"?S?"/4HM1!:_;R[/T$G M&$,6='C!#T-&UJ7**J%:">3+S49IB5GYMRUD/6)H1S0G]5HU+(.E@T=1@=R# MD_[ZBQ][O]OD_D]@3\2'H_AP"CW] PL+*E8$"PC1!9!'8-*FN(>).AA32O;I MI9]XL\!+%N[^5(W%D 8T"7QO-'S"-!J91I-,WSPT6"H@)V7_O31^+PF9V(-\ MM!'NT>)3'J'G14%TQM=F-T_\*++3C4>Z\71@!;_$X])B6=M40 #9LTF>-_D_6)6PCFNB!6EDB7E@K=_B#:)O M^-]A^NO'!R9W)5>D@BU">E&PO=V]R M:W-H965T9V04FI16'9FS%XY#5 MDI(25AR)NB@P_WT+E#61Y5J'@0>RS:4>L..PPEM8@WRL5ESU[%XE)064@K 2 M<<@B:^[>+*8:;P!/!!HQ:".=9,/8L^[IS"/K@X52R'!-Y0-K[J#+8PPFC KS1$V+ M#10XJ85D14=6#@I2MF^\[_9A0'"#%PA>1_#.)?@=P3=!6V<-8AK MM%+3#;,WAJW2D%+_BVO)U2Q1/!G?EPDK 'W#>Q#H8@D2$RJ0>XFNT>-ZB2[> M7H:V5.MHM)UTFK>MIO>"YA*2"?+=*^0YGC="7YQ/=X_IMDK71_3ZB)[1\_\: M$2V)2"@3-0?T8[X1DJM3]',L8*L8C"OJFW4C*IQ 9*FK(X#OP(K?O7%GSL>Q MN/])["B\WX?W3ZFKSK-/F-;87/DY534'EPF,66^59P-+U^/>QX"GS$][\]/7 MF_^JZC#+SLUP&PO=V]R:W-H965TFZ/4Q[<. 2K!K,;!/2?S_;$)9T--O# M\A!L<\_Q.1=\"&LN'F6&J&"7LT).G4RI\M)U99QA3N0%+['0=U(N@S#5FLT,;&\L6KNAA7F*]TKHNU3C M5'1=Q#Q'^$)V*.%LB8I0)N&6"$%,?\_A+3S<+^'L]7GH*KV?0;EQRSUON/T7 MN(<^W/!"91*NB@238P)7"^W4^GNU<_\DXQ+C"PB& _ ]W^\1M/AW^/"$G*!K M7F#Y@K\V#Y94QHS+2B!\GZVE$OK]_-'7LH9QU,]HSNRE+$F,4TN)$$\Z5VLB$MGG M8?R'M,FHST)/7=#GP#TX]CF*C4U#";'I87.FNM4N<&9_IB@, 7Z?LJYVD_,!MWG M*?H%4$L#!!0 ( 'N(<5;L4[\\- , ,<* 9 >&PO=V]R:W-H965T MBKDK%P))9)VRU/4]K^MFA#(GZ-FUB0AZ/%H;A<3H6=NA1+1#)FDG(' MN.]<-,^'9\;>&MQ17,F-,1@E,\X?S&0<]1W/$,(40V40B/Y9XA#3U !I&H\E MIE.%-(Z;XS7Z-ZM=:YD1B4.>_J*12OK.J0,1QB1/U0U??<=23\?@A3R5]@VK MTM9S(,REXEGIK!EDE!6_Y*G,PX9#L_N*@U\Z^"\=VJ\XM$J'EA5:,+.R1D21 MH"?X"H2QUFAF8'-CO;4:RDP5ITKH7:K]5##-9Q(?%@A(K05,(U M$8*8)!_"$=Q.1W#P^;#G*AW4N+IA&6!0!/!?"=#TX8HSE4BX9!%&VP"N9EM1 M]M>4!WXMX@C#8V@U&^![OK^#T/#M[LT:.JTJ@RV+UWH5+T8A,((AS_3=DL0> MSPN=.S;'S"1V154"8Q;1)8URDC;@\BE,\XBR.4P3(O!HH,]A!!/RG-D*$*8G M7"J!BHH"8H ,8ZKW[G_H\#!6F,G?NXI1<&WOYFH^">=R04+L._K.2Q1+=((O MGYI=[^NN1.X);"NM[2JM[3KTX#K/9BB QR!-CB10*?.7YZ?07 !U+9#Y:BT# M_0TS3\]=;LKYUZYCGFYEMD6T4Q'MU!(=)A1C75(,]6XKO_T>'O[C.M>P+;2NM)E=:3?1W^DS<>_MJ 'Y1S6LDY MK95C"PT3H>_%+@F%\^F&!._8\U_PKXWP0?YG%?^S>OZ*AP\PMC6 42[,X9V@ MH#QJP!U)XAQ5JJTC%(V P M5!, T !X;"]S='EL97,N>&ULW5A=;]HP%/TKD;M.K30U0-:4K("T(56: MM$V5VH>]588X8,FQ,\=TL%\_WS@)'_5%K \;+*C$OL?GW&/[IG$[*,U*L(A66A&4U+(.4B['4Z<9A3 M+LEH(!?Y76[*8*H6T@Q)W(8"=_N<#DDW?D\")S=6*1N2IXNW/Q;*W+X)W/WL MW=E9Y^GR=C=^40&7)/2*7A\@>M5Q%RK>#,"2Q(/2=]L2S?#SZU6RSW' MR'T/>6A8=0-*SME0CS $_L]V])>9AO[VH%= ME6W3&JJ;3L9U0']3S6EORO9>I1L4_%F93PL['5GUH5K8O6897U;]9=8:P-2[ MN#HM"K'Z*/A,YLQ-_N"$HP%M>,%<:?[+9H-2F=H TR1X9MKPZ6;DIZ;%(UN: MIIR6&>ZY=X*>_^XZSYADFHI-T[;VCWF57^VX?L7]"\_5KY5=QUZ3TZQ? MZ\=N,CX%DR>QW?U3,)D6W!(UNVO+.6+/&E'W<-"U*/6[2\P MO6[<'@1M+BY3MF3IN.[JV:1J!K9AL]87$':1N^KR(QC'87X$,"P/Y@#C.!:6 MYW^:3Q^=C\,P;WTOTDBOT3A&5B>&CW]_L*1^%S7LJ7/\?;?0;4$L#!!0 ( 'N( M<5:7BKL

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end XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 124 192 1 false 44 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://protokinetix.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS Sheet http://protokinetix.com/role/BalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://protokinetix.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS Sheet http://protokinetix.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://protokinetix.com/role/StatementOfStockholdersEquity STATEMENT OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00000006 - Statement - STATEMENTS OF CASH FLOWS Sheet http://protokinetix.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation ??? Going Concern Uncertainties Sheet http://protokinetix.com/role/BasisOfPresentationGoingConcernUncertainties Basis of Presentation ??? Going Concern Uncertainties Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Prepaid Expenses and Deposits Sheet http://protokinetix.com/role/PrepaidExpensesAndDeposits Prepaid Expenses and Deposits Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets Sheet http://protokinetix.com/role/IntangibleAssets Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - Stock Options Sheet http://protokinetix.com/role/StockOptions Stock Options Notes 11 false false R12.htm 00000012 - Disclosure - Warrants Sheet http://protokinetix.com/role/Warrants Warrants Notes 12 false false R13.htm 00000013 - Disclosure - Stockholders' Equity Sheet http://protokinetix.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 00000014 - Disclosure - Related Party Transactions and Balances Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalances Related Party Transactions and Balances Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingency Sheet http://protokinetix.com/role/CommitmentsAndContingency Commitments and Contingency Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://protokinetix.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://protokinetix.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://protokinetix.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Prepaid Expenses and Deposits (Tables) Sheet http://protokinetix.com/role/PrepaidExpensesAndDepositsTables Prepaid Expenses and Deposits (Tables) Tables http://protokinetix.com/role/PrepaidExpensesAndDeposits 19 false false R20.htm 00000020 - Disclosure - Intangible Assets (Tables) Sheet http://protokinetix.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://protokinetix.com/role/IntangibleAssets 20 false false R21.htm 00000021 - Disclosure - Stock Options (Tables) Sheet http://protokinetix.com/role/StockOptionsTables Stock Options (Tables) Tables http://protokinetix.com/role/StockOptions 21 false false R22.htm 00000022 - Disclosure - Warrants (Tables) Sheet http://protokinetix.com/role/WarrantsTables Warrants (Tables) Tables http://protokinetix.com/role/Warrants 22 false false R23.htm 00000023 - Disclosure - Income Taxes (Tables) Sheet http://protokinetix.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://protokinetix.com/role/IncomeTaxes 23 false false R24.htm 00000024 - Disclosure - Basis of Presentation ??? Going Concern Uncertainties (Details Narrative) Sheet http://protokinetix.com/role/BasisOfPresentationGoingConcernUncertaintiesDetailsNarrative Basis of Presentation ??? Going Concern Uncertainties (Details Narrative) Details http://protokinetix.com/role/BasisOfPresentationGoingConcernUncertainties 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies 25 false false R26.htm 00000026 - Disclosure - Prepaid Expenses and Deposits (Details) Sheet http://protokinetix.com/role/PrepaidExpensesAndDepositsDetails Prepaid Expenses and Deposits (Details) Details http://protokinetix.com/role/PrepaidExpensesAndDepositsTables 26 false false R27.htm 00000027 - Disclosure - Intangible Assets (Details) Sheet http://protokinetix.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://protokinetix.com/role/IntangibleAssetsTables 27 false false R28.htm 00000028 - Disclosure - Intangible Assets (Details Narrative) Sheet http://protokinetix.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://protokinetix.com/role/IntangibleAssetsTables 28 false false R29.htm 00000029 - Disclosure - Stock Options (Details) Sheet http://protokinetix.com/role/StockOptionsDetails Stock Options (Details) Details http://protokinetix.com/role/StockOptionsTables 29 false false R30.htm 00000030 - Disclosure - Stock Options (Details 1) Sheet http://protokinetix.com/role/StockOptionsDetails1 Stock Options (Details 1) Details http://protokinetix.com/role/StockOptionsTables 30 false false R31.htm 00000031 - Disclosure - Stock Options (Details 2) Sheet http://protokinetix.com/role/StockOptionsDetails2 Stock Options (Details 2) Details http://protokinetix.com/role/StockOptionsTables 31 false false R32.htm 00000032 - Disclosure - Stock Options (Details Narrative) Sheet http://protokinetix.com/role/StockOptionsDetailsNarrative Stock Options (Details Narrative) Details http://protokinetix.com/role/StockOptionsTables 32 false false R33.htm 00000033 - Disclosure - Warrants (Details) Sheet http://protokinetix.com/role/WarrantsDetails Warrants (Details) Details http://protokinetix.com/role/WarrantsTables 33 false false R34.htm 00000034 - Disclosure - Warrants (Details 1) Sheet http://protokinetix.com/role/WarrantsDetails1 Warrants (Details 1) Details http://protokinetix.com/role/WarrantsTables 34 false false R35.htm 00000035 - Disclosure - Warrants (Details 2) Sheet http://protokinetix.com/role/WarrantsDetails2 Warrants (Details 2) Details http://protokinetix.com/role/WarrantsTables 35 false false R36.htm 00000036 - Disclosure - Warrants (Details Narrative) Sheet http://protokinetix.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://protokinetix.com/role/WarrantsTables 36 false false R37.htm 00000037 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://protokinetix.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://protokinetix.com/role/StockholdersEquity 37 false false R38.htm 00000038 - Disclosure - Related Party Transactions and Balances (Details Narrative) Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative Related Party Transactions and Balances (Details Narrative) Details http://protokinetix.com/role/RelatedPartyTransactionsAndBalances 38 false false R39.htm 00000039 - Disclosure - Commitments and Contingency (Details Narrative) Sheet http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative Commitments and Contingency (Details Narrative) Details http://protokinetix.com/role/CommitmentsAndContingency 39 false false R40.htm 00000040 - Disclosure - Income Taxes (Details) Sheet http://protokinetix.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://protokinetix.com/role/IncomeTaxesTables 40 false false R41.htm 00000041 - Disclosure - Income Taxes (Details 1) Sheet http://protokinetix.com/role/IncomeTaxesDetails1 Income Taxes (Details 1) Details http://protokinetix.com/role/IncomeTaxesTables 41 false false R42.htm 00000042 - Disclosure - Income Taxes (Details Narrative) Sheet http://protokinetix.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://protokinetix.com/role/IncomeTaxesTables 42 false false R43.htm 00000043 - Disclosure - Subsequent Events (Details Narrative) Sheet http://protokinetix.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://protokinetix.com/role/SubsequentEvents 43 false false All Reports Book All Reports pktx_10k-123122.htm ex4x4.htm ex4x5.htm ex4x6.htm pktx-20221231.xsd pktx-20221231_cal.xml pktx-20221231_def.xml pktx-20221231_lab.xml pktx-20221231_pre.xml dheader.jpg footer.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "pktx_10k-123122.htm": { "axisCustom": 0, "axisStandard": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 358, "http://xbrl.sec.gov/dei/2022": 32 }, "contextCount": 124, "dts": { "calculationLink": { "local": [ "pktx-20221231_cal.xml" ] }, "definitionLink": { "local": [ "pktx-20221231_def.xml" ] }, "inline": { "local": [ "pktx_10k-123122.htm" ] }, "labelLink": { "local": [ "pktx-20221231_lab.xml" ] }, "presentationLink": { "local": [ "pktx-20221231_pre.xml" ] }, "schema": { "local": [ "pktx-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 328, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 22, "http://protokinetix.com/20221231": 9, "http://xbrl.sec.gov/dei/2022": 4, "total": 35 }, "keyCustom": 39, "keyStandard": 153, "memberCustom": 29, "memberStandard": 12, "nsprefix": "PKTX", "nsuri": "http://protokinetix.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://protokinetix.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Intangible Assets", "menuCat": "Notes", "order": "10", "role": "http://protokinetix.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PKTX:StockOptionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Stock Options", "menuCat": "Notes", "order": "11", "role": "http://protokinetix.com/role/StockOptions", "shortName": "Stock Options", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PKTX:StockOptionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PKTX:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Warrants", "menuCat": "Notes", "order": "12", "role": "http://protokinetix.com/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PKTX:WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "13", "role": "http://protokinetix.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Related Party Transactions and Balances", "menuCat": "Notes", "order": "14", "role": "http://protokinetix.com/role/RelatedPartyTransactionsAndBalances", "shortName": "Related Party Transactions and Balances", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Commitments and Contingency", "menuCat": "Notes", "order": "15", "role": "http://protokinetix.com/role/CommitmentsAndContingency", "shortName": "Commitments and Contingency", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "16", "role": "http://protokinetix.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "17", "role": "http://protokinetix.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "18", "role": "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PKTX:AccountsReceivableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Prepaid Expenses and Deposits (Tables)", "menuCat": "Tables", "order": "19", "role": "http://protokinetix.com/role/PrepaidExpensesAndDepositsTables", "shortName": "Prepaid Expenses and Deposits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PKTX:AccountsReceivableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://protokinetix.com/role/BalanceSheets", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Intangible Assets (Tables)", "menuCat": "Tables", "order": "20", "role": "http://protokinetix.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "PKTX:StockOptionsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Stock Options (Tables)", "menuCat": "Tables", "order": "21", "role": "http://protokinetix.com/role/StockOptionsTables", "shortName": "Stock Options (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "PKTX:StockOptionsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "PKTX:WarrantsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PKTX:ScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Warrants (Tables)", "menuCat": "Tables", "order": "22", "role": "http://protokinetix.com/role/WarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "PKTX:WarrantsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "PKTX:ScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "23", "role": "http://protokinetix.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2015-01-012015-12-31", "decimals": "0", "first": true, "lang": null, "name": "PKTX:PaymentToAcquireIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Basis of Presentation \u2013 Going Concern Uncertainties (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://protokinetix.com/role/BasisOfPresentationGoingConcernUncertaintiesDetailsNarrative", "shortName": "Basis of Presentation \u2013 Going Concern Uncertainties (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2015-01-012015-12-31", "decimals": "0", "first": true, "lang": null, "name": "PKTX:PaymentToAcquireIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "PKTX:AccountsReceivableTableTextBlock", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepositsAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Prepaid Expenses and Deposits (Details)", "menuCat": "Details", "order": "26", "role": "http://protokinetix.com/role/PrepaidExpensesAndDepositsDetails", "shortName": "Prepaid Expenses and Deposits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "PKTX:AccountsReceivableTableTextBlock", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepositsAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Intangible Assets (Details)", "menuCat": "Details", "order": "27", "role": "http://protokinetix.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireIntangibleAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Intangible Assets (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative", "shortName": "Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-012022-12-31_srt_MinimumMember", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "PKTX:StockOptionsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2021-12-31_us-gaap_StockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "PKTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Stock Options (Details)", "menuCat": "Details", "order": "29", "role": "http://protokinetix.com/role/StockOptionsDetails", "shortName": "Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "PKTX:StockOptionsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2020-12-31_us-gaap_StockOptionMember", "decimals": "INF", "lang": null, "name": "PKTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://protokinetix.com/role/BalanceSheetsParenthetical", "shortName": "BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "PKTX:StockOptionsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Stock Options (Details 1)", "menuCat": "Details", "order": "30", "role": "http://protokinetix.com/role/StockOptionsDetails1", "shortName": "Stock Options (Details 1)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "PKTX:StockOptionsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Stock Options (Details 2)", "menuCat": "Details", "order": "31", "role": "http://protokinetix.com/role/StockOptionsDetails2", "shortName": "Stock Options (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "PKTX:StockOptionsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "PKTX:StockOptionsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Stock Options (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://protokinetix.com/role/StockOptionsDetailsNarrative", "shortName": "Stock Options (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "PKTX:StockOptionsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-03-012022-03-15", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Warrants (Details)", "menuCat": "Details", "order": "33", "role": "http://protokinetix.com/role/WarrantsDetails", "shortName": "Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "PKTX:ScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlock", "PKTX:WarrantsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "PKTX:WarrantsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Warrants (Details 1)", "menuCat": "Details", "order": "34", "role": "http://protokinetix.com/role/WarrantsDetails1", "shortName": "Warrants (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "PKTX:WarrantsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "PKTX:StockOptionsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Warrants (Details 2)", "menuCat": "Details", "order": "35", "role": "http://protokinetix.com/role/WarrantsDetails2", "shortName": "Warrants (Details 2)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "PKTX:ScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlock", "PKTX:WarrantsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Warrants (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://protokinetix.com/role/WarrantsDetailsNarrative", "shortName": "Warrants (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "PKTX:WarrantsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_WarrantMember147064093", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "PKTX:CommonStockSharesAuthorizeds", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Stockholders' Equity (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://protokinetix.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders' Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "PKTX:CommonStockSharesAuthorizeds", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Related Party Transactions and Balances (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative", "shortName": "Related Party Transactions and Balances (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Commitments and Contingency (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative", "shortName": "Commitments and Contingency (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2017-01-012017-01-02_custom_ConsultantMember", "decimals": "0", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://protokinetix.com/role/StatementsOfOperations", "shortName": "STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "40", "role": "http://protokinetix.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:IncomeTaxReconciliationTaxCredits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Income Taxes (Details 1)", "menuCat": "Details", "order": "41", "role": "http://protokinetix.com/role/IncomeTaxesDetails1", "shortName": "Income Taxes (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Income Taxes (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://protokinetix.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "43", "role": "http://protokinetix.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-012022-12-31_srt_ChiefExecutiveOfficerMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "5", "role": "http://protokinetix.com/role/StatementOfStockholdersEquity", "shortName": "STATEMENT OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://protokinetix.com/role/StatementsOfCashFlows", "shortName": "STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Basis of Presentation \u2013 Going Concern Uncertainties", "menuCat": "Notes", "order": "7", "role": "http://protokinetix.com/role/BasisOfPresentationGoingConcernUncertainties", "shortName": "Basis of Presentation \u2013 Going Concern Uncertainties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://protokinetix.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Prepaid Expenses and Deposits", "menuCat": "Notes", "order": "9", "role": "http://protokinetix.com/role/PrepaidExpensesAndDeposits", "shortName": "Prepaid Expenses and Deposits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pktx_10k-123122.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 44, "tag": { "PKTX_AccountsReceivableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of prepaid expenses" } } }, "localname": "AccountsReceivableTableTextBlock", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/PrepaidExpensesAndDepositsTables" ], "xbrltype": "textBlockItemType" }, "PKTX_AdditionalPatentApplications": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Additional patent applications" } } }, "localname": "AdditionalPatentApplications", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/BasisOfPresentationGoingConcernUncertaintiesDetailsNarrative", "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PKTX_Amortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization" } } }, "localname": "Amortization", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "PKTX_CFOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "C F O [Member]" } } }, "localname": "CFOMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_ChiefExecutiveandDirectorOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Executiveand Director Officer [Member]" } } }, "localname": "ChiefExecutiveandDirectorOfficerMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_ChiefExecutiveandOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Executiveand Officer [Member]" } } }, "localname": "ChiefExecutiveandOfficerMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_ClassOfWarrantOrRightOutstandings": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase" } } }, "localname": "ClassOfWarrantOrRightOutstandings", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PKTX_ClassOfWarrantOrRightsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Exercise Price", "label": "Warrant weighted average exercise price" } } }, "localname": "ClassOfWarrantOrRightsExercisePrice", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "perShareItemType" }, "PKTX_CommonStockSharesAuthorizeds": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares authorized" } } }, "localname": "CommonStockSharesAuthorizeds", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PKTX_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_DepositShareholderMeeting": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deposit on February 11, 2022 shareholder meeting" } } }, "localname": "DepositShareholderMeeting", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/PrepaidExpensesAndDepositsDetails" ], "xbrltype": "monetaryItemType" }, "PKTX_DisclosureStockOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options" } } }, "localname": "DisclosureStockOptionsAbstract", "nsuri": "http://protokinetix.com/20221231", "xbrltype": "stringItemType" }, "PKTX_DisclosureWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "DisclosureWarrantsAbstract", "nsuri": "http://protokinetix.com/20221231", "xbrltype": "stringItemType" }, "PKTX_ExpectedForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Custom Element.", "label": "Expected forfeiture rate" } } }, "localname": "ExpectedForfeitureRate", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails1", "http://protokinetix.com/role/WarrantsDetails2" ], "xbrltype": "percentItemType" }, "PKTX_ExpiryDateOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Custom Element.", "label": "Expiry Date" } } }, "localname": "ExpiryDateOfWarrant", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "PKTX_ExtensionOfTermsOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Extension of the terms of warrants" } } }, "localname": "ExtensionOfTermsOfWarrants", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PKTX_FairValueOfCompensatoryOptionsGranted": { "auth_ref": [], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value of compensatory options granted" } } }, "localname": "FairValueOfCompensatoryOptionsGranted", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PKTX_GrantYoungMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant Young [Member]" } } }, "localname": "GrantYoungMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_InvestorsEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors Eight [Member]" } } }, "localname": "InvestorsEightMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_InvestorsFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors Five [Member]" } } }, "localname": "InvestorsFiveMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_InvestorsFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors Four [Member]" } } }, "localname": "InvestorsFourMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_InvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors [Member]" } } }, "localname": "InvestorsMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_InvestorsNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors Nine [Member]" } } }, "localname": "InvestorsNineMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_InvestorsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors One [Member]" } } }, "localname": "InvestorsOneMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_InvestorsSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors Seven [Member]" } } }, "localname": "InvestorsSevenMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_InvestorsSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors Six [Member]" } } }, "localname": "InvestorsSixMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_InvestorsThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors Three [Member]" } } }, "localname": "InvestorsThreeMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_InvestorsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors Two [Member]" } } }, "localname": "InvestorsTwoMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_IssuanceOfCommonStockPursuantToCashlessOptionExerciseAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock pursuant to cashless option exercise" } } }, "localname": "IssuanceOfCommonStockPursuantToCashlessOptionExerciseAmount", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PKTX_IssuanceOfCommonStockPursuantToCashlessOptionExerciseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock pursuant to cashless option exercise, Shares" } } }, "localname": "IssuanceOfCommonStockPursuantToCashlessOptionExerciseShares", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PKTX_IssuanceOfCommonStockPursuantToWarrantExercise": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock pursuant to warrant exercise" } } }, "localname": "IssuanceOfCommonStockPursuantToWarrantExercise", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "PKTX_IssuanceOfCommonStockPursuantToWarrantExerciseShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock pursuant to warrant exercise, Shares" } } }, "localname": "IssuanceOfCommonStockPursuantToWarrantExerciseShares", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "PKTX_ModificationIncrementalFairValueOption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Modification incremental fair value option" } } }, "localname": "ModificationIncrementalFairValueOption", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PKTX_NetLossPerCommonShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per common share (basic and diluted)" } } }, "localname": "NetLossPerCommonShareBasicAndDiluted", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "PKTX_OptionsExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option expiration date" } } }, "localname": "OptionsExpirationDate", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "dateItemType" }, "PKTX_PatentApplicationRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Custom Element.", "label": "Patent Application Rights [Member]" } } }, "localname": "PatentApplicationRightsMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetails", "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_PaymentToAcquireIntangibleAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash consideration" } } }, "localname": "PaymentToAcquireIntangibleAssets", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/BasisOfPresentationGoingConcernUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "PKTX_RelatedPartyTransactionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsPolicyTextBlock", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "PKTX_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionTableTextBlock", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "PKTX_ScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlock", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "PKTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant weighted average exercise price, cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "PKTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant weighted average exercise price, exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "PKTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled", "negatedLabel": "Warrants cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCancelled", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "PKTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 13 [Member]", "verboseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGranted", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PKTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PKTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement ByShare Based Payment Awards Options Outstanding Number", "periodEndLabel": "Outstanding, ending", "periodStartLabel": "Outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsOptionsOutstandingNumber", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "PKTX_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsOutstandingNumber", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PKTX_SharebasedCompensationArrangementBySharebasedPaymenstAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymenstAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails1", "http://protokinetix.com/role/WarrantsDetails2" ], "xbrltype": "durationItemType" }, "PKTX_StockOption1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 1 [Member]" } } }, "localname": "StockOption1Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails2" ], "xbrltype": "domainItemType" }, "PKTX_StockOption2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 2 [Member]" } } }, "localname": "StockOption2Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails2" ], "xbrltype": "domainItemType" }, "PKTX_StockOption3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option 3 [Member]" } } }, "localname": "StockOption3Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails2" ], "xbrltype": "domainItemType" }, "PKTX_StockOptionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StockOptionsTextBlock", "verboseLabel": "Stock Options" } } }, "localname": "StockOptionsTextBlock", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockOptions" ], "xbrltype": "textBlockItemType" }, "PKTX_TechnologyTransferAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Technology Transfer Agreement [Member]" } } }, "localname": "TechnologyTransferAgreementMember", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "PKTX_ThereWereNoNoncashFinancingOrInvestingActivities.": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "There were no non-cash financing or investing activities." } } }, "localname": "ThereWereNoNoncashFinancingOrInvestingActivities.", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "PKTX_TravelExpensesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Travel expenses term" } } }, "localname": "TravelExpensesTerm", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative" ], "xbrltype": "durationItemType" }, "PKTX_Warrant1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 1 [Member]" } } }, "localname": "Warrant1Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "PKTX_Warrant2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 2 [Member]" } } }, "localname": "Warrant2Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "PKTX_Warrant3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 3 [Member]" } } }, "localname": "Warrant3Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "PKTX_Warrant4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 4 [Member]" } } }, "localname": "Warrant4Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "PKTX_Warrant5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 5 [Member]" } } }, "localname": "Warrant5Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "PKTX_Warrant6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 6 [Member]" } } }, "localname": "Warrant6Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "PKTX_Warrant7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 7 [Member]" } } }, "localname": "Warrant7Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "PKTX_Warrant8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 8 [Member]" } } }, "localname": "Warrant8Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "PKTX_Warrant9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant 9 [Member]" } } }, "localname": "Warrant9Member", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "PKTX_WarrantExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised" } } }, "localname": "WarrantExercised", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PKTX_WarrantExpiringDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant expiring date" } } }, "localname": "WarrantExpiringDate", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "dateItemType" }, "PKTX_WarrantIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant issued" } } }, "localname": "WarrantIssued", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/BasisOfPresentationGoingConcernUncertaintiesDetailsNarrative", "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PKTX_WarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants issued" } } }, "localname": "WarrantsIssued", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PKTX_WarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsTextBlock", "verboseLabel": "Warrants" } } }, "localname": "WarrantsTextBlock", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "PKTX_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding (basic and diluted)" } } }, "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted", "nsuri": "http://protokinetix.com/20221231", "presentation": [ "http://protokinetix.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r321", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r321", "r323", "r324" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r321", "r323", "r324" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r321", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://protokinetix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://protokinetix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r155", "r156", "r157", "r158", "r186", "r271", "r292", "r298", "r299", "r304", "r305", "r309", "r345", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative", "http://protokinetix.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r155", "r156", "r157", "r158", "r186", "r271", "r292", "r298", "r299", "r304", "r305", "r309", "r345", "r358", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative", "http://protokinetix.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r155", "r156", "r157", "r158", "r184", "r186", "r214", "r215", "r216", "r270", "r271", "r292", "r298", "r299", "r304", "r305", "r309", "r342", "r345", "r359", "r360", "r361", "r362", "r363" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative", "http://protokinetix.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r155", "r156", "r157", "r158", "r184", "r186", "r214", "r215", "r216", "r270", "r271", "r292", "r298", "r299", "r304", "r305", "r309", "r342", "r345", "r359", "r360", "r361", "r362", "r363" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative", "http://protokinetix.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r340", "r354" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://protokinetix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://protokinetix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r8", "r308" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r3", "r308" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r219", "r220", "r221", "r337", "r338", "r339", "r352" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r19", "r33", "r37" ], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://protokinetix.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization \u2013 intangible assets (Note 4)", "terseLabel": "Amortization of Intangible Assets", "verboseLabel": "Amortization \u2013 intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative", "http://protokinetix.com/role/StatementsOfCashFlows", "http://protokinetix.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r82", "r85", "r97", "r113", "r140", "r142", "r144", "r146", "r159", "r160", "r162", "r163", "r164", "r165", "r166", "r168", "r169", "r245", "r249", "r254", "r308", "r343", "r344", "r356" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r94", "r99", "r113", "r146", "r159", "r160", "r162", "r163", "r164", "r165", "r166", "r168", "r169", "r245", "r249", "r254", "r308", "r343", "r344", "r356" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r189", "r190", "r191", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r213", "r214", "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails", "http://protokinetix.com/role/StockOptionsDetailsNarrative", "http://protokinetix.com/role/StockholdersEquityDetailsNarrative", "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://protokinetix.com/role/WarrantsDetails", "http://protokinetix.com/role/WarrantsDetails1", "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r16", "r21", "r24" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of year", "periodStartLabel": "Cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r16", "r79" ], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r330" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant exercise price", "periodEndLabel": "Warrant weighted average exercise price, ending", "periodStartLabel": "Warrant weighted average exercise price, beginning" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetails", "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments and Contingency" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/CommitmentsAndContingency" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r337", "r338", "r352" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheetsParenthetical", "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r2", "r41" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r2", "r308" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0000053 par value; 500,000,000 common shares authorized; 322,880,151 and 297,393,485 shares issued and outstanding for 2022 and 2021 respectively (Note 7)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Prepaid Expenses and Deposits" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/PrepaidExpensesAndDeposits" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r70", "r350" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Deferred Tax Assets, Capital Loss Carryforwards" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Deferred Tax Assets, Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative", "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsAssets": { "auth_ref": [ "r331" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.", "label": "Rental deposit" } } }, "localname": "DepositsAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/PrepaidExpensesAndDepositsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r73", "r74", "r75", "r76", "r301" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DirectOperatingCosts": { "auth_ref": [ "r12" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate direct operating costs incurred during the reporting period.", "label": "Direct operating costs" } } }, "localname": "DirectOperatingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsReceivable": { "auth_ref": [ "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of dividends declared but not received.", "label": "Dividends declared" } } }, "localname": "DividendsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r8", "r161", "r162", "r163", "r167", "r168", "r169", "r265", "r336" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r26", "r27" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss per Share and Potentially Dilutive Securities" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r41", "r92", "r103", "r104", "r105", "r116", "r117", "r118", "r120", "r125", "r127", "r134", "r147", "r183", "r219", "r220", "r221", "r235", "r236", "r252", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity", "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r19", "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value adjustment of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BasisOfPresentationGoingConcernUncertaintiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r77", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Intangible assets useful lives" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r96", "r152" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r150", "r151", "r152", "r153", "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetails", "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r36", "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetails", "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r34", "r35" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetails", "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r36", "r276" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets (Note 4)", "verboseLabel": "Net carrying amounts" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets", "http://protokinetix.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r13" ], "calculation": { "http://protokinetix.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r114", "r227", "r228", "r233", "r237", "r239", "r241", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r115", "r126", "r127", "r139", "r226", "r238", "r240", "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Total income tax expense (recovery)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r102", "r224", "r225", "r228", "r229", "r232", "r234" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Non-deductible expenses" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).", "label": "Adjustment to prior years provision versus statutory tax returns" } } }, "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "negatedLabel": "Expected income tax recovery" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r18" ], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in current receivables (due within one year or one operating cycle) to be collected from the reporting entity's executives and owners.", "label": "Increase (Decrease) in Due from Officers and Stockholders, Current" } } }, "localname": "IncreaseDecreaseInDueFromOfficersAndStockholdersCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r18" ], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaid expenses and deposits" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r35", "r272", "r273", "r274", "r276", "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible assets \u2013 patent and patent application costs" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r106", "r109", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r7", "r83", "r87", "r308", "r335", "r341", "r353" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r95", "r113", "r146", "r159", "r160", "r162", "r163", "r164", "r165", "r166", "r168", "r169", "r246", "r249", "r250", "r254", "r308", "r343", "r356", "r357" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r108" ], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r108" ], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS USED IN INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r16", "r17", "r20" ], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS USED IN OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r11", "r20", "r84", "r88", "r93", "r100", "r101", "r105", "r113", "r119", "r121", "r122", "r123", "r124", "r126", "r127", "r130", "r140", "r141", "r143", "r145", "r146", "r159", "r160", "r162", "r163", "r164", "r165", "r166", "r168", "r169", "r253", "r254", "r303", "r343" ], "calculation": { "http://protokinetix.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss for the year", "verboseLabel": "Net loss for the year" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesDetails", "http://protokinetix.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r121", "r122", "r123", "r124", "r128", "r129", "r131", "r132", "r140", "r141", "r143", "r145", "r303" ], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "verboseLabel": "Net loss for the year" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://protokinetix.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "negatedTotalLabel": "Operating Income (Expenses)" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r72" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Basis of Presentation \u2013 Going Concern Uncertainties" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BasisOfPresentationGoingConcernUncertainties" ], "xbrltype": "textBlockItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r14" ], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Intangible assets", "negatedLabel": "Purchase of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative", "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Additions" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r98", "r148", "r149", "r300" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and deposits (Note 3)", "verboseLabel": "Total Prepaid Expenses and Deposits" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets", "http://protokinetix.com/role/PrepaidExpensesAndDepositsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r15" ], "calculation": { "http://protokinetix.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Issuance of common stock for cash" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Total proceeds" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r89", "r90" ], "calculation": { "http://protokinetix.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees (Note 8)" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r93", "r100", "r101", "r107", "r113", "r119", "r126", "r127", "r140", "r141", "r143", "r145", "r146", "r159", "r160", "r162", "r163", "r164", "r165", "r166", "r168", "r169", "r244", "r247", "r248", "r253", "r254", "r290", "r303", "r306", "r307", "r333", "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss for the year" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r185", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative", "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative", "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative", "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r81", "r264" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r185", "r264", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r355" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative", "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative", "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative", "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r262", "r263", "r265", "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions and Balances" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalances" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r67", "r91", "r364" ], "calculation": { "http://protokinetix.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative", "http://protokinetix.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r4", "r42", "r86", "r296", "r297", "r308" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r92", "r116", "r117", "r118", "r120", "r125", "r127", "r147", "r219", "r220", "r221", "r235", "r236", "r252", "r293", "r295" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r47", "r48", "r49", "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative", "http://protokinetix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r34", "r35", "r276" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetails", "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Intangible asset transactions" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Schedule of options by exercise price" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r187", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r213", "r214", "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails", "http://protokinetix.com/role/StockOptionsDetailsNarrative", "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://protokinetix.com/role/WarrantsDetails", "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r53", "r59", "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Share-based Compensation, Stock Options, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r43", "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of outstanding and exercisable" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r18" ], "calculation": { "http://protokinetix.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation (Notes 5 and 8)" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Warrant weighted average exercise price, expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Warrant weighted average exercise price, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.", "label": "Expiring date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails1", "http://protokinetix.com/role/WarrantsDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails1", "http://protokinetix.com/role/WarrantsDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails1", "http://protokinetix.com/role/WarrantsDetails2" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails", "http://protokinetix.com/role/StockOptionsDetailsNarrative", "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://protokinetix.com/role/WarrantsDetails", "http://protokinetix.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "negatedLabel": "Warrants expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative", "http://protokinetix.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Warrant granted", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative", "http://protokinetix.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r54", "r55" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Warrant outstanding, ending", "periodStartLabel": "Warrant outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Number of options exercisable", "verboseLabel": "Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails2", "http://protokinetix.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share based compensation exercisable per share", "verboseLabel": "Exercisable price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative", "http://protokinetix.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Number of shares cancelled", "negatedLabel": "Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails", "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Option granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Share based compensation exercisable per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetailsNarrative", "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Number of outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails2" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Weighed average exercise price", "periodEndLabel": "Weighed average exercise price ending balance", "periodStartLabel": "Weighted average exercise price beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails", "http://protokinetix.com/role/StockOptionsDetails2" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r189", "r190", "r191", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r213", "r214", "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails", "http://protokinetix.com/role/StockOptionsDetailsNarrative", "http://protokinetix.com/role/StockholdersEquityDetailsNarrative", "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://protokinetix.com/role/WarrantsDetails", "http://protokinetix.com/role/WarrantsDetails1", "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price, cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price, granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r192", "r211", "r212", "r213", "r214", "r217", "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative", "http://protokinetix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r25", "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r10", "r41", "r92", "r103", "r104", "r105", "r116", "r117", "r118", "r120", "r125", "r127", "r134", "r147", "r183", "r219", "r220", "r221", "r235", "r236", "r252", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity", "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r116", "r117", "r118", "r134", "r275" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r1", "r2", "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative", "http://protokinetix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Issuance of common stock pursuant to private placement offering, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r1", "r2", "r41", "r42", "r198" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r1", "r2", "r41", "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative", "http://protokinetix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Issuance of common stock pursuant to private placement offering" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r1", "r2", "r42", "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Fair value of share-based compensation", "verboseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementOfStockholdersEquity", "http://protokinetix.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative", "http://protokinetix.com/role/StockOptionsDetails", "http://protokinetix.com/role/StockOptionsDetailsNarrative", "http://protokinetix.com/role/StockholdersEquityDetailsNarrative", "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r2", "r5", "r6", "r31", "r308", "r335", "r341", "r353" ], "calculation": { "http://protokinetix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets", "http://protokinetix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r44", "r112", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r183", "r251" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Common stock" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplementary information \u2013 non-cash transactions:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TravelAndEntertainmentExpense": { "auth_ref": [ "r13" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses incurred for travel and entertainment during the period.", "label": "Travel and entertainment expense" } } }, "localname": "TravelAndEntertainmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r28", "r29", "r30", "r135", "r136", "r137", "r138" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://protokinetix.com/role/StockholdersEquityDetailsNarrative", "http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://protokinetix.com/role/WarrantsDetails", "http://protokinetix.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r311": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r312": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r313": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r314": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r315": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r316": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r317": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r318": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r319": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r321": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r322": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r323": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r324": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r325": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r326": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r327": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r328": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r329": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 65 0001079973-23-000353-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-23-000353-xbrl.zip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end